

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

A2

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/00</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/03012</b>
			(43) International Publication Date: 20 January 2000 (20.01.00)
(21) International Application Number: <b>PCT/US99/15473</b>		(81) Designated States: BR, CA, JP, MX, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 10 July 1999 (10.07.99)			
(30) Priority Data: 09/113,244 10 July 1998 (10.07.98) US 09/316,847 21 May 1999 (21.05.99) US		<b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (for all designated States except US): CALGENE LLC [US/US]; 1920 Fifth Street, Davis, CA 95616 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): MCBRIDE, Kevin, E. [US/US]; 1309 Marina Circle, Davis, CA 95616 (US). NEHRA, Narender [AU/US]; 14971 Appalachina Trail, Chesterfield, MO 63017 (US). RUSSELL, Douglas, A. [US/US]; 1610 Frisch Road, Madison, WI 53711 (US). STALKER, David, M. [US/US]; 870 W. Southwood, Woodland, CA 945695 (US).			
(74) Agent: PATENT DEPARTMENT CENTRAL; Monsanto/G.D. Searle, P.O. Box 5110, Chicago, IL 60680-5110 (US).			
(54) Title: EXPRESSION OF EUKARYOTIC PEPTIDES IN PLANT PLASTIDS			
(57) Abstract <p>Constructs and methods are provided for expressing peptides derived from eukaryotic organisms in plant plastids. Constructs have a promoter functional in a plant plastid, a DNA sequence encoding a peptide derived from an eukaryotic organism and a transcription termination region. Other elements include a selectable marker for selection of plant cells comprising a plastid expressing the marker and DNA regions of homology to the genome of the plastid and optionally a ribosome binding site joined to the promoter. By methods using such constructs high levels of eukaryotic peptides, such as mammalian proteins, are produced in a plant cell by growing plant cells under conditions whereby the DNA encoding sequences are expressed to produce eukaryotic peptide in said plastid.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## EXPRESSION OF EUKARYOTIC PEPTIDES IN PLANT PLASTIDS

5

### INTRODUCTION

#### Technical Field

This invention relates to the application of genetic engineering techniques to  
10 plants. Specifically, the invention relates to compositions and methods for enhancing  
expression of proteins in plant plastids.

#### Background

The plastids of higher plants are an attractive target for genetic engineering. Plant  
15 plastids (chloroplasts, amyloplasts, elaioplasts, etioplasts, chromoplasts, etc.) are the major  
biosynthetic centers that, in addition to photosynthesis, are responsible for production of  
industrially important compounds such as amino acids, complex carbohydrates, fatty acids,  
and pigments. Plastids are derived from a common precursor known as a proplastid and  
thus the plastids present in a given plant species all have the same genetic content. Plant  
20 cells contain 500-10,000 copies of a small 120-160 kilobase circular genome, each  
molecule of which has a large (approximately 25kb) inverted repeat. Thus, it is possible to  
engineer plant cells to contain up to 20,000 copies of a particular gene of interest which  
potentially can result in very high levels of foreign gene expression. In addition, plastids  
of most plants are maternally inherited. Consequently, unlike heterologous genes  
25 expressed in the nucleus, heterologous genes expressed in plastids are not pollen  
disseminated, therefore, a trait introduced into a plant plastid will not be transmitted to  
wild-type relatives.

There remains a need for improved regulatory elements for expression of genes in a  
plant plastid. To date, the expression signals used routinely for plastid transgene  
30 expression derive from endogenous plastid genes. The plastid expression signals are  
typically derived from promoter regions of highly expressed plastid genes such as the  
promoter regions from the 16S ribosomal RNA operon (*Prm*), *psbA* gene (*PpsbA*) or the  
*rbcL* gene (*PrbcL*). The *psbA* and *rbcL* genes are highly transcribed, but their translation is

controlled by tissue-specific and light-regulated factors which limits their usefulness. In the case of *Prm*, a synthetic ribosome binding site (RBS) patterned after the plastid *rbcl* gene leader has been typically used to direct translation. However, this *Prm*/RBS is translated inefficiently due to poor ribosome binding.

Plastids of higher plants present an attractive target for genetic engineering. As mentioned above, plastids of higher plants are maternally inherited. This offers an advantage for genetic engineering of plants for tolerance or resistance to natural or chemical conditions, such as herbicide tolerance, as these traits will not be transmitted to wild-type relatives. In addition, the high level of foreign gene expression is attractive for engineered traits such as the production of pharmaceutically important proteins.

Expression of nucleic acid sequences encoding for enzymes providing for herbicide tolerance as well as pharmaceutical proteins from plant plastid genome offers an attractive alternative to expression from the plant nuclear genome.

15 SUMMARY OF THE INVENTION

The present invention provides nucleic acid sequences useful in enhancing expression of a wide variety of genes, both eukaryotic and prokaryotic, in plant plastids. Furthermore, plastid expression constructs are provided which are useful for genetic engineering of plant cells and which provide for enhanced expression of the EPSP synthase proteins or the hGH protein in plant cell plastids. The transformed plastids should be metabolically active plastids, and are preferably maintained at a high copy number in the plant tissue of interest, most preferably the chloroplasts found in green plant tissues, such as leaves or cotyledons.

25           The plastid expression constructs for use in this invention generally include a plastid promoter region capable of providing for enhanced expression of a DNA sequence, a DNA sequence encoding an EPSPS protein or human growth hormone (hGH), and a transcription termination region capable of terminating transcription in a plant plastid.

The plastid promoter region of the present invention is preferably linked to a  
30 ribosome binding site which provides for enhanced translation of mRNA transcripts in a  
plant plastid.

The plastid expression construct of this invention is preferably linked to a construct having a DNA sequence encoding a selectable marker which can be expressed in a plant



plastid. Expression of the selectable marker allows the identification of plant cells comprising a plastid expressing the marker.

In a preferred embodiment, vectors for transfer of the construct into a plant cell include means for inserting the expression and selection constructs into the plastid genome. The vectors preferably comprise regions of homology to the target plastid genome which flank the constructs.

The constructs of the present invention preferably comprise a promoter sequence linked to a ribosome binding site capable of enhancing the translation of mRNA transcripts in the plant plastid. The ribosome binding site is preferably derived from the T7 bacteriophage gene 10 leader sequence.

Of particular interest in the present invention is the high level of expression of nucleic acid sequences in plant plastids. Of particular interest is the high level expression of nucleic acid sequences encoding for enzymes involved in herbicide tolerance and encoding for pharmaceutical proteins.

The constructs of the present invention preferably comprise a DNA sequence encoding 5-Enolpyruvylshikimate-3-phosphate synthase (USPN 5,633,435, the entirety of which is incorporated herein by reference), nitrilase, phytoene desaturase, aprotinin or a DNA sequence encoding human growth hormone (USPN 5,424,199, the entirety of which is incorporated herein by reference).

Plant cell plastids containing the constructs are also contemplated in the invention, as are plants, plant seeds, plant cells or progeny thereof containing plastids comprising the construct.

The present invention also includes methods for enhanced expression of DNA sequences in plant plastids.

The invention also includes a method for the enhanced expression of an enzyme encoding hGH in plastids of the plant cell.

The present invention further includes methods for obtaining a protein expressed from a plant cell, including a plastid, having a non-methionine N-terminus. In addition, plant cells and plastids which include non-methionine N-terminus proteins are contemplated.

Thus, the present invention relates to a chimeric gene containing a coding sequence of a pharmaceutical protein, a plant plastid expression vector containing a promoter operably linked to a T7 Bacteriophage Polymerase gene 10 ribosome binding site capable

of enhanced expression in a plant plastid operably linked to a herbicide tolerance or pharmaceutical coding gene, a plant transformation vector having inserted therein a herbicide tolerance or pharmaceutical coding gene expressed from a plastid promoter linked to a T7 Bacteriophage Polymerase gene 10 ribosome binding site, plant cells  
5 transformed using such vectors and plants regenerated therefrom which exhibit a substantial degree of expression of nucleic acid sequences and proteins and methods for producing such plants and such plants.

## 10 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleotide sequence of the G10L ribosome binding site.

Figure 2 provides an amino acid sequence encoding for aprotinin.

Figure 3 provides the results of RP-HPLC analysis for characterization of hGH protein expressed in the plastid. Peak I (tallest peak) indicates the expected retention time  
15 for properly folded, native 22 kDa GP2000.

Figure 4 provides an electrospray ionization mass spectrometry (MS) analysis using a Micromass Q-ToF electrospray time-of-flight mass spectrometer. In particular, a series of ions corresponding to the specie(s) present in the sample with varying numbers of protons attached is provided. The axes of the spectrum are intensity versus mass-to-charge  
20 ratio of the specie(s) present.

Figure 5 provides a graphic representation of the bioactivity of hGH expressed from a plant plastid. The samples represented on the graph are bovine prolactin (bPL), hGH expressed from *E. coli* (Ala-hGH), and a null transgenic spiked with bovine prolactin (SPFF Null Spike) as positive controls, a null transgenic (SPFF Null) as a negative control,  
25 and transgenic samples from a sepharose column (SPFF Sample, SPFF Sample) and a transgenic sample eluted from the sepharose column at pH3.5 (SPFF pH3.5 Eln).

## DETAILED DESCRIPTION OF THE INVENTION

In accordance with the subject invention, plastid expression constructs are provided  
30 which generally comprise a promoter functional in a plant plastid, a ribosome binding site derived from the T7 Bacteriophage Polymerase gene 10 leader, a DNA sequence encoding for a gene of interest, and a transcription termination region capable of terminating

transcription in a plant plastid. These elements are provided as operably joined components in the 5' to 3' direction of transcription.

Furthermore, the constructs of the present invention may also include a nucleic acid sequence encoding a peptide capable of targeting said DNA sequence encoding a protein to the thylakoid lumen within the chloroplast.

Of particular interest in the present invention are methods for the production of proteins in a host plant cell plastid having a non-methionine N-terminus. Such methods generally involve the use of fusion proteins having an N-terminus sequence which is recognized by an endogenous protease. In particular, a DNA sequence encoding a cleavable ubiquitin peptide is fused to a DNA sequence encoding a protein of interest. After expression of the fusion protein in the plastid, an endogenous protease acts on the fusion to cleave off the ubiquitin portion of the protein.

Also of interest in the present invention is the use of the plastid expression constructs to direct the high level transcription and translation (expression) of nucleic acid sequences. Such plastid expression constructs find use in directing the high level expression of DNA sequences encoding for enzymes involved in herbicide tolerance or encoding for the production of pharmaceutical proteins.

Of more particular interest in the present invention is the use of the plastid expression constructs to direct the high level translation of transcribed messenger RNA.

DNA sequence and biochemical data reveal a similarity of the plastid organelle's transcriptional and translational machineries and initiation signals to those found in prokaryotic systems. In fact, plastid derived promoter sequences have been reported to direct expression of reporter genes in prokaryotic cells. In addition, plastid genes are often organized into polycistronic operons as they are in prokaryotes.

Despite the apparent similarities between plastids and prokaryotes, there exist fundamental differences in the methods used to control gene expression in plastids and prokaryotes. As opposed to the transcriptional control mechanisms typically observed in prokaryotes, plastid gene expression is controlled predominantly at the level of translation and mRNA stability by trans-acting nuclear encoded proteins.

Translation is a multi-stage process which first involves the binding of messenger RNA (mRNA) to ribosomes. Beginning at the translation start codon, the mRNA codons are read sequentially as the ribosomes move along the mRNA molecule. The specified

amino acids are then sequentially added to the growing polypeptide chain to yield the protein or polypeptide encoded in the mRNA.

As mentioned, the first step in the translation process is the binding of the mRNA molecule to the ribosome. The nature of this interaction (i.e. binding) has been only partially elucidated. Analysis of RNase-resistant oligonucleotides isolated from bacterial translation initiation complexes indicate that a RNA fragment approximately 30 to 40 nucleotides in length comprises the initial ribosome binding site (RBS). Thus, a RBS is hereinafter understood to comprise a sequence of mRNA surrounding the translation start codon which is responsible for the binding of the ribosome and for initiation of translation.

Recently, ribosome binding sites have been identified which are capable of directing translation in a prokaryotes. For example, a ribosome binding site derived from the T7 bacteriophage gene 10 leader, G10L (USPN 5,232,840, the entirety of which is incorporated herein by reference), has been identified which enhances expression of nucleic acid sequences in prokaryotes.

Herbicides such as N-phosphonomethylglycine, halogenated hydroxybenzonitriles, and norflurazon have been the subject of a large amount of investigation.

N-phosphonomethylglycine, commonly referred to as glyphosate, inhibits the shikimic acid pathway which leads to the biosynthesis of aromatic compounds including amino acids, plant hormones and vitamins. Specifically, glyphosate curbs the conversion of phosphoenolpyruvic acid (PEP) and 3-phosphoshikimic acid to 5-enolpyruvyl-3-phosphoshikimic acid by inhibiting the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (hereinafter referred to as EPSP synthase or EPSPS).

Glyphosate tolerant plants have been produced by transformation of various EPSP synthase genes into the nuclear genome of a plant. A gene for EPSP synthase has been cloned from *Agrobacterium tumefaciens* sp strain CP4 (USPN 5,633,435) and confers a high level of glyphosate tolerance in plants. Furthermore, high levels of glyphosate tolerance has been achieved in a number of crop plants by fusing EPSPS to a chloroplast transit peptide (CTP) for targeted expression in plastids. In addition, variants of the wild-type EPSPS enzyme have been isolated which are glyphosate tolerant as a result of alterations in the EPSPS amino acid coding sequence (Kishore and Shah, *Ann. Rev. Biochem.* (1988) 57:627-663; Shulze et al., *Arch. Microbiol.* (1984) 137:121-123; Kishore et al., *Fed. Proc.* (1986) 45:1506). These variants typically have a higher  $K_i$  for glyphosate than the wild-type EPSPS enzyme which confers the glyphosate tolerant phenotype. but

these variants are also characterized by a high  $K_m$  for PEP which makes the enzyme kinetically less efficient (Kishore and Shah, *Ann. Rev. Biochem.* (1988) 57:627-663; Sost et al., *FEBS Lett.* (1984) 173: 238-241; Shulze et al., *Arch. Microbiol.* (1984) 137:121-123; Kishore et al., *Fed. Proc.* (1986) 45:1506; Sost and Amrhein, *Arch. Biochem. Biophys.* (1990) 282: 433-436).

In addition to engineering plants for glyphosate tolerance, plants have also been engineered to tolerate other classes of herbicides such as halogenated hydroxybenzonitriles, and norflurazon using nucleic acid sequences expressed in the nucleus.

Halogenated hydroxybenzonitriles, such as Bromoxynil, are suggested to act herbicidally by inhibiting the quinone-binding protein complex of photosystem II, inhibiting electron transfer (Van Rensen (1982) *Physiol. Plant* 54:515-520, and Sanders and Pallett (1986) *Pestic. Biochem. Physiol.* 26:116-122). Herbicides such as norflurazon inhibit the production of carotenoids.

Plants which are resistant to Bromoxynil have been produced by expressing DNA sequences encoding for enzymes capable of detoxifying Bromoxynil (nitrilases) in the plant cell nucleus. DNA sequences encoding for such nitrilases have been cloned from bacteria such as *Klebsiella pneumoniae* and used to construct vectors to direct the expression of the DNA sequence in plant cell nucleus (USPN 4,810,648, the entirety of which is incorporated herein by reference).

Plants which are resistant to Norflurazon have been engineered by expressing nucleic acid sequences which encode for enzymes in the carotenoid biosynthetic pathway in plant cell nuclei. For example, expressing a phytoene desaturase from *Erwinia uredovora* provides tolerance to norflurazon.

While plants transformed to express nucleic acid sequences encoding for such enzymes from the nuclear genome have found utility in engineering herbicide tolerant plants, it would be increasingly beneficial to obtain herbicide tolerant plants via plastidial expression.

In the examples provided herein, DNA sequences encoding for enzymes involved in herbicide tolerance are used in constructs to direct the expression of the sequences from the plant plastid. DNA sequences encoding for 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS), bromoxynil nitrilase (Bxn), phytoene desaturase (crtI (Misawa et al, (1993) *Plant Journal* 4:833-840, and (1994) *Plant Jour* 6:481-489), and acetohydroxyacid

synthase (AHAS (Sathasiivan *et al.* (1990) *Nucl. Acids Res.* 18:2188-2193)) are used in the expression constructs of the present invention to direct the expression of said herbicide tolerance nucleotide sequences from the plant plastid.

Transplastomic tobacco plants are identified which are homoplasmic for the DNA sequences encoding the herbicide tolerance genes. Homoplasmic plants demonstrate a high level of protein expression from the plastid. Furthermore, homoplasmic plants demonstrate a high level of tolerance for the respective herbicide. For example, as described in more detail in the example below, plants transformed to express EPSPS from the plastid demonstrate a high level of tolerance for the herbicide glyphosate. In addition, homoplasmic tobacco lines expressing nitrilase or phytoene desaturase demonstrate high levels of tolerance for the herbicides bromoxynil and norflurazon, respectively.

An artisan skilled in the art to which the present invention pertains will recognize that additional sequences may be employed to in the plastid expression constructs of the instant invention to produce herbicide tolerant plants. Other nucleic acid sequence which may find use in the plastid expression constructs herbicide tolerant plants include the *bar* gene for tolerance to glufosinate (DeBlock, *et al.* (1987) *EMBO J.* 6:2513-2519).

Furthermore, additional glyphosate tolerance genes may be employed in the constructs of the present invention. Additional glyphosate tolerant EPSPS genes are described in U.S. Patent Number 5,627,061, Padgett *et al.* (1996) *Herbicide Resistant Crops*, Lewis Publishers, 53-85, and in Penaloza-Vazquez, *et al.* (1995) *Plant Cell Reports* 14:482-487, the entireties of which are incorporated herein by reference.

It should be noted that the herbicide tolerance constructs of the present invention may also include sequences encoding genes involved in other stress tolerance genes, for example insect or disease resistance/tolerance genes. As described in more detail in the examples that follow, plastid expression constructs are used to regenerate plants which are resistant to the herbicide Buctril, and which also express the *Bacillus thuringiensis cry1Ac* protein.

In addition, the plastid expression constructs also find use in directing the production of human biological proteins (pharmaceutical proteins) from the plant plastid. As set forth in detail in the examples, constructs are provided for expression of aprotinin and human growth hormone in the plant plastid. Other sequences which may find use in the expression constructs of the present invention for the production of human biologics include sequences encoding for insulin or insulin precursors. However, the skilled artisan

will recognize that many nucleotide sequences encoding for human biologics may be employed in the constructs of the present invention to direct their expression from a plant plastid such as those described in Goodman and Gelman (1990) *Pharmacological Basis of Therapeutics*, Pergaman Press, 8<sup>th</sup> Edition, Sections 14 and 15. As, it is contemplated that  
5 any protein for which the nucleotide sequence has been identified can be used in the constructs of the present invention.

The present invention also provides methods for producing a pharmaceutical protein with a non-methionine N-terminus in a plant plastid. In general, the methods comprise expressing a fusion protein including a ubiquitin gene fused to a protein of  
10 interest in a plastid. The ubiquitin gene is obtained from a natural source and cloned into an appropriate vector, as described in WO 88/02406, supra, the disclosure of which is incorporated herein by reference, or it is synthesized chemically, using, e.g., the method described by Ecker et al., J. Biol. Chem., 262:3524-3527 (1987) and Ecker et al., J. Biol. Chem., 262: 14213-14221 (1987), the disclosures of which are incorporated by reference.  
15 The ubiquitin fusion proteins are recognized by ubiquitin protease, contrary to previous reports (Vierstra (1996) *Plant Mol. Biol.* 32:275-302), which cleaves immediately downstream of the carboxy terminal glycine residue of ubiquitin. This property has allowed production of recombinant proteins containing N-terminal residues other than methionine (Baker (1996) *Current Opin. Biotech.* 7:541-546).

20 Additional methods for the production of pharmaceutical proteins with a non-methionine N-terminus in a plant plastid are also provided. As described more fully in the Examples below, constructs are prepared to direct the production of a methionine-hGH (M-hGH) in a plant cell plastid. The constructs generally comprise a transcriptional initiation region and a DNA sequence encoding hGH. Surprisingly, N-terminal amino  
25 acid sequencing of the extracted hGH produced in transplastomic plants reveals that the N-terminal methionine is cleaved from the mature hGH protein, producing hGH with an alanine N-terminus (A-hGH). This result indicates the interaction of the expressed hGH with a methionine amino peptidase (MAP) in the plant cell. While it is anticipated that any amino acid may follow in the N-terminal methionine, the second amino acid is  
30 preferably selected from the group consisting of alanine, cysteine, glycine, proline, serine, threonine, and valine.

As described in more detail below, nucleic acid sequences encoding for the human growth hormone (hGH) are employed in plastid expression constructs of the present

invention. Further, transplastomic tobacco plants containing such constructs demonstrate a high level of expression of hGH. In addition, the hGH protein expressed from the plant plastid exhibits characteristics of proper processing as well as proper protein folding.

Human growth hormone (hGH) participates in much of the regulation of normal human growth and development. This 22,000 dalton pituitary hormone exhibits a multitude of biological effects including linear growth (somatogenesis), lactation, activation of macrophages, insulin-like and diabetogenic effects among others (Chawla, *Ann. Rev. Med.*(1983) 34:519; Edwards, *et al.*, *Science* (1988) 239:769; Thorner *et al.*, *J. Clin. Invest.* (1988) 81:745). hGH is a member of a family of homologous hormones that include placental lactogens, prolactins, and other genetic and species variants or growth hormone (Nicoll, *et al.*, *Endocrine Reviews*(1986) 7:169). hGH is unusual among these in that it exhibits broad species specificity and binds to either the cloned somatogenic (Leung, *et al.*, *Nature* (1987) 33:537) or prolactin receptor (Boutin, *et al.*, *Cell* (1988) 53:69). The primary use of hGH is in the treatment of hypopituitary dwarfism in children. Additional indications are in treatment of Turner syndrome, chronic renal failure, HIV wasting syndrome and the treatment of the elderly and critically ill (Tritos, *et al.* (1998) *Am. J. Med.* 105:44-57).

As produced in the pituitary gland, hGH enters the secretory system, coincident with removal of its signal peptide and formation of two disulfide bonds (Chawla, *et al.* (1983) *supra*). In the pituitary gland, removal of the signal peptide from hGH (also referred to as human somatotropin or hST) during secretion leaves phenylalanine as the N-terminal amino acid (Chawla, *et al.* (1983) *Annu. Rev. Med.* 34:519-547). As normal translation in plastids initiates at methionine, a ubiquitin-hGH fusion was designed to yield a phenylalanine N-terminus (F-hGH) in the final hGH product.

Surprisingly, although ubiquitin protease was previously reported to not be present in chloroplasts (Vierstra (1996) *Plant Mol. Biol.* 32:275-302), the ubiquitin-hGH fusion was processed during synthesis, accumulation or purification from the plants to produce a phenylalanine N-terminus hGH product (F-hGH). The control construct carrying the full-length cDNA encoded methionine and alanine as the first amino acids of hGH.

As described in the Examples below, constructs comprising nucleic acid sequences encoding aprotinin (also known as bovine pancreatic trypsin inhibitor, BPTI) were employed in plastid expression constructs of the present invention. Aprotinin is a basic protein present in several bovine organs and tissues, such as the lymph nodes, pancreas,



lungs, parotid gland, spleen and liver. Aprotinin is known to inhibit various serine proteases, including trypsin, chymotrypsin, plasmin and kallikrein, and is used therapeutically in the treatment of acute pancreatitis, various stages of shock syndrome, hyperfibrinolytic hemorrhage and myocardial infarction. In addition, administration of

5 aprotinin in high doses significantly reduces blood loss in connection with cardiac surgery, including cardiopulmonary bypass (Bidstrup, *et al.* (1989) *Cardiovasc Surg.* 44:640-645)

In developing the constructs, the various fragments comprising the regulatory regions and open reading frame may be subjected to different processing conditions, such as ligation, restriction enzyme digestion, PCR, *in vitro* mutagenesis, linkers and adapters

10 addition, and the like. Thus, nucleotide transitions, transversions, insertions, deletions, or the like, may be performed on the DNA which is employed in the regulatory regions or the DNA sequences of interest for expression in the plastids. Methods for restriction digests, Klenow blunt end treatments, ligations, and the like are well known to those in the art and are described, for example, by Maniatis *et al.* (in *Molecular Cloning: A Laboratory*

15 *Manual* (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

During the preparation of the constructs, the various fragments of DNA will often be cloned in an appropriate cloning vector, which allows for amplification of the DNA, modification of the DNA or manipulation of the DNA by joining or removing sequences, linkers, or the like. Preferably, the vectors will be capable of replication to at least a

20 relatively high copy number in *E. coli*. A number of vectors are readily available for cloning, including such vectors as pBR322, vectors of the pUC series, the M13 series vectors, and pBluescript vectors (Stratagene; La Jolla, CA).

In order to provide a means of selecting the desired plant cells, vectors for plastid transformation typically contain a construct which provides for expression of a selectable

25 marker gene. Marker genes are plant-expressible DNA sequences which express a polypeptide which resists a natural inhibition by, attenuates, or inactivates a selective substance, including, but not limited to, antibiotic, herbicide *etc.*

Alternatively, a marker gene may provide some other visibly reactive response, *i.e.*, may cause a distinctive appearance or growth pattern relative to plants or plant cells not

30 expressing the selectable marker gene in the presence of some substance, either as applied directly to the plant or plant cells or as present in the plant or plant cell growth media.

In either case, the plants or plant cells containing such selectable marker genes will have a distinctive phenotype for purposes of identification, *i.e.*, they will be

distinguishable from non-transformed cells. The characteristic phenotype allows the identification of cells, cell groups, tissues, organs, plant parts or whole plants containing the construct.

Detection of the marker phenotype makes possible the selection of cells having a second gene to which the marker gene has been linked. This second gene typically comprises a desirable phenotype which is not readily identifiable in transformed cells, but which is present when the plant cell or derivative thereof is grown to maturity, even under conditions wherein the selectable marker phenotype itself is not apparent.

The use of such a marker for identification of plant cells containing a plastid construct has been described by Svab *et al.* (1993, *supra*). In the examples provided below, a bacterial *aadA* gene is expressed as the marker under the regulatory control of chloroplast 5' promoter and 3' transcription termination regions, specifically the regulatory regions of the *psbA* gene (described in Staub *et al.*, *EMBO J.*(1993) 12(2):601-606). Numerous additional promoter regions can also be used to drive expression of the selectable marker gene, including various plastid promoters and bacterial promoters which have been shown to function in plant plastids.

Expression of the *aadA* gene confers resistance to spectinomycin and streptomycin, and thus allows for the identification of plant cells expressing this marker. The *aadA* gene product allows for continued growth and greening of cells whose chloroplasts comprise the selectable marker gene product. Cells which do not contain the selectable marker gene product are bleached. Selection for the *aadA* gene marker is thus based on identification of plant cells which are not bleached by the presence of streptomycin, or more preferably spectinomycin, in the plant growth medium.

A number of markers have been developed for use with plant cells, such as resistance to chloramphenicol, the aminoglycoside G418, hygromycin, or the like. Other genes which encode a product involved in chloroplast metabolism may also be used as selectable markers. For example, genes which provide resistance to plant herbicides such as glyphosate, bromoxynil or imidazolinone may find particular use. Such genes have been reported (Stalker *et al.*, *J. Biol. Chem.* (1985) 260:4724-4728 (glyphosate resistant EPSP); Stalker *et al.*, *J. Biol. Chem.* (1985) 263:6310-6314 (bromoxynil resistant nitrilase gene); and Sathasivan *et al.*, *Nucl. Acids Res.* (1990) 18:2188 (AHAS imidazolinone resistance gene)).

Stable transformation of tobacco plastid genomes by particle bombardment is reported (Svab *et al.* (1990), *supra*) and Svab *et al.* (1993), *supra*). The methods described therein may be employed to obtain plants homoplasmic for plastid expression constructs.

5 Generally, bombarded tissue is cultured for approximately 2 days on a cell division-promoting media, after which the plant tissue is transferred to a selective media containing an inhibitory amount of the particular selective agent, as well as the particular hormones and other substances necessary to obtain regeneration for that particular plant species. Shoots are then subcultured on the same selective media to ensure production and  
10 selection of homoplasmic shoots.

Transplastomic tobacco plants are analyzed for a pure population of transformed plastid genomes (homoplasmic lines). Homoplasmy is verified using Southern analysis employing nucleic acid probes spanning a region of the transgene and chloroplast genome (i.e. the insertion region). Transplastomic plants which are heteroplasmic (i.e. contain a  
15 mixture of plastid genomes containing and lacking the transgene) are characterized by a hybridization pattern of wild type and transgenic bands. Homoplasmic plants show a hybridization pattern lacking the wild type band.

Alternatively, homoplasmy may be verified using the polymerase chain reaction (PCR). PCR primers are utilized which are targeted to amplify from sequences from the  
20 insertion region. For example, a pair of primers may be utilized in a PCR reaction. One primer amplifies from a region in the transgene, while the second primer amplifies from a region proximal to the insertion region towards the insertion region. A second PCR reaction is performed using primers designed to amplify the region of insertion.

Transplastomic lines identified as homoplasmic produce the expected size fragment in the  
25 first reaction, while they do not produce the predicted size fragment in the second reaction.

Where transformation and regeneration methods have been adapted for a given plant species, either by *Agrobacterium*-mediated transformation, bombardment or some other method, the established techniques may be modified for use in selection and regeneration methods to produce plastid-transformed plants. For example, the methods  
30 described herein for tobacco are readily adaptable to other solanaceous species, such as tomato, petunia and potato.

For transformation of soybean, particle bombardment as well as *Agrobacterium*-mediated nuclear transformation and regeneration protocols have been described (Hinchee

*et al.* USPN 5,416,011, and Christou *et al.* USPN 5,015,580). The skilled artisan will recognize that protocols described for soybean transformation may be used

In *Brassica*, *Agrobacterium*-mediated transformation and regeneration protocols generally involve the use of hypocotyl tissue, a non-green tissue which might contain a low plastid content. Thus, for *Brassica*, preferred target tissues would include microspore-derived hypocotyl or cotyledonary tissues (which are green and thus contain numerous plastids) or leaf tissue explants. While the regeneration rates from such tissues may be low, positional effects, such as seen with *Agrobacterium*-mediated transformation, are not expected, thus it would not be necessary to screen numerous successfully transformed plants in order to obtain a desired phenotype.

For cotton, transformation of *Gossypium hirsutum* L. cotyledons by co-cultivation with *Agrobacterium tumefaciens* has been described by Firoozabady *et al.*, *Plant Mol. Bio.* (1987) 10:105-116 and Umbeck *et al.*, *Bio/Technology* (1987) 5:263-266. Again, as for *Brassica*, this tissue may contain insufficient plastid content for chloroplast transformation. Thus, as for *Brassica*, an alternative method for transformation and regeneration of alternative target tissue containing chloroplasts may be desirable, for instance targeting green embryogenic tissue.

Other plant species may be similarly transformed using related techniques. Alternatively, microprojectile bombardment methods, such as described by Klein *et al.* (*Bio/Technology* 10:286-291) may also be used to obtain nuclear transformed plants comprising the viral single subunit RNA polymerase expression constructs described herein. Cotton transformation by particle bombardment is reported in WO 92/15675, published September 17, 1992. Suitable plants for the practice of the present invention include, but are not limited to, soybean, cotton, alfalfa, oil seed rape, flax, tomato, sugar beet, sunflower, potato, tobacco, *maize*, wheat, rice and lettuce.

The vectors for use in plastid transformation preferably include means for providing a stable transfer of the plastid expression construct and selectable marker construct into the plastid genome. This is most conveniently provided by regions of homology to the target plastid genome. The regions of homology flank the construct to be transferred and provide for transfer to the plastid genome by homologous recombination, via a double crossover into the genome. The complete DNA sequence of the plastid genome of tobacco has been reported (Shinozaki *et al.*, *EMBO J.* (1986) 5:2043-2049). Complete DNA sequences of the plastid genomes from liverwort (Ohshima *et al.*, *Nature*

(1986) 322:572-574) and rice (Hiratsuka *et al.*, *Mol. Gen. Genet.* (1989) 217:185-194), have also been reported.

Where the regions of homology are present in the inverted repeat regions of the plastid genome (known as IRA and IRB), two copies of the transgene are expected per transformed plastid. Where the regions of homology are present outside the inverted repeat regions of the plastid genome, one copy of the transgene is expected per transformed plastid. The regions of homology within the plastid genome are approximately 1kb in size. Smaller regions of homology may also be used, and as little as 100 bp can provide for homologous recombination into the plastid genome. However, the frequency of recombination and thus the frequency of obtaining plants having transformed plastids decreases with decreasing size of the homology regions.

Examples of constructs having regions of homology within the plastid genome are described in Svab *et al.* (1990 *supra*), Svab *et al.* (1993 *supra*) and Zoubenko *et al.* (*Nuc Acid Res* (1994) 22(19):3819-3824).

As described in more detail in the examples below, constructs are described which provide for enhanced expression of DNA sequences in plant plastids. Various promoter/ribosome binding site sequences are employed to direct expression in plant plastids. Promoter sequences of the 16S ribosomal RNA operon (*Prrn*) are linked to a ribosome binding site (RBS) derived from the T7 bacteriophage gene 10 leader sequence (G10L). DNA sequences expressed under the regulatory control of the *Prrn*/G10L sequence show a significantly higher level of protein expression than those levels obtained under the control of other promoter/RBS combinations, while expression of mRNA may or may not be higher in these plants.

In the examples below, nucleic acid sequences encoding CP4 EPSP synthase (USPN 5,633,435) are placed into expression constructs for expression of EPSP synthase enzyme from the plant plastid. Furthermore, a DNA sequence encoding for hGH (USPN 5,424,199) is also placed into expression construct for the expression of human growth hormone from the plant plastid. The constructs prepared utilize a ribosome binding site designed after the T7 bacteriophage gene 10 leader (G10L) to increase the expression of the nucleic acid sequences in the plant plastid.

Plastid expression constructs encoding for the expression of EPSPS and hGH are introduced via a chloroplast transformation vector.

Tobacco lines containing the native encoding sequence to the EPSPS enzyme expressed in plastids under the control of the *Prrn*/G10L promoter/ribosome binding site sequence demonstrate a significantly higher level of protein expression than those levels obtained from EPSPS expressed under the control of the *Prrn*/rbcL RBS sequence.

5 However, EPSPS mRNA is expressed at a higher level in plants expressing CP4 EPSPS from the plastid under the control of the *Prrn*/rbcL(RBS). These results indicate that translation from transcripts containing the T7 bacteriophage gene 10 ribosome binding site is more efficient. In addition, protein expression levels of EPSPS obtained from transplastomic tobacco lines expressing EPSPS under the control of the *Prrn*/G10L RBS  
10 provide for a high level of glyphosate tolerance.

Furthermore, transplastomic tobacco lines transformed to express hGH under the control of the *Prrn*/G10L promoter/ribosome binding site sequence demonstrate a significantly higher level of protein expression than those levels obtained from hGH expressed under the control of the *PpsbA* promoter/RBS sequence.

15 Increases in protein expression levels of at least approximately 200 fold may be obtained from constructs utilizing *Prrn*/G10L ribosome binding site for expression of EPSPS and hGH over the expression levels obtained from other promoter/RBS combinations for plastid expression. In addition, protein levels obtained from plastid expression constructs utilizing the *Prrn*/G10L promoter/RBS sequence may accumulate 50  
20 to 3500 fold higher levels than from nuclear expression constructs. Thus, inclusion of the G10L ribosome binding site in plastid expression constructs may find use for increasing the levels of protein expression from plant plastids.

Furthermore, the constructs of the present invention may also include sequences to target the expressed protein to a particular suborganellar region, for example, the thylakoid  
25 lumen of the chloroplast. For example, as described in the examples below, a nucleotide sequence encoding a peptide from the plastid genome cytochrome *f* targets the expressed aprotinin protein to the thylakoid membrane. Such targeting of expressed proteins may provide for a compartmentalization of the protein allowing for increased oxidative stability and proper protein folding.

30

The invention now being generally described, it will be more readily understood by reference to the following examples which are included for purposes of illustration only and are not intended to limit the present invention.

## EXAMPLES

### Example 1 Expression Constructs

5        Constructs and methods for use in transforming the plastids of higher plants are described in Zoubenko *et al.* (*Nuc Acid Res* (1994) 22(19):3819-3824), Svab *et al.* (*Proc. Natl. Acad. Sci.*(1990) 87:8526-8530 and *Proc. Natl. Acad. Sci.*(1993) 90:913-917) and Staub *et al.* (*EMBO J.* (1993) 12:601-606). Constructs and methods for use in transforming plastids of higher plants to express DNA sequences under the control of a  
10        nuclearly encoded, plastid targeted T7 polymerase are described in U.S. Patent Number 5,576,198. The complete DNA sequences of the plastid genome of tobacco are reported by Shinozaki *et al.* (*EMBO J.* (1986) 5:2043-2049). All plastid DNA references in the following description are to the nucleotide number from tobacco.

      The complete nucleotide sequence encoding the tobacco cytochrome *f* (*petA*) is  
15        described in Bassham *et al.*, (1991) *J Biol Chem* 266:23606-23610 and Konishi *et al.* (1993) *Plant Cell Physiol* 34:1081-1087.

#### 1A. Promoter/Ribosome Binding Site Sequences

      The promoter region of the plastid 16S ribosomal RNA operon (*Prrn*) is linked to a  
20        synthetic ribosome binding site (RBS) patterned on the plastid *rbcL* gene leader to create the *Prrn/rbcLRBS* fragment. The *Prrn/rbcLRBS* sequence is as described in Svab *et al.* (1993, *supra*) for the *Prrn/rbcL(S)* fragment.

      The promoter region of the plastid *psbA* promoter (*PpsbA*) and terminator sequences (*TpsbA*) are described in Staub *et al.* (1993, *EMBO J.*, 12, 601-606).

25        The *Prrn/G10L* sequence was constructed by annealing two oligonucleotide sequences, T7lead1 and T7lead2 (Table 1), to create the G10L plastid ribosome binding site (Figure 1). The G10L sequence was ligated to the 3' terminus of the *Prrn* promoter sequence as an *EcoRI/NcoI* fragment to create the *Prrn/G10L* sequence.

Table 1

T7lead1	5'-AAT TGT AGA AAT AAT TTT GTT TAA CTT TAA GAA GGA GAT ATA CC-3'
5 T7lead2	5'-CAT GGG TAT ATC TCC TTC TTA AAG TTA AAC AAA ATT ATT TCT AC-3'

Chimeric genes are preferably inserted into the expression vector to direct their transcription from the *Prrn* promoter. Thus, in the plastid genome, chimeric genes are transcribed from the *Prrn*/RBS promoter, or the *Prrn*/G10L promoter in the plant plastid.

10

#### 1B. CP4 EPSPS Plastid Expression Constructs

A plastid expression vector pMON30117 is constructed from a precursor vector pPRV111B (Zoubenko, *et al.* 1994, *supra*, GenBank accession U12813). The vector pMON30117 carries a multiple cloning site for insertion of a passenger gene in a *Prrn*/rbcLRBS/*Trps16* expression cassette. The *Prrn*/rbcLRBS sequence is cloned into pPRV111B vector as an *EcoRI*/*NcoI* fragment, and the terminator region from the plastid *rps16* gene(*Trps16*) is cloned 3' of the *Prrn* promoter as a *HindIII*/*NcoI* fragment. The *Trps16* fragment comprises the *rps16* gene 3'-regulatory region from nucleotides 5,087 to 4,939 in the tobacco plasmid DNA.

The pPRV111B backbone of the vector pMON30117 contains a marker gene, *aadA*, for selection on spectinomycin and streptomycin, and *rps 7/12* for the integration, by homologous recombination, of the passenger DNA into *tmV-rps7/12* intergenic region.

The plastid expression construct pMON30118 was prepared by cloning the native CP4 EPSPS gene fused with the N-terminal five (5) amino acids from the plastid *rbcL* (described in Svab *et al.*, 1993 *supra*) gene as an *NcoI*/*SmaI* fragment into the multiple cloning site of the vector pMON30117.

The plastid expression construct pMON30123 is essentially the same as pMON30118 with the exception of the deletion of the N-terminal five (5) amino acids from the plastid *rbcL*.

The plastid expression construct pMON30130 was created by replacing the native CP4 EPSPS of pMON30123, with a synthetic CP4 gene. This construct also lacks the N-terminal 5 amino acid fusion from the plastid *rbcL* gene.



The plastid expression construct pMON38773 was constructed by replacing the *Prrn*/RBS sequence of pMON30123 with the *Prrn*/G10L promoter sequence described above. The EPSPS DNA sequence of pMON38773 also lacks the N-terminal 5 amino acid fusion from the plastid *rbcL* gene.

5 A plastid expression construct, pMON38766 was constructed using the promoter from T7 phage gene 10 (P-T7), including G10L, CP4 (native) gene coding region, and the terminator sequence from plastid *rps16* gene (Trps16).

A plastid expression construct, pMON38797 was constructed using the promoter from T7 phage gene 10 (P-T7), including G10L, CP4 (synthetic) gene coding region,  
10 terminator from plastid *rps16* gene (Trps16).

A plastid expression construct, pMON38798 was constructed using the promoter of the 16SrDNA operon (*Prrn*), G10L, CP4 (synthetic) gene coding region, terminator from plastid *rps16* gene (Trps16).

A plastid expression construct, pMON38793 was constructed using the promoter  
15 of the 16SrDNA operon (*Prrn*), a synthetic ribosome binding site (RBS) patterned from the plastid *rbcL* gene, the glyphosate tolerant *Petunia* EPSP synthase gene (P-EPSPS, Padgett, *et al.* (1987) *Arch. Biochem. Biophys.* 258:564-573) carrying the mutation Glycine to Alanine at amino acid position 101, terminator from plastid *rps16* gene (Trps16).

20 A plastid expression construct, pMON38796 was constructed using the promoter of the 16SrDNA operon (*Prrn*), synthetic ribosome binding site (RBS) patterned from the plastid *rbcL* gene, the glyphosate tolerant *Achromobacter* (strain LBAA) EPSP synthase gene (U.S. Patent Number 5,627,061, the entirety of which is incorporated herein by reference) carrying the mutation Glycine to Alanine at amino acid position 100, terminator  
25 from plastid *rps16* gene (Trps16).

A plastid expression construct, pMON45204, was constructed using the promoter of the 16SrDNA operon (*Prrn*) with the G10L, the glyphosate tolerant *Pseudomonas* (strain LBAA) EPSP synthase gene carrying the mutation Glycine to Alanine at amino acid position 100, terminator from plastid *rps16* gene (Trps16).

30 A plastid expression construct, pMON45201, was constructed using the promoter of the 16SrDNA operon (*Prrn*), synthetic ribosome binding site (RBS) patterned from the plastid *rbcL* gene, wild-type glyphosate tolerant *Bacillus subtilis* *aroE* (EPSPS) (U.S. Patent Number 5,627,061) gene, terminator from plastid *rps16* gene (Trps16).

*1C. Bucril (bxn) Plastid Expression Constructs*

The *bxn* herbicide resistance gene (U.S. Patent Number 4,810,648, the entirety of which is incorporated herein by reference) was removed from the plasmid pBrx47 as an  
5 *Nco* I to *Asp*718 restriction fragment and cloned into *Nco*/*Asp*718 cut pUC120 resulting in plasmid pBrx87. Plasmid pBrx87 was then digested with *Nco*/*Xba* and cloned into the *Nco*/*Xba* sites of the plasmid pLAA21 which contains the *Prrn* plastid promoter and the *rpsL* 3' region for plastid expression. The resulting plasmid was designated pBrx89. Plasmid pBrx89 was digested with *Sac* I and *Hind* III and the 1.5 kb chimeric *bxn* gene  
10 with plastid expression signals was inserted into the *Sac*/*Hind* III sites of the tobacco plastid homology vector pOVZ44B (Zoubenko et al, Nuc Acids Res 22: 3819-3824 (1994)) to create plasmid pCGN5175.

To construct plasmid pCGN6114, plasmid pBrx90 (a Bluescript plasmid containing the *bxn* gene encoding the bromoxynil specific nitrilase) was digested with *Nco*  
15 *I*/*Asc* I and the *bxn* structural gene was substituted for the GUS gene in the *Nco*/*Asc* digested plasmid pCGN5063 resulting in plasmid pCGN6107. This plasmid contains the *bxn* gene under the control of the T7 promoter/gene10 leader at the 5' end and the *psbA*/T7 hybrid transcriptional terminator at the 3' end of the chimeric gene. This T7 promoter/*bxn* chimeric gene was excised from pCGN6107 as a *Hind* III/*Not* I DNA  
20 segment and moved into the chloromphenical plasmid BCSK+ (Stratagene) at the *Hind* III/*Not* sites to create plasmid pCGN6109. The chimeric gene was then moved as a *Hind* III/*Not* fragment from pCGN6109 into the chloroplast homology vector pOVZ44B described above to create plasmid pCGN6114. Tobacco plants transformed with pCGN6114 require the T7 RNA polymerase be provided in the plant plastid background to  
25 activate transcription of the chimeric *bxn* gene via the T7 promoter. This system has previously been detailed in McBride *et al.*, PNAS, 91:7301-7305 (1994) and McBride *et al.*, US Patent Number 5,576,198.

*1D. BXN/AHAS Plastid Expression Constructs*

30 A plastid expression construct, pCGN5026, is prepared to direct the expression of BXN and AHAS from the plant plastid. The AHAS nucleotide sequence (described in EP Publication Number 0 525 384 A2, the entirety of which is incorporated herein by reference) is translationally linked to the BXN nucleotide sequence (U.S. Patent Number

4,810,648, the entirety of which is incorporated herein by reference). The AHAS structural gene encoding acetohydroxyacid synthase was cloned from the plasmid pCGN4277 as an *Nco* I to *Age* DNA fragment into the *Nco*/*Xma* sites of plasmid pUC120 to create plasmid pCGN5022. This plasmid was then digested with the enzymes *Bam*H I and *Pst* and a 1.3 kb *Bam*/*Pst* DNA segment containing the *bxn* gene encoding the bromoxynil-specific nitrilase was excised from the plasmid pBrx26 and cloned into the *Bam*/*Pst* sites of pCGN5022 to create plasmid pCGN5023. Plasmid pCGN5023 contained a 3.3 kb DNA segment containing the AHAS/*bxn* operon segment and this fragment. This plasmid was cut at the unique *Pst* site and this *Pst* site was removed and replaced with a synthetic linker containing a unique *Xba* I restriction site generating plasmid pCGN5024. Plasmid pCGN5024 was digested with *Nco*/*Xba* and the 3.3 kb *Nco*/*Xba* DNA fragment was cloned into the plastid promoter cassette vector pLAA21(*Pst*) that had been digested with *Nco* and *Xba* to remove the GUS gene. The plasmid resulting from this cloning was designated plasmid pCGN5025 and contained the herbicide operon under the control of the plastid promoter *Prrn* and the *rpsL* 3' DNA segment. The entire chimeric herbicide operon under the control of the plastid expression elements was excised from pCGN5025 as a *Sac* I/*Pst* DNA fragment and cloned into the *Sac*/*Pst* sites of the plastid homology cassette vector pOVZ44B (Zoubenko *et al*, *Nuc Acids Res* 22:3819-3824 (1994)) to facilitate transfer into the tobacco chloroplast genome.

20

#### *1E. Bt cryIAC and bxn Plastid Expression Construct*

Plasmid pBrx9 (Stalker and McBride, (1987) *J Bacteriol* 169:955-960), an original clone from *Klebsiella* containing a *bxn* gene DNA segment, was used as a template to generate an ~450 bp *Bam*H I/*Cla* I PCR DNA fragment that encompasses the N-terminal end of the *bxn* gene and includes 44 bp of the 5' untranslated portion of the native gene. This fragment was exchanged with the ~400 bp *Bam*/*Cla* fragment in the plasmid pBrx90 resulting in plasmid pBrx90.1. This plasmid contains the entire *bxn* gene and the 44 bp untranslated 5' DNA segment. The *bxn* gene was excised from plasmid pBrx90.1 as a *Bam*/*Asc* I DNA segment and inserted into plasmid pCGN5146 at the *Bgl* II/*Asc* I sites to generate plasmid pCGN5191. Plasmid pCGN5146 is a pKK233-2 (Pharmacia) derivative containing the full-length *cryIAC* gene encoding the HD-73 Bt protoxin. Plasmid pCGN5191 then contains the *cryIAC* and *bxn* genes in an operon configuration with the *bxn* gene being the distal gene in the operon. Both genes are under the control of the *Ptac*

30

promoter for *E coli* expression in 5191. Plasmid pCGN5191 was digested with *Nco/Asc* and the *Nco/Asc* DNA fragment containing the *Bt/bxn* operon was cloned into the *Nco/Asc* sites of the chloroplast homology vector pCGN5155, a derivative of pOVZ44B. The resulting plasmid, pCGN5197 contains the *Bt/bxn* operon under the control of the *Prn* plastid promoter and *rpsL* transcription terminator regions. This plasmid facilitated transfer of the *Bt/bxn* chimeric operon into the tobacco plastid genome.

#### 1F. Phytoene desaturase Plastid Expression Constructs

The *crtI* gene was obtained as a *Hind III/Sal I* PCR fragment from the original plasmid containing the *Erwinia carotova crt* operon (Misawa et al, (1994) *Plant Jour* 6:481-489)) and cloned as a *Hind III/Sal I* DNA segment into BCSK+ (Stratagene) at the *Hind III/Sal I* sites to generate plasmid pCGN5172. The *crtI* fragment was cloned from pCGN5172 as an *Nco I/Sal I* fragment into pCGN5038 (a derivative of pOVZ44B) to create the plastid expression construct pCGN5177. This construct directs the expression of the *crtI* sequence from the *Prn* promoter and the *rps16* terminator sequence. This plasmid facilitated the transfer of the chimeric *crtI* gene into the tobacco plastid genome.

#### 1G. hGH Expression Constructs for Plant Transformation

##### Nuclear Expression Constructs

The construct pWRG4747 was constructed to direct the expression of hGH in the plant nuclear genome. This vector contains the hGH operably linked to the Figwort Mosaic Virus promoter (USPN 5,378,619, the entirety is incorporated herein by reference) and the CTP2 leader for directing the hGH protein into the plastid. The FMV/CTP2L::hGH::NpA fragment is cloned along with the DNA sequence conferring resistance to Kanamycin between the right and left borders (RB and LB) of the transfer DNA (tDNA) of *Agrobacterium tumefaciens* to direct the integration into the nuclear genome.

The nuclear transformation vector pWRG4744 contains essentially the same elements as pWRG4747 except the construct lacks the CTP2 leader and the hGH protein is directed to the plant cell cytoplasm.

### Plastid Expression Constructs

The plastid expression vector pWRG4838 was constructed using the full length hGH gene expressed from the promoter and terminator region from the psbA gene, PpsbA and TpsbA, respectively (described in Staub *et al.* (1993), *supra*). This chimeric promoter-gene-terminator fusion (PpsbA::hGH::TpsbA) is cloned adjacent to the selectable marker gene *aadA* also driven by the plastid expression elements of the psbA gene. The two chimeric gene sequences are cloned into a vector between two sequences which direct the integration of the chimeric gene sequences into the tobacco plastid genome upstream of the plastid 16SrDNA. This is joined to a 1 kb Ampicillin resistance gene which provides for selection of *E. coli* containing the construct and the pUC origin of replication for plasmid maintenance in *E. coli*.

The plastid expression construct pMON38755 was prepared using the hGH DNA sequence translationally fused at the N-terminus with the yeast ubiquitin gene (Ozkaynak, *et al.* (1984) *Nature* 312:663-666), creating the Ubi-hGH fusion gene. The Ubi-hGH fusion gene is cloned next to the *aadA* gene for selection of transplastomic tobacco on media containing spectinomycin or streptomycin (from pPRV112B described in Zoubenko *et al.* (1994) *supra*). Sequences are included for the homologous recombination of sequences encoding for hGH and *aadA* expression. These sequences are obtained from the vector pPRV112B described in Zoubenko *et al.* (1994, *supra*). These sequences are joined to a 1 kb ampicillin resistance gene which provides for selection of *E. coli* containing the construct and the pUC origin of replication for plasmid maintenance in *E. coli*.

The plastid expression construct pMON38794 contains essentially the same elements as pMON38755, with the exception that the 0.15 kb psbA promoter sequence is replaced with the *Prm/G10L* promoter sequence described above.

### *1H. Constructs for the Expression of Aprotinin in Plastids*

A series of constructs were prepared to direct the expression of the pharmaceutical protein aprotinin from the plastid. The nucleic acid sequence encoding for aprotinin (Figure 2) was cloned into a plastid expression construct to control the expression of aprotinin from the T7 gene 10 leader promoter which is induced from a nuclearly expressed, plastid targeted T7 Polymerase. The constructs used in which the aprotinin sequence was cloned are as described in U.S. Patent Number 5,576,198, the entirety of

which is incorporated herein by reference. The plastid transformation vector pCGN6146 is designed by replacing the DNA sequence encoding for GUS from pCGN4276 (described in USPN 5,576,198) with the coding sequence of aprotinin. The tobacco plastid transformation construct pCGN6147 contains the same elements as pCGN6146 except pCGN6147 contains the six 5' amino acids of the GUS encoding sequence ligated to the 5' terminus of the aprotinin encoding sequence. The six amino acids of the 5' terminus of the GUS nucleotide sequence are included to aid in the translation of the aprotinin protein. The tobacco plastid transformation vector pCGN6156 is essentially the same as pCGN4276 except the coding region of aprotinin is cloned to the 3' end of the GUS coding sequence. Thus, pCGN6156 contains as operably linked the T7 promoter, a DNA sequence encoding for GUS fused with the DNA sequence encoding for aprotinin and the psbA 3' transcription termination sequence.

A plastid expression construct, pCGN6154, was constructed from pCGN4276 by replacing the GUS coding sequence with the aprotinin protein operably linked to the 3' terminus of the coding sequence of cytochrome *f* (*petA*) of the tobacco chloroplast. Thus, pCGN6154 contains the T7 promoter sequence operably linked to the nucleotide sequence of *petA* and aprotinin. The *petA* sequence is included to direct the expressed aprotinin protein to the thylakoid.

## 20 **Example 2 Plant Transformation**

### 2A. Nuclear Transformation

Tobacco plants transformed to express the constructs pWRG4744 and pWRG4747 in the nucleus of a plant cell may be obtained as described by Horsch *et al.* (*Science* (1985) 227:1229-1232).

### 2B. Plastid Transformation

Tobacco plastids are transformed by particle gun delivery of microprojectiles as described by Svab and Maliga (*Proc. Natl. Acad. Sci.* (1993) 90:913-917), and described herein.

Dark green, round leaves are cut, preferably from the middle of the shoots, from 3-6 week old *Nicotiana tabacum* cv. Havana which have been maintained *in vitro* on hormone free MS medium (Murashige and Skoog, (1962) *Physiol Plant.* 15, 473-497) supplemented with B5 vitamins in Phytatrays or sundae cups with a 16 hour photoperiod at

24°C. Each cut leaf is then placed adaxial side up on sterile filter paper over tobacco shoot regeneration medium (TSO medium: MS salts, 1mg/l *N*<sup>6</sup>-benzyladenine, 0.1mg/l 1-naphthaleneacetic acid, 1 mg/l thiamine, 100mg/l inositol, 7g/l agar pH 5.8 and 30g/l sucrose). Leaves are preferably placed in the center of the plate with as much contact with the medium as possible. The plates are preferably prepared immediately prior to use, but may be prepared up to a day before transformation by particle bombardment by wrapping in plastic bags and storing at 24°C overnight.

Tungsten or gold particles are sterilized for use as microcarriers in bombardment experiments. Particles (50mg) are sterilized with 1 ml of 100% ethanol, and stored at -20°C or -80°C. Immediately prior to use, particles are sedimented by centrifugation, washed with 2 to 3 washes of 1 ml sterile deionised distilled water, vortexed and centrifuged between each wash. Washed particles are resuspended in 500 µl 50% glycerol.

Sterilized particles are coated with DNA for transformation. Twenty-five microliter aliquots of sterilized particles are added to a 1.5 ml microfuge tube, and 5 µg of DNA of interest is added and mixed by tapping. Thirty-five microliters of a freshly prepared solution of 1.8M CaCl<sub>2</sub> and 30 mM spermidine is added to the particle/DNA mixture, mixed gently, and incubated at room temperature for 20 minutes. The coated particles are sedimented by centrifuging briefly. The particles are washed twice by adding 200µl 70% ethanol, mixing gently, and centrifuging briefly. The coated particles are resuspended in 50µl of 100% ethanol and mixed gently. Five to ten microliters of coated particles are used for each bombardment.

Transformation by particle bombardment is carried out using the PDS 1000 Helium gun (Bio Rad, Richmond, CA) using a modified protocol described by the manufacturer.

Plates containing the leaf samples are placed on the second shelf from the bottom of the vacuum chamber and bombarded using the 1100 p.s.i. rupture disk. After bombardment, petriplates containing the leaf samples are wrapped in plastic bags and incubated at 24°C for 48 hours.

After incubation, bombarded leaves are cut into approximately 0.5 cm<sup>2</sup> pieces and placed abaxial side up on TSO medium supplemented with 500 µg/ml spectinomycin.

After 3 to 4 weeks on the selection medium, small, green spectinomycin resistant shoots will appear on the leaf tissue. These shoots will continue to grow on spectinomycin containing medium and are referred to as primary putative transformants.

When the primary putative transformants have developed 2 to 3 leaves, 2 small pieces (approximately 0.5 cm<sup>2</sup>) are cut from each leaf and used for either selection or for a second round of shoot regeneration. One piece is placed abaxial side up on plates containing TSO medium supplemented with 500 µg/ml spectinomycin, and the other piece is placed abaxial side up on TSO medium supplemented with 500 µg/ml each of spectinomycin and streptomycin. Positive transformants are identified as the shoots which form green callus on the TSO medium containing spectinomycin and streptomycin.

After 3 to 4 weeks, the tissue placed on TSO medium containing only spectinomycin, which has been identified as positive on the TSO medium with spectinomycin and streptomycin, will develop green shoots. Two to four shoots of each positive transformant are selected and transferred to TSO medium supplemented with 500 µg/ml spectinomycin for generation of roots. Southern analysis is performed on 2 shoots to confirm homoplasmy as described below. Shoots from homoplasmic events are transferred to the greenhouse for seed production, while transformants which are not homoplasmic are sent through a second round of regeneration on TSO medium with 500 µg/ml spectinomycin to attain homoplasmy.

### **Example 3 Analysis of Transplastomic Tobacco Plants Transformed with Herbicide Tolerance Constructs**

#### **3A. Southern Analysis**

Transformed plants selected for marker *aadA* marker gene expression are analyzed to determine whether the entire plastid content of the plant has been transformed (homoplasmic transformants). Typically, following two rounds of shoot formation and spectinomycin selection, approximately 50% of the transgenic plantlets which are analyzed are homoplasmic, as determined by Southern blot analysis of plastid DNA. Homoplasmic plantlets are selected for further cultivation.

Genomic DNA is isolated from transformed tobacco plants, electrophoresed, and transferred to filters as described in Svab *et al.* ((1993), *Proc Natl Acad Sci*, 90:913-917).

Homoplasmic tobacco plants transformed to express CP4 EPSPS in plastids were identified using a probe prepared from a 2.4 kb *EcoRI/EcoRV* fragment from the vector pOVZ2 (similar to pOVZ15 described in Zoubenko, *et al.* 1994, *supra*). The 2.4 kb probe fragment encompasses part of the targeting sequence.



Results of the Southern hybridizations identified 3 homoplasmic lines from tobacco transformed with the constructs pMON30123 and pMON30130 and 1 line from tobacco transformed with pMON38773 for further analysis.

5 The complete disappearance of the 3.27 Kb native tobacco *Bam*HI fragment in the lines 30123-19-1A, 30123-23-2A, 30123-18-1B, 30130-51-2A, 30130-51-2P, 30130-57-1P, and 38773-6 with a probe covering the region of integration, and the appearance of expected sized bands for the inserted DNA fragments in those transformants, 5.14 kb and 0.9 kb, establishes that the transformed plants are homoplasmic for the intended constructs.

10 Results of the Southern hybridizations identified 3 homoplasmic lines from tobacco transformed with pCGN5177, lines 74-1B-P, 74-2 and 74-7.

Transplastomic 5175 and 6114 tobacco lines were analyzed by Southern hybridization for homoplasmy as described above. Results of the Southern hybridizations identified 4 homoplasmic lines from tobacco transformed with pCGN6114.

15 Results from hybridizations of 5175 transplastomic tobacco lines identified one line, 76-4A-F, as homoplasmic, and a second line as 95% homoplasmic.

Homoplasmic tobacco plants transformed to express BXN/AHAS in plastids were identified using Southern hybridizations as described above.

20 Results of the Southern hybridizations identified 14 homoplasmic lines from tobacco transformed with pCGN5026. The filters were reprobed with a BXN gene fragment, and 21 lines were found to contain BXN, 14 lines of which were homoplasmic.

### 3B. Northern Analysis

25 In order to determine the level of transcription of the EPSPS, BXN or AHAS mRNA expressed in the transplastomic tobacco plants, Northern blot hybridizations were performed with total RNA isolated from each of the lines identified. Total RNA was isolated using TRIzol reagent (Gibco-BRL Life Technologies, Gaithersburg, MD) according to the manufacturers protocol. Total RNA, 2µg, was separated on a denaturing agarose gel and transferred to nylon membrane (Maniatis *et al.*, 1989, *supra*). Radioactive probes for hybridizations were prepared using random primer labeled (using Random Primer labeling kit from Boehringer Mannheim) CP4 EPSPS, phytoene desaturase, BXN, 30 or AHAS fragments and hybridizations were carried out in 2x SSPE (Maniatis, *et al.*, 1989, *supra*), at 60°C. Filters were stripped and reprobed with a plastid 16S ribosomal

RNA gene probe (from pPRV112A, Zoubenko, *et al.*, 1994, *supra*) to confirm homogenous loading of RNA on the filter.

Results of the Northern hybridizations performed with EPSPS probes demonstrate that all seven (7) lines examined express CP4 EPSPS mRNA. Hybridizations performed with the 16S ribosome probe confirm that denaturing gels were loaded with similar amounts of total RNA for each sample. Furthermore, transplastomic tobacco lines expressing EPSPS from the *Prm/rbcL*(RBS) (pMON30123) regulatory elements express EPSPS mRNA to higher levels than tobacco plants homoplasmic for EPSPS controlled by the *Prm/G10L* (pMON38773) promoter/RBS sequences.

Results of Northern hybridizations performed with BXN, AHAS and *crtI* probes demonstrates that all homoplasmic 5026, 5175, and 5177 tobacco lines expressed *crtI*, BXN and/or AHAS mRNA.

### 3C. Western Blot Analysis of Tobacco CP4 EPSPS

To determine the expression of the EPSPS, Western blot analysis was performed on a single line from each construct, pMON30123, pMON30130, and pMON38773.

Total soluble protein was extracted from frozen leaf tissue by grinding 250 mg tissue in 250µl of PBS buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, Na<sub>2</sub>HPO<sub>4</sub>, 0.137M NaCl, 2.7 mM KCl pH 7.0) containing protease inhibitors. The homogenate is centrifuged for 5 minutes, and the supernatant is transferred to a fresh tube. The concentration of the protein in the supernatant is determined using a protein concentration assay (BioRad, Richmond, CA).

Extracted total protein is electrophoresed on a 4-20% SDS-PAGE gel (Sigma, St Louis, MO), and transferred to PVDF membrane in 1x SDS-PAGE buffer (Maniatis *et al.* 1989, Cold Spring Harbor Press). Standards of quantitated purified CP4 EPSPS protein were used to quantify the expression of the CP4 EPSPS as expressed in the plant plastid.

Western hybridizations are performed as described in Staub and Maliga (1993) *EMBO Journal*, 12(2) 601-606, except using antibodies raised to EPSPS. PVDF membranes containing the transferred electrophoresed protein were incubated in a blocking solution of PBS buffer containing 0.05% Tween-20 (PBS-T) and 5% milk overnight at 4°C. The membranes are then incubated in a solution of PBS-T containing 1% milk and a primary antibody raised in goats to the CP4 EPSPS for 2 hours at room temperature. The membranes are washed three times in a solution of PBS-T containing

0.1% milk, each wash for 5 minutes at room temperature. The membranes are then incubated in a solution of PBS-T containing 1% milk and sheep anti-goat antibody for 1 hour at room temperature, and washed again in PBS-T containing 0.1% milk, three times for 10 minutes at room temperature. A final wash using only PBS-T is performed before  
 5 developing the membranes using a nonradioactive detection kit (ECL, Amersham).

Table 2

Construct Number	Event Number	% Total Soluble Protein
pMON30123	T18-23-2A	0.001
pMON30130	T18-51-2P	0.002
pMON38773	9706-6-1	0.2

10

The results listed in Table 2 demonstrate that significant increases in the level of EPSPS protein may be obtained from plants transformed to express EPSPS from the *Prrm*/G10L promoter. These results demonstrate that EPSPS expression driven by the *Prrm*/rbcLRBS regulatory sequences may produce approximately 0.001% of the total  
 15 soluble protein as EPSPS, while in plants expressing EPSPS from the *Prrm*/G10L regulatory sequences express 0.2% of the total soluble protein as EPSPS. Subsequent lines have demonstrated total soluble protein of about 1% EPSPS when expressed from the *Prrm*/G10L regulatory sequences. These results, taken together with the results of the Northern hybridizations above, indicate that more efficient translation may be obtained  
 20 from the G10L ribosome binding site.

Western immunoblot hybridization were also performed on 2 homoplasmic 5026 tobacco lines as described above, using antibodies raised against bromoxynil. The results of Western immunoblot analysis of total soluble protein extracted from tobacco lines transformed with pCGN5026 demonstrated that both homoplasmic lines produced nitrilase  
 25 protein.

Western immunoblot analysis was performed as described above from total protein extracted from tobacco lines transformed with pCGN6114 and pCGN5197.

The results of the analysis demonstrated that bromoxynil was produced in 6114 tobacco lines ranging from 1% to 2% of the total soluble leaf protein.

5 The results of the Western analysis of the 20 5197 tobacco lines demonstrated that bromoxynil and Bt were both produced as 1% of the total soluble leaf protein.

### 3D. Analysis of EPSPS Enzyme Activity

10 The EPSPS enzyme activity in transplastomic tobacco plants containing the plastid expression vector pMON38773 was determined using a high pressure liquid chromatography (HPLC) assay.

Methods for the analysis of EPSPS enzyme activity are described in Padgett *et al.* (*J. Biol. Chem.* (1988)263:1798-1802 and *Arch. Biochem. Biophys.* (1987)258:564-573) and Wibbenmeyer *et al.* (*Biochem. Biophys. Res. Commun.* (1988)153:760-766).

15 The results are summarized in Table 3 below.

**Table 3**

<u><b>Nuclear</b></u> <b>Enzymatic Activity</b> <b>Range</b>	<u><b>Nuclear</b></u> <b>% Total Plants</b> <b>In Range</b>	<u><b>Chloroplast</b></u> <b>38773-6</b>
1-3.7 $\mu\text{mol/mg}$	1%	
>0.1 $\mu\text{mol/mg}$	16%	
>10 $\text{nmol/mg}$	55%	16.39 $\text{nmol/mg}$
>1 $\text{nmol/mg}$	32%	
0 $\text{nmol/mg}$	3%	

20 These results demonstrate that EPSPS expression in plastids produces active EPSPS enzyme.

### 3E. Analysis for Glyphosate Tolerance

A transplastomic tobacco line homoplasmic for the construct pMON38773 was tested *in vitro* to determine the highest level of glyphosate tolerance. Explant tissue was prepared from leaf pieces of nontransgenic wild type tobacco control, *Havanna*, plants and the homoplasmic tobacco line 38773-6 and cultured for regeneration of shoots on TSO medium (described above) supplemented with glyphosate levels of 50 $\mu$ M, 75 $\mu$ M, 100 $\mu$ M, 150 $\mu$ M and 200 $\mu$ M. The results are summarized in Table 4 below. The number of explants producing shoots was determined at 3 weeks and 6 weeks after explant preparation and culturing on glyphosate containing medium.

10

Table 4

Glyphosate Level ( $\mu$ M)	Total Number Explants	Number Regenerating 3 Weeks	Number Regenerating 6 Weeks	% Explant Regeneration
<b>Wild Type</b>				
50	10	0	0	0
75	10	0	0	0
100	10	0	0	0
150	10	0	0	0
200	10	0	0	0
<b>38773-6</b>				
50	8	5	8	100
75	18	14	18	100
100	17	12	15	88
150	18	10	16	89
200	16	8	15	86

The above results demonstrate that at all levels of glyphosate examined, shoots regenerated from explants prepared from a tobacco line homoplasmic for pMON38773,

15

while no shoots regenerated from explants prepared from nontransformed control plants. These results suggest that tobacco plants expressing EPSPS in plastids demonstrate tolerance to glyphosate levels of at least 200 $\mu$ M.

Additional transplastomic lines were tested *in vitro* for glyphosate tolerance as described above. The results are shown in Table 5.

TABLE 5

**Summary of tobacco plastid transformation experiments with various constructs containing EPSPS genes.**

Construct	Spec/strep (+)	No. of shoots
		Gly 50 $\mu$ M(+)
pMON38766 (Wild)	1	0
15 pMON38766 (T7)	6	0
pMON38773 (Wild)	9	5 (1)
pMON38797 (Wild)	2	0
pMON38798	6	6
pMON38793	8	0
20 pMON38796	4	0
pMON45201	9	3
pMON45204	12	*

(No. of shoots positive at 1 mM glyphosate)

25

These results demonstrate that these transplastomic lines show tolerance to glyphosate. The numbers in parentheses are the number of shoots resistant to selection at 1 mM glyphosate. Thus, as can be seen in table 5, tobacco lines are generated that are tolerant of selection at 1 mM glyphosate.

30 Homoplasmic tobacco plants of the line 38773-6 are sprayed with glyphosate using a track sprayer at concentrations corresponding to 0oz/acre, 16oz/acre, 32oz/acre and 64oz/acre to test for whole plant tolerance. Plant height was measured before and after

spraying with glyphosate. The vegetative injury data was collected two weeks after spraying, while the reproductive injury data was collected at plant maturity.

Initial results indicate that homoplasmic tobacco lines sprayed are tolerant of glyphosate at the concentration of 16oz/acre as demonstrated in the vegetative tissue injury (Table 6). As can be seen in Table 5 transplastomic lines were generated which demonstrated a good level of glyphosate tolerance at 32oz/Acre. In subsequent experiments with additional transformed lines, transplastomic lines have shown tolerance to glyphosate at a level of 64oz/Acre.

Tolerance is characterized by the continued growth and greening of tissues sprayed with glyphosate. However, as the concentration of glyphosate applied increased, there was a corresponding increase in the level of vegetative injury. In contrast, nontransformed control plants which were highly susceptible to glyphosate concentrations as low as 16 oz/Acre.

15

Table 6

Plant No.	Construct	Roundup rate (oz/A)	Plant height (cm) before spray	Plant height (cm) after spray	Vegetative injury	Fertility rating
1	38773	0	12.2	30.5	0	0
2	38773	0	13.6	34.0	0	0
3	38773	0	8.6	23.8	0	0
4	38773	0	8.6	26.2	0	0
5	38773	0	7.8	28.8	0	0
6	38773	0	12.8	31.5	0	0
7	38773	0	12.2	31.6	0	0
8	38773	0	11.6	35.5	0	0
9	38773	16	9.0	29.0	1	0
10	38773	16	14.4	31.0	0	0
11	38773	16	13.4	32.0	0	0
12	38773	16	13.2	30.0	0	0
13	38773	16	14.2	30.5	0	1
14	38773	16	14.0	33.0	0	0
15	38773	16	13.2	30.2	0	0
16	38773	16	14.9	30.4	0	0
17	38773	32	12.0	26.5	2	4
18	38773	32	11.6	25.4	1	1
19	38773	32	9.4	22.0	1	3
20	38773	32	11.2	23.0	2	4
21	38773	32	13.8	25.8	1	2
22	38773	32	12.4	23.0	1	4
23	38773	32	10.2	19.0	2	4
24	38773	32	13.8	23.2	2	3
26	38773	64	11.8	20.0	2	5
27	38773	64	13.0	22.0	2	5
28	38773	64	12.2	18.0	3	5



29	38773	64	15.8	23.0	2	5
30	38773	64	10.4	17.5	2	5
32	38773	64	15.0	18.5	2	5
33	38773	64	13.8	21.8	2	5
34	38773	64	13.6	19.0	3	5
35	38773	64	10.8	16.0	3	5
36	Wild type	0	21.0	40.6	0	0
37	Wild type	0	16.0	38.0	0	0
38	Wild type	0	15.0	34.6	0	0
39	Wild type	0	17.6	32.2	0	0
40	Wild type	0	15.0	31.6	0	0
41	Wild type	0	14.0	32.0	0	0
42	Wild type	16	10.0	11.8	3	5
43	Wild type	16	8.0	10.0	3	5
44	Wild type	16	8.6	11.0	3	5
45	Wild type	16	8.0	14.0	3	5
46	Wild type	16	9.8	11.0	3	5
47	Wild type	16	10.4	14.0	3	5
48	Wild type	32	10.8	13.2	3	5
49	Wild type	32	9.0	13.0	3	5
50	Wild type	32	8.0	10.2	3	5
51	Wild type	32	11.0	14.0	4	5
52	Wild type	32	9.8	13.0	3	5
53	Wild type	32	8.0	10.8	4	5
54	Wild type	64	7.5	8.6	4	5
55	Wild type	64	11.2	12.5	4	5
56	Wild type	64	10.2	12.8	4	5
57	Wild type	64	11.5	13.0	4	5
58	Wild type	64	13.0	15.0	4	5
59	Wild type	64	9.8	11.2	4	5

Vegetative injuries:

0=normal plant

1=slight chlorosis of new leaves and stunting

2=severe chlorosis of new leaves, malformation of new leaves, and severe stunting

3=dying plant

4=dead plant

Fertility ratings:

0 = Fertile, no delay in maturity, lots of seed

1 = Some abortion, slight delay in seed set, seed

2 = Significant abortion, significant delay in seed set, some seed

3 = Very severe abortion, immature seed pots, a few seed

4 = malformed flowers; if flowered, extreme delay in flowering and no seed produced

5=dead plant

### 3F. *BT/BXN* Analysis

Homoplasmic tobacco plants of the lines 5175 and 5197 are sprayed with Buctril herbicide at a concentration of 4% to test for whole plant tolerance.

Results of the spray test with Buctril demonstrated that all 5197 lines expressing *bxn* were completely resistant when sprayed with a solution containing 4% Buctril herbicide.

Two lines out of six 5175 lines tested were completely resistant to the herbicide when sprayed with a 4% solution containing Buctril.

### 10 3G. *Norflurazon* Resistance Analysis

An experiment was set up to determine the efficacy of the *Crt I* trait with respect to resistance to the herbicide Norflurazon. Three 5177 transformed lines, 74-1B-P, 74-2-A, and 74-7-C and three control lines were planted. Plants were grown for seven weeks and then watered with a 3μM Norflurazon solution. Plants negative for the presence of the *crtI* plastid-borne gene were bleached by Norflurazon treatment, positive plants stayed green and continued to grow.

The results show that the three homoplasmic 5177 tobacco lines were resistant to the 3 $\mu$ M Norflurazon solution, while the control plants were all susceptible to the solution (Table 7).

5

Table 7

Line	Control/Transgenic	Result
Xanthi	Control	Susceptible
2560A Xanthi	Control	Susceptible
75-5D-A	Control	Susceptible
74-1B-P	homoplasmic	Resistant
74-2-A	homoplasmic	Resistant
74-7-C	homoplasmic	Resistant

#### Example 4 Analysis of hGH Transgenic Tobacco Plants

##### 4A. Southern Analysis

10 Transformed plants selected for *aadA* marker gene expression are analyzed to determine whether the entire plastid content of the plant has been transformed (homoplasmic transformants). Homoplasmic plants are selected using Southern hybridization for further cultivation.

15 Genomic DNA is isolated from transformed tobacco plants, electrophoresed, and transferred to filters as described in Svab *et al.* ((1993), *Proc Natl Acad Sci*, 90:913-917).

Homoplasmic tobacco plants transformed to express hGH were identified using a probe prepared from a 2.4 kb *EcoRI/EcoRV* fragment from the vector pOVZ2 (similar to pOVZ15 described in Zoubenko, *et al.* 1994, *supra*). The 2.4 kb probe fragment encompasses part of the targeting sequence.

20 The complete disappearance of the 3.27 Kb native tobacco *Bam*HI fragment in the lines with a probe covering the region of integration, and the appearance of the expected size band for the inserted DNA fragments in those transformants, 5.6 kb, establishes that the transformed plants are homoplasmic for the intended constructs.

#### 4B. Protein Expression Analysis

Homoplasmic tobacco lines expressing hGH and nuclear tobacco transformants are used to determine the expression of the hGH protein. Western blot analysis was performed on tobacco lines containing constructs pWRG4838, pMON38755 and pMON38794 for plastid expression and an ELISA assay was used for transgenic tobacco lines containing pWRG4744 and pWRG4747 for nuclear expression of hGH.

Total protein extractions and western blot procedures were performed as described above, with the exception of the primary antibody was raised against hGH.

10

**Table 8**

**Expression Levels of hGH in Tobacco Nuclear Genome and Plastid genome**

Construct	Expression	Expression Level % Total Soluble Protein
pWRG4744	nuclear	0.002-0.125%
pWRG4747	nuclear	0.002-0.025%
pWRG4838	plastid	0.2%
pMON38755	plastid	1.0%
pMON38794	plastid	7.0%

Results of the Western analysis (Table 8) demonstrates that hGH expressed in plastids of plant cells accumulates to significantly higher levels than hGH expressed in the nucleus and targeted to either the cytoplasm or plastid of plant cells. Tobacco plants transformed to express hGH in the nucleus accumulated hGH levels of 0.002% (cytoplasmic targeted) to 0.025% (plastid targeted) of total soluble leaf protein, while tobacco plants expressing hGH in the plastid accumulated hGH levels of 0.2% to 7.0% of the total soluble leaf protein as hGH. Furthermore, homoplasmic tobacco plants expressing hGH directed from the *Prrn*/G10L regulatory sequences accumulate 35 fold higher levels of hGH than homoplasmic tobacco plants expressing hGH directed from the *PpsbA* promoter sequence. The higher level of expression may be due to the strong *Prrn* promoter and/or to enhanced translation of the fusion gene mediated by the gene 10 leader rbs region. Leaves of different ages had varied hGH accumulation patterns, with mature

and old leaves having similar levels and younger leaves much less hGH. This is consistent with the lower chloroplast number in young leaves.

Interestingly, both ubiquitin-hGH and processed hGH accumulated in the post-harvest extracts of the Nt-38755 and Nt-38794 lines. Ubiquitin processing was often  
5 observed at >50% of total hST protein species, depending on extraction conditions. This result confirms the utility of the fusion protein approach in chloroplast-expressed proteins. The appearance of an extra band observed in the Nt-4838 sample is consistent with an hGH dimer.

For comparison of expression systems in plants, nuclear transgenic plants were  
10 generated that express hGH from two different sets of expression signals. The wrg4747 and wrg4776 constructs expresses hGH using the strong Figwort Mosaic Virus promoter or the Cauliflower Mosaic Virus 35S promoter, respectively. The wrg4747 construct employs a chloroplast transit peptide to post-translationally target hGH to chloroplasts (FMV::CTP-hGH), whereas the wrg4776 construct targets the hGH through the  
15 endoplasmic reticulum (ER) to the secretory pathway (35S::ER-hST). Transgenic lines for both constructs were obtained through particle bombardment. Expression of hST was quantitated by ELISA assay and shown to be less than 0.025% tsp. This level of expression is at least 300-fold lower than the pMON38794 lines, proving the feasibility of the chloroplast expression system for the potential production of hST.

#### 20 4C. Characterization of hGH Protein Expressed in the Plastid

In order to determine whether the hGH expressed from plastids was properly processed, experiments were performed to determine correct folding and bioactivity.

Two bottom leaves of transplastomic tobacco lines containing pMON38794 were  
25 used to extract and purify hGH. Large veins were removed from the excised leaves, and the leaf tissue was cut into small sections (approximately 0.5 cm<sup>2</sup>). The leaf pieces were flash frozen in liquid nitrogen and ground to a fine powder in a chilled mortar and pestle. Ten grams of frozen, ground leaf tissue was added to ice cold 100 mM Tris base solution (30 ml) and mixed vigorously by vortexing for 5 minutes. The solution was filtered  
30 through a single layer of cheese cloth.

From the filtered solution, three separate samples were prepared. The first sample was prepared by centrifuging 4 ml of the filtrate for 1 minute at 16,000 rpm. The centrifugate was aliquoted into 1 ml vials and frozen in dry ice. The remaining filtrate was

centrifuged for 10 minutes at 4800 rpm, and several 0.5 ml aliquots were frozen as above for the second sample. To the remaining centrifuged filtrate (approximately 25 ml), 200 $\mu$ l of glacial acetic acid was added to lower the pH from 8.2 to 4.56. The solution was centrifuged at 4800 rpm for 30 minutes, and the supernatant was frozen over dry ice for the third sample.

Total soluble protein (TSP, Table 9) was calculated in these samples by standard protein assay procedures (Maniatis, ), and the percent purity of hGH was calculated based on results from Western blot analysis using known concentrations of starting material.

Table 9

Sample ID	TSP mg/mL	GP2000 mg/L	% Purity
Filtered Extract immediately centrifuged and frozen	6.3	28	0.45 %
Filtered extract centrifuged at 4800 rpm for 10 min and frozen	6.4	28	0.45
pH adjusted and centrifuged extract	0.75	21	2.8%

The pH adjusted and centrifuged extract was purified by Reverse Phase-HPLC (RP-HPLC) for electrospray mass spectrometry and amino-terminal amino acid sequencing. RP-HPLC was performed using a Perkin-Elmer series 200 pump and autosampler and a Vydac C8 (250 by 4.6 mm) RP-HPLC column. 750 microliters of sample was loaded onto the column equilibrated with 20 mM trifluoroacetic acid (TFA) and 50 % acetonitrile. After loading, the column was washed for 2 minutes with 50 % acetonitrile, 20 mM TFA followed by a 2% linear acetonitrile gradient over 10 minutes followed by a 10 % acetonitrile gradient over 1 minute. The flow rate was a constant 1.5 ml/minute with the column eluate monitored at 278 nm with a Perkin-Elmer 785 detector. Data was collected and analyzed with a PE-Nelson Turbochrom data system.

The results of the RP-HPLC analysis are shown in figure 3. Peak I (tallest peak) has the retention time expected for properly folded, native 22 kDa GP2000. This peak was

collected and dried down in a Savant Speed-Vac for amino terminal sequencing and electrospray mass spectrometry.

Electrospray ionization mass spectrometry (MS) analysis used a Micromass Q-ToF electrospray time-of-flight mass spectrometer. The samples were prepared by resuspending in 50% methanol + 2% acetic acid, and infused into the source of the mass spectrometer at a rate of 4mL/min. The raw data shown in Figure 4 shows a series of ions corresponding to the specie(s) present in the sample with varying numbers of protons attached. The axes of this spectrum are intensity versus mass-to-charge ratio of the specie(s) present. A deconvolution algorithm is used to convert this series of multiply charged ions into a molecular weight spectrum.

The results of the mass spectrometry of the RP-HPLC peak I shows 4 major protein species of different molecular mass. The 21,997 kDa species represents the predicted mass of hGH with the predicted N-terminal Phe removed by over-cleavage of the Ubiquitin protease with an N-terminal proline residue (P-hGH). The 22,124 kDa species represents the predicted mass of properly processed, correct amino acid sequence of hGH having the N-terminal phenylalanine (F-hGH). The 22,507 kDa and 22,664 kDa species are thought to represent an hGH with the N-terminal Phe and hGH which has been modified during plant extraction procedures, respectively. The calculated molecular mass of the proteins suggests that the hGH expressed from the plastid is properly folded (i.e. the correct disulfide bonds are created).

Equivalent mobility to refolded *E. coli* produced protein indicates formation of the two disulfide bonds and proper folding of the chloroplast derived hGH. This result was surprising because of the prokaryotic nature of chloroplasts. There are no known, plastid-expressed proteins that have disulfide bonds. However, nuclear-encoded, imported enzymes can be activated by disulfide bond oxidation/reduction cycles, presumably using the chloroplast thioredoxin system (Jacquot, *et al.* (1997) *New Phytol.* 136:543-570) or a recently discovered chloroplast protein disulfide isomerase (Kim and Mayfield (1997) *Science* 278:1954-1957). This result suggests that the prokaryotic organelle has the machinery needed to fold complex eukaryotic proteins in the soluble chloroplast stroma compartment. This is distinct from *E. coli*, where recombinant proteins tend to accumulate within inclusion bodies, and then require solubilization and refolding.

Amino terminal sequencing was done by standard Edman degradation, and confirmed the N-terminal sequences discussed above.

#### 4D. Bioactivity of hGH Expressed in Plant Plastids

Bioactivity of the pH adjusted and centrifuged extract was tested using cells from an Nb2 cell line. These cells proliferate in the presence of growth hormone and other estrogenic type compounds. The assay involves putting various concentrations of growth hormone-containing extract into a 96 well plate. Then a constant amount of cells are added to each well. The plate is incubated for 48hrs and then a reagent called MTS is added. Metabolizing cells take up the MTS and convert it to a blue colored substance. The more cells there are the more blue color in the well. The blue color is measured using a spectrophotometer. The number of cells should be proportional to the concentration of growth hormone in the media. At some high concentration one expects that the cells will become saturated with growth hormone and that the dose response will level off. At very low hGH concentrations essentially no enhanced growth is seen. A sigmoidal shape graph is expected to be produced graphing the cell number (or absorbance) versus hGH concentration graph.

Proper disulfide pairing in the chloroplast hGH implies that the protein should be biologically active. To test this hypothesis *in vitro*, a rat lymphoma cell line, Nb2, that proliferates in the presence of somatotropin (hGH) and other estrogenic type compounds was employed. Proliferation of this cell line is proportional to the amount of somatotropin in the culture medium, until saturation is reached. The ion exchange column eluate from transplastomic Nt-4838 and Nt-38794 plants or identically treated wild-type plants was added to the Nb2 cell culture medium. As control, *E. coli* produced, refolded hGH was used. The wild-type plant extract showed no activity in this assay, indicating that there is no endogenous plant compound capable of stimulating growth of the Nb2 cell line. In contrast, the Nt-4838 and Nt-38794 extracts both stimulated proliferation of the cell line to an equal extent as the positive controls: either wild-type plant extract that had been spiked with purified *E. coli* hGH or the pure hGH alone.

The Nb2 cell results show that the chloroplast derived hGH is biologically active. Previous studies of recombinant somatotropin produced in *E. coli* showed equivalent pharmacokinetics of the protein with either an N-terminal methionine or phenylalanine (Moore, *et al.* (1988) *Endocrinology* 122:2920-2926). In this study, ubiquitin cleavage of the fusion protein in Nt-38794 lines generated predominantly P-hST, suggesting that this species is also bioactive. The hST from Nt-4838 extracts was also characterized. Amino



acid analysis indicated >95% protein species with alanine at the N-terminus. This result suggests that a methionine aminopeptidase activity generated the alanine-hST, which is also bioactive. A similar aminopeptidase activity exists in *E. coli* (Meinzel, *et al.* (1993) *Biochimie* 75:1061-1075). This finding in plastids may be exploited in the future as an alternative means to generate a non-methionine N-terminus.

The results of the bioactivity assay (Figure 5) demonstrates that the hGH expressed from a plant plastid has a sigmoidal shape when graphed as absorbance versus hGH concentration.

## 10 Example 5 Analysis of Aprotinin Transplastomic Tobacco Plants

### 5A. Western Analysis of Aprotinin Expression in Plastids

Homoplasmic tobacco lines expressing are used to determine the expression of the aprotinin protein. Western blot analysis was performed on tobacco lines containing constructs pCGN6146, pCGN6147, pCGN6154 and pCGN6156 for plastid expression of aprotinin.

Total protein extractions and western blot procedures were performed as described above, with the exception of the primary antibody was raised against aprotinin.

The results of the Western analysis is shown in Figure 6. These results indicate that aprotinin is expressed from the T7 polymerase promoter when the aprotinin coding sequence is fused with either the PetA or full length GUS gene. Furthermore, these results indicate that the petA sequence efficiently targets the aprotinin protein to the plant cell thylakoid.

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claim.

## CLAIMS

What is claimed is:

5

1. A construct comprising the following components in the 5' to 3' direction of transcription:

- 10
- a) a promoter functional in a plant plastid;
  - b) a DNA sequence encoding a peptide derived from an eukaryotic organism; and
  - c) a transcription termination region;
- wherein said eukaryotic peptide is other than a peptide of a plant plastid.

15

2. The construct according to Claim 1, wherein said construct further comprises (d) a gene encoding a selectable marker for selection of plant cells comprising a plastid expressing said marker and (e) DNA regions of homology to the genome of said plastid, wherein said regions of homology in (e) flank components (a), (b), (c) and (d).

20

3. The construct according to Claim 1, wherein said construct further comprises (f) a ribosome binding site joined to said promoter component (a).

4. The construct according to Claim 3, wherein said ribosome binding site (f) is from a leader sequence selected from the group consisting of sites derived from plastid, bacterial or bacteriophage leader sequences.

25

5. The construct according to Claim 4, wherein said ribosome binding site is selected from the group consisting of the binding site of the gene 10 leader and the rbcLRBS site.

30

6. The construct according to Claim 1 wherein said DNA sequence encodes a plant nuclear peptide.

7. The construct according to Claim 6 wherein said plant nuclear peptide is a carbon cycle gene.

8. The construct according to Claim 7 wherein said a carbon cycle gene is selected from the group consisting of fructose 1,6 biphosphatase aldolase and seduheptulose biphosphatase,

5

9. The construct according to Claim 6 wherein said plant nuclear peptide is an antifungal peptide.

10. The construct according to Claim 1 wherein said DNA sequence encodes a  
10 mammalian peptide.

11. The construct according to Claim 10 wherein said mammalian peptide is a protein selected from the group consisting of interferons, monclonal antibodies, hematopoeitic agents, pituitary hormones, thyroid hormones, hypothalamic hormones,  
15 albumins and pancreatic hormones.

12. The construct according to Claim 11 wherein said mammalian peptide is the pancreatic hormone insulin.

20 13. The construct according to Claim 11 wherein said mammalian peptide is a pituitary hormone selected from the group consisting of somatomammotropic hormones, gonadotropic hormones, thyrotropic hormones and chorticotropic hormones.

14. The construct according to Claim 13 wherein said pituitary hormone is a  
25 gonadotropic hormone selected from the group consisting of chorionic gonadotropins, luteinizing hormones and follicle stimulating hormones.

15. The construct according to Claim 13 wherein said pituitary hormone is a somatomammotropic hormone selected from the group consisting of prolactin and growth  
30 hormones.

16. The construct according to Claim 15 wherein said somatomammotropic hormone is the growth hormone bGH.

17. The construct according to Claim 15 wherein said somatomammotropic hormone is the growth hormone hGH.

5        18. The construct according to Claim 15 wherein said somatomammotropic hormone is the prolactin hormone pBL.

19. The construct according to Claim 11 wherein said mammalian peptide is a hematopoietic agent selected from the group consisting of erythropoietins, interleukins,  
10        and colony stimulating factors.

20. The construct according to Claim 19 wherein said mammalian peptide is the colony stimulating factor G-CSF.

15        21. The construct according to Claim 11 wherein said monoclonal antibody is a single-chain F variable antibody.

22. The construct according to Claim 10 wherein said mammalian peptide is the non-enzymatic coagulation protein selected from the group consisting of factor V and  
20        factor VIII cofactor proteins.

23. The construct according to Claim 10 wherein said mammalian peptide is a proteinase inhibitor.

25        24. The construct according to Claim 10 wherein proteinase inhibitor is aprotinin.

25. The construct according to Claim 2 wherein said selectable marker is a selected from the group of aadA, spectinomycin resistance, streptomycin resistance kanamycin resistance and a glyphosate tolerance gene.

30        26. The construct according to Claim 1 wherein said DNA encoding sequence is the native encoding sequence to said gene.

27. The construct according to Claim 1 wherein said DNA encoding sequence is a synthetic encoding sequence to said gene.

5           28. A plant cell plastid containing the construct according to Claim 1.

29. A plant, plant seed, plant cell or progeny thereof containing a plant plastid according to Claim 29.

10           30. A method for producing a protein in a plant cell, wherein said method comprises transforming plastids of said plant cell with a construct comprising the following as operably joined components in the 5' to 3' direction of transcription:

(a) a promoter functional in a plant plastid;

15           (b) a DNA sequence encoding a peptide of an eukaryotic cell other than a peptide of a plant plastid; and

(c) a transcription termination region.,

and growing plant cells comprising said transformed plastids under conditions wherein said DNA encoding sequence is expressed to produce said eukaryotic peptide in said plastid.

20

31. The method according to Claim 30, wherein said construct further comprises (d) a gene encoding a selectable marker for selection of plant cells comprising a plastid expressing said marker and (e) DNA regions of homology to the genome of said plastid, wherein said regions of homology in (e) flank components (a), (b), (c) and (d).

25

32. The method according to Claim 30, wherein said construct further comprises (f) a ribosome binding site joined to said promoter component (a).

33. The method according to Claim 32, wherein said ribosome binding site (f) is from a leader sequence selected from the group consisting of sites derived from plastid, bacterial or bacteriophage leader sequences.

30

34. The method according to Claim 33, wherein said ribosome binding site is selected from the group consisting of the binding site of the gene 10 leader and the rbcLRBS site.

5           35. A plant cell produced according to the method of Claim 31 and comprising greater than about 0.01 % of total soluble protein as said eukaryotic peptide.

36. A plant cell according to Claim 31 and comprising greater than about 0.2 % of total soluble protein said eukaryotic peptide.

10

37. A plant cell according to Claim 31 and comprising greater than about 1 % of total soluble protein said eukaryotic peptide.

38. A plant cell according to Claim 31 and comprising 7 % or more of total  
15 soluble protein as said eukaryotic peptide.

39. A plant cell according to Claim 30 wherein said selectable marker comprises a glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthase.

20           40. A plant cell having a transformed plastid produced according to the method of Claim 30.

41. A plant, plant seed or plant part comprising a plant cell according to Claim 41.

25           42. The method according to Claim 30, wherein said construct further comprises (g) a coding sequence to a secondary protein fused to said DNA sequence encoding a peptide of an eukaryotic cell in (b).

43. The method according to Claim 42, wherein secondary protein is the  
30 thylakoid-targetting terminus of cytochrome f.

44. The method according to Claim 42, wherein secondary protein is the cleavable ubiquitin N-terminus.

45. The method according to Claim 44 whereby said cleavable ubiquitin N-terminus fusion is cleaved from said eukaryotic peptide by the step of harvesting said plant cells and exposing the contents of said transformed plastid to the cytosol of said plant cell.

5

46. The method according to Claim 45 whereby expression of said eukaryotic peptide is enhanced.

47. The method according to Claim 30 wherein said eukaryotic peptide other than a peptide of a plant plastid expressed in said plant plastid is folded with the correct number of disulfide bonds.

10

48. The method according to Claim 47 wherein said eukaryotic peptide is hGH

15

49. The method according to Claim 30 wherein said eukaryotic peptide other than a peptide of a plant plastid expressed in said transformed plant plastid is bioactive when isolated from said transformed plant plastid.

20

50. The method according to Claim 49 wherein said eukaryotic peptide is hGH.

51. A method for producing a non-methionine N-terminus protein in a plastid, wherein said method comprises:

transforming a plastid with a construct comprising, as operably joined components in the 5' to 3' direction of transcription

25

- (a) a promoter functional in a plastid,
- (b) a DNA sequence encoding a cleavable ubiquitin peptide,
- (c) a DNA sequence encoding a protein of interest, and
- (d) a transcription termination region; and

growing a plant cell comprising said transformed plastid under suitable conditions for expression of said protein of interest and said cleavable ubiquitin sequence in said plastid.

30

52. The method according to claim 51, wherein said construct further comprises (e) at least two DNA regions of homology to the genome of said plastid.

53. The method according to claim 51, wherein said construct further comprises (f) a gene encoding a selectable marker for selection of a plant cell comprising a plastid expressing said marker.

54. The method according to claim 51, wherein said construct further comprises (g) a ribosome binding site joined to said promoter (a).

10

55. The method according to claim 54, wherein said ribosome binding site is derived from a leader sequence selected from the group consisting of a plastid leader sequence, a bacterial leader sequence and a bacteriophage leader sequence.

15

56. The method according to claim 54, wherein said ribosome binding site is selected from the group consisting of the binding site of the gene 10 leader and the rbcLRBS site.

20

57. A plastid having a protein of interest produced according to the method of claim 51.

58. The plastid according to claim 57 wherein said protein of interest comprises at least about 1.0 % of total soluble protein in said plastid.

25

59. The plastid according to claim 58 wherein said protein of interest comprises at least about 7.0% of total soluble protein in said plastid.

30

60. A plastid comprising a stably incorporated portion of the construct of claim 51 within its genome.

61. A plant cell comprising a plastid comprising a stably incorporated portion of the construct of claim 51 within its genome.



62. A plant cell comprising a transformed plastid produced according to the method of claim 51.

5 63. A plant, plant seed or plant part comprising a plastid according to claim 57.

64. A plant, plant seed or plant part comprising a plastid according to claim 60.

10 61. 65. A plant, plant seed or plant part comprising a plant cell according to claim

66. A plant, plant seed or plant part comprising a plant cell according to claim 62.

15 67. The method according to claim 51 wherein said protein of interest is folded with the correct number of disulfide bonds.

68. The method according to claim 51 wherein said protein of interest is hGH.

20 69. The method according to claim 51 wherein said protein of interest is bioactive when isolated from said plant cell.

70. The method according to claim 69 wherein said protein of interest is hGH.

25 71. A plastid comprising:  
a portion of a construct according to claim 51 stably integrated into its genome; and  
a non-methionine N-terminus protein.

30 72. A plant cell comprising a plastid having:  
a portion of a construct according to claim 51 stably integrated into its genome; and  
a non-methionine N-terminus protein.

73. A method for producing a non-methionine N-terminus protein in a plastid, wherein said method comprises:

transforming a plastid with a construct comprising, as operably joined components in the 5' to 3' direction of transcription

- 5 (a) a promoter functional in a plastid,  
(b) a DNA sequence encoding a protein of interest, wherein said protein of interest is capable of being recognized by a plant cell Methionine Amino Peptidase, and  
(c) a transcription termination region; and  
growing a plant cell comprising said transformed plastid under suitable conditions  
10 for expression of said protein of interest having a non-Methionine N-terminus.

74. The method according to Claim 73, further comprising the step of growing a plant having said plant cell.

- 15 75. The method according to Claim 74, further comprising the step of harvesting said plant and subjecting cells of said plant to means for substantially purifying said protein of interest.

76. The method according to Claim 73, wherein said plant cell Methionine Amino  
20 Peptidase cleaves the N-terminal methionine.

77. The method according to Claim 73, wherein the second amino acid of said protein is selected from the group consisting of alanine, cysteine, glycine, proline, serine, threonine and valine.

25


78. The method according to Claim 73, wherein the second amino acid of said protein is alanine.

5'-AAT TGT AGA AAT AAT TTT GTT TAA CTT TAA GAA GGA GAT ATA CC-3'  
TTA ACA TCT TTA TTA AAA CAA ATT GAA ATT CTT CCT CTA TAT GG

**FIGURE 1**


Arg-Pro-Asp-Phe-Cys-Leu-Glu-Pro-Pro-Tyr-Thr-Gly-Pro-Cys-  
Lys-Ala-Arg-Ile-Ile-Arg-Tyr-Phe-Tyr-Asn-Ala-Lys-Ala-Gly-  
Leu-Cys-Gln-Thr-Phe-Val-Tyr-Gly-Gly-Cys-Arg-Ala-Lys-Arg-  
Asn-Asn-Phe-Lys-Ser-Ala-Glu-Asp-Cys-Met-Arg-Thr-Cys-Gly-  
Gly-Ala

**FIGURE 2**



RP-HPLC analysis shown above. Peak I (tallest peak) has the retention time expected for properly folded, native 22 kDa GP2000. This peak was collected and dried down in a Savant Speed-Vac for amino terminal sequencing and electrospray mass spectrometry.

**FIGURE 3**



Mass spectrometry of RP-HPLC peak I shown above. Note that there are 4 major protein species, of different molecular mass.

21977 kDa - This is the predicted mass of "des-Phe"-GP2000, ie. GP2000 with the predicted N-terminal Phe removed by over-cleavage of Ubiquitin protease.


\*\*\*\*22124 kDa - This is the predicted mass of properly processed, correct amino acid sequence GP2000

22507 kDa - This is probably des-Phe-GP2000 modified during plant extraction procedures

22664 kDa - This is probably GP2000 modified during plant extraction procedures

Amino terminal sequencing was done by standard Edman degradation, and confirmed the N-terminal sequences discussed above.

**Figure 4**



**FIGURE 5**

## SEQUENCE LISTING

&lt;110&gt; Calgene LLC

&lt;120&gt; Expression of Eukaryotic Peptides in Plant Plastids

&lt;130&gt; 15346WO

&lt;140&gt; new application

&lt;141&gt; 1999-07-07

&lt;150&gt; 09/316847

&lt;151&gt; 1999-05-21

&lt;150&gt; 09/113244

&lt;151&gt; 1998-07-10

&lt;160&gt; 2

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 88

&lt;212&gt; DNA

&lt;213&gt; from T7 bacteriophage from gene 10

<400> 1  
aattgtagaa ataattttgt ttaactttaa gaaggagata taccttaaca tctttattaa 60  
aacaaattga aattcttctt ctatatgg 88

&lt;210&gt; 2

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Arg Pro Asp Phe Cys Leu Glu Pro Pro Tyr Thr Gly Pro Cys Lys Ala  
1 5 10 15

Arg Ile Ile Arg Tyr Phe Tyr Asn Ala Lys Ala Gly Leu Cys Gln Thr  
20 25 30

Phe Val Tyr Gly Gly Cys Arg Ala Lys Arg Asn Asn Phe Lys Ser Ala  
35 40 45

Glu Asp Cys Met Arg Thr Cys Gly Gly Ala  
50 55





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/15, 15/18, 15/62, 15/82,</b> <b>5/10, A01H 5/00, 5/10</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/03012</b> <b>(43) International Publication Date:</b> 20 January 2000 (20.01.00)
<b>(21) International Application Number:</b> PCT/US99/15473 <b>(22) International Filing Date:</b> 10 July 1999 (10.07.99)  <b>(30) Priority Data:</b> 09/113,244 10 July 1998 (10.07.98) US 09/316,847 21 May 1999 (21.05.99) US  <b>(71) Applicant (for all designated States except US):</b> CALGENE LLC [US/US]; 1920 Fifth Street, Davis, CA 95616 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> MCBRIDE, Kevin, E. [US/US]; 1309 Marina Circle, Davis, CA 95616 (US). NEHRA, Narender [AU/US]; 14971 Appalachina Trail, Chesterfield, MO 63017 (US). RUSSELL, Douglas, A. [US/US]; 1610 Frisch Road, Madison, WI 53711 (US). STALKER, David, M. [US/US]; 870 W. Southwood, Wood- land, CA 945695 (US).  <b>(74) Agent:</b> PATENT DEPARTMENT CENTRAL; Monsanto/G.D. Searle, P.O. Box 5110, Chicago, IL 60680-5110 (US).		<b>(81) Designated States:</b> BR, CA, JP, MX, US. European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 8 June 2000 (08.06.00)
<b>(54) Title:</b> EXPRESSION OF EUKARYOTIC PEPTIDES IN PLANT PLASTIDS  <b>(57) Abstract</b>  Constructs and methods are provided for expressing peptides derived from eukaryotic organisms in plant plastids. Constructs have a promoter functional in a plant plastid, a DNA sequence encoding a peptide derived from an eukaryotic organism and a transcription termination region. Other elements include a selectable marker for selection of plant cells comprising a plastid expressing the marker and DNA regions of homology to the genome of the plastid and optionally a ribosome binding site joined to the promoter. By methods using such constructs high levels of eukaryotic peptides, such as mammalian proteins, are produced in a plant cell by growing plant cells under conditions whereby the DNA encoding sequences are expressed to produce eukaryotic peptide in said plastid.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

Intern al Application No  
PCT/US 99/15473

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/15 C12N15/18 C12N15/62 C12N15/82 C12N5/10  
A01H5/00 A01H5/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MAREK, LAURA FREDRICK ET AL: "Chlamydomonas chloroplast transformation using human carbonic anhydrase." PLANT PHYSIOLOGY (ROCKVILLE), (1994) VOL. 105, NO. 1 SUPPL., PP. 84. MEETING INFO.: ANNUAL MEETING OF THE AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS PORTLAND, OREGON, USA JULY 30-AUGUST 3, 1994, XP002118154 abstract	1-4,6, 9-16,18, 21,22, 25-33, 40,41,57
X	US 5 693 507 A (DANIELL HENRY ET AL) 2 December 1997 (1997-12-02)	57
A	see esp. example 4	1-8, 25-47,49
A	WO 98 26083 A (MONSANTO CO) 18 June 1998 (1998-06-18) the whole document	6,9
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

8 March 2000

Date of mailing of the international search report

03. 04 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kania, T

## INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/US 99/15473

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 437 320 A (KOREA INST SCIENCE TECHNOLOGY) 17 July 1991 (1991-07-17) the whole document ---	10-12
A	WO 91 13993 A (UPJOHN CO) 19 September 1991 (1991-09-19) the whole document ---	10,11, 13-16,18
A	WO 97 42313 A (SCRIPPS RESEARCH INST) 13 November 1997 (1997-11-13) the whole document ---	10,11,21
A	US 5 723 755 A (FORTIN MARC G) 3 March 1998 (1998-03-03) the whole document ---	10,22
A	MATSUMOTO S ET AL: "CHARACTERIZATION OF A HUMAN GLYCOPROTEIN ( ERYTHROPOIETIN ) PRODUCED IN CULTURED TOBACCO CELLS" PLANT MOLECULAR BIOLOGY, (MAR 1995) VOL. 27, NO. 6, PP. 1163-1172. ISSN: 0167-4412., XP002132161 the whole document ---	10,11,19
A	SAFFORD R. ET AL.: "Regulated expression of the rat medium chain hydrolase gene in transgenic rape seed" TRANSGENIC RESEARCH, vol. 2, 1993, pages 191-198, XP000884365 the whole document ---	10-29
A	KWON S Y ET AL: "EXPRESSION OF ACTIVE HUMAN INTERLEUKIN -6 IN TRANSGENIC TOBACCO" MOLECULES AND CELLS, (31 OCT 1995) VOL. 5, NO. 5, PP. 486-492. ISSN: 1016-8478., XP000884550 the whole document ---	10,11,19
A	LEE J S ET AL: "Establishment of a transgenic tobacco cell suspension culture system for producing murine granulocyte-macrophage colony stimulating factor." MOLECULES AND CELLS, (1997 DEC 31) 7 (6) 783-7. , XP000884527 the whole document ---	10,11, 19,20
A	CA 2 188 220 A (UNIV KINGSTON ;MINI OF AGRICULTURE AND AGRI F (CA)) 18 April 1998 (1998-04-18) see esp. ex. 4 ---	10,11,19
	---	
	-/--	

# INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 99/15473

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DANIELL ET AL: "Containment of herbicide resistance through genetic engineering of the chloroplast genome" NATURE BIOTECHNOLOGY, vol. 16, 1 April 1998 (1998-04-01), pages 345-348, XP002090409 ISSN: 1087-0156 the whole document ---	1-8, 25-47,49
A	WO 95 16783 A (CALGENE INC ;MCBRIDE KEVIN E (US); STALKER DAVID M (US)) 22 June 1995 (1995-06-22) the whole document ---	1-8, 25-47,49
A	WO 98 11235 A (CIBA GEIGY AG ;HEIFETZ PETER (US); LEBEL EDOUARD (US); UKNES SCOTT) 19 March 1998 (1998-03-19) see esp. example C ---	1-8, 25-47,49
A	MCBRIDE ET AL: "Amplification of a chimeric Bacillus gene in chloroplasts leads to an extraordinary level of an insecticidal protein in tobacco" BIO/TECHNOLOGY, vol. 13, 13 April 1995 (1995-04-13), pages 362-365, XP002090404 ISSN: 0733-222X the whole document ---	1-8, 25-47,49
A	WO 95 24492 A (CALGENE INC ;STATE UNIVERSITY OF NEW JERSEY (US)) 14 September 1995 (1995-09-14) the whole document ---	1-8, 25-47,49
A	WO 97 17453 A (HOWARD JOHN A) 15 May 1997 (1997-05-15)  the whole document ---	1-5,10, 23-41, 47,49
A	WO 98 06860 A (CIBA GEIGY AG ;VERNOOIJ BARNARDUS THEODORUS M (NL); CHANDLER DANIE) 19 February 1998 (1998-02-19) see esp. ex. 6 ---	1-5,10, 25-41, 47,49
A	WO 91 02800 A (CAMBRIDGE ADVANCED TECH ;AGRICULTURAL GENETICS CO (GB); BIOTAL LTD) 7 March 1991 (1991-03-07) the whole document ---	43
A	WO 89 09829 A (MASSACHUSETTS INST TECHNOLOGY) 19 October 1989 (1989-10-19) the whole document ---	51-78
	-/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/15473

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BAKER R.: "Protein expression using ubiquitin fusion and cleavage" CURRENT OPINION IN BIOTECHNOLOGY, vol. 7, 1996, pages 541-546, XP002132162 cited in the application see esp. p.544 ---	51-78
A	US 5 773 705 A (CALLIS JUDY ET AL) 30 June 1998 (1998-06-30) see the whole document; esp. pp.4,5 ---	51-78
P,X	WO 98 31823 A (SCRIPPS RESEARCH INST ;MAYFIELD STEPHEN (US)) 23 July 1998 (1998-07-23)  see esp. examples ---	1-4,10, 11,21, 25-33, 40,47,49
P,X	WO 99 10513 A (DANIELL HENRY ;UNIV AUBURN (US)) 4 March 1999 (1999-03-04)  see the whole document; esp. pp.29-35; claims 100-121 ---	1-4, 10-12, 25-33, 40,41
T	WO 98 58069 A (MONSANTO CO) 23 December 1998 (1998-12-23) see examples -----	1-8, 25-47,49

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/15473

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-8,25-47,49 all partially

Plant plastid expression constructs comprising: a promoter functional in a plant plastid, a DNA sequence, native or synthetic, encoding a eukaryotic peptide not being a peptide of a plant plastid, optionally being a fusion protein with cytochrome f thylakoid targetting terminus or cleavable ubiquitin N-terminus, a transcription termination region. Said constructs further comprising a selectable marker as specified, DNA regions of homology to the plastid genome flanking the other component, a ribosome binding site, preferably the binding site of the gene 10 leader or rbcLRBS.

Said DNA sequence encoding the plant nuclear peptide fructose 1,6 biphosphate aldolase. Plant cell plastids, plant cells, plants, and seeds comprising said constructs. Use of said constructs in a method for producing a protein in a plant cell. Said protein optionally having the correct number of disulfide bonds and being bioactive. Plant cells derived from said method comprising more than 0.01%-7% of said soluble protein. Plants and seeds derived from said method.

2. Claims: 1-8,25-47,49 all partially

idem, the peptide being seduheptulose biphosphatase

3. Claims: 1-7,25-47,49 all partially; 9 completely

idem, the peptide being a plant nuclear peptide, preferably a carbon cycle peptide, or an antifungal peptide not comprised in subjects 1 and 2

4. Claims: 1-5,10,11,25-47,49 all partially; 12 completely

idem, the peptide being insulin

5. Claims: 1-5,10,11,13-15,25-47,49 all partially; 16,17,48, 50 completely

idem, the peptide being a growth hormone

6. Claims: 1-5,10,11,13-15,25-47, 49 all partially; 18 completely



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

idem, the peptide being prolactin

7. Claims: 1-5,10,11,13,14,25-47,49 all partially

idem, the peptide being a mammalian hormone not comprised in subjects 4-6

8. Claims: 1-5,10,11,19,25-47,49 all partially; 20 completely

idem, the peptide being G-CSF

9. Claims: 1-5,10,11,19,25-47,49 all partially

idem, the peptide being a hematopoietic agent not comprised in subject 8

10. Claims: 1-5,10,11,25-47,49 all partially; 21 completely

idem, the peptide being an antibody, preferably a single-chain F variable antibody

11. Claims: 1-5,10,11,25-47,49 all partially; 22 completely

idem, the peptide being a non-enzymatic coagulation protein, preferably selected from the group consisting of factor V and factor VIII cofactor proteins

12. Claims: 1-5,10,23,25-47,49 all partially; 24 completely

idem, the peptide being the proteinase inhibitor aprotinin

13. Claims: 1-5,10,23,35-47,49 all partially

idem, the peptide being a proteinase inhibitor not comprised in subject 12

14. Claims: 1-5,10,25-47,49 all partially

idem, the peptide being a mammalian peptide not comprised in subjects 4-13

15. Claims: 42,44-46 all partially; 51-78 completely

A method for producing a non-methionine N-terminus in a plastid comprising: transforming a plastid with a construct comprising a promoter functional in a plant plastid, DNA

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

sequences encoding a cleavable ubiquitin peptide and a protein of interest, a transcription termination region, and growing said plant cell in order to express said DNA sequences. Said construct further comprising DNA regions of homology to the plastid genome, a selectable marker, a ribosome binding site, preferably the gene 10 leader or rbcLRBS. Said protein being folded with the correct number of disulfide bonds and being bioactive, preferably being hGH. A plastid having a protein of interest produced according to said method, said protein comprising at least 1-7% of the soluble protein in said plastid. Plant cells, plants and seeds comprising said plastids.

A method for producing a non-methionine N-terminus in a plastid comprising: transforming a plastid with a construct comprising a promoter functional in plant plastid, a DNA sequence encoding a protein of interest capable of being recognized by a plant cell methionine amino peptidase, a transcription termination region, and growing said plant cell in order to express said DNA sequences.

Said method wherein said plant cell methionine amino peptidase cleaves the N-terminal methionine, the second amino acid of said protein being preferably alanine.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No  
PCT/US 99/15473

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5693507 A	02-12-1997	US 5932479 A	03-08-1999
WO 9826083 A	18-06-1998	AU 5794898 A	03-07-1998
		EP 0946739 A	06-10-1999
EP 0437320 A	17-07-1991	NONE	
WO 9113993 A	19-09-1991	AU 7583691 A	10-10-1991
		EP 0519011 A	23-12-1992
WO 9742313 A	13-11-1997	US 5959177 A	28-09-1999
		AU 2932397 A	26-11-1997
		EP 0946717 A	06-10-1999
US 5723755 A	03-03-1998	WO 9909187 A	25-02-1999
		AU 3936697 A	08-03-1999
CA 2188220 A	18-04-1998	NONE	
WO 9516783 A	22-06-1995	US 5576198 A	19-11-1996
		CA 2178645 A	22-06-1995
		EP 0734446 A	02-10-1996
		JP 9510342 T	21-10-1997
WO 9811235 A	19-03-1998	AU 4414697 A	02-04-1998
		CN 1230224 A	29-09-1999
		EP 0925362 A	30-06-1999
		PL 331767 A	02-08-1999
WO 9524492 A	14-09-1995	US 5545818 A	13-08-1996
		CA 2185340 A	14-09-1995
		EP 0749490 A	27-12-1996
		JP 10511261 T	04-11-1998
WO 9717453 A	15-05-1997	US 5824870 A	20-10-1998
		AU 1156797 A	29-05-1997
		CA 2233538 A	15-05-1997
		EP 0859852 A	26-08-1998
WO 9806860 A	19-02-1998	AU 4205297 A	06-03-1998
		CN 1228123 A	08-09-1999
		EP 0918873 A	02-06-1999
		PL 331563 A	19-07-1999
WO 9102800 A	07-03-1991	CA 2064903 A	15-02-1991
		EP 0487618 A	03-06-1992
		JP 7501681 T	23-02-1995
WO 8909829 A	19-10-1989	US 5132213 A	21-07-1992
		CA 1339842 A	28-04-1998
		EP 0408661 A	23-01-1991
		JP 2894357 B	24-05-1999
		JP 3503606 T	15-08-1991
		US 5496721 A	05-03-1996
		US 5093242 A	03-03-1992
		US 5646017 A	08-07-1997
		US 5847097 A	08-12-1998
		US 5196321 A	23-03-1993

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/US 99/15473

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5773705	A	30-06-1998	NONE	
WO 9831823	A	23-07-1998	AU 6027598 A	07-08-1998
WO 9910513	A	04-03-1999	AU 8457398 A	16-03-1999
WO 9858069	A	23-12-1998	AU 8144598 A	04-01-1999



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/15, 15/18, 15/62, 15/82, 5/10, A01H 5/00, 5/10</b>		(11) International Publication Number: <b>WO 00/03012</b>
(21) International Application Number: <b>PCT/US99/15473</b>		(43) International Publication Date: <b>20 January 2000 (20.01.00)</b>
(22) International Filing Date: <b>10 July 1999 (10.07.99)</b>		(81) Designated States: <b>BR, CA, JP, MX, US</b> , European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> <b>8 June 2000 (08.06.00)</b>
(30) Priority Data: 09/113,244                      10 July 1998 (10.07.98)                      US 09/316,847                      21 May 1999 (21.05.99)                      US		
(71) Applicant (for all designated States except US): <b>CALGENE LLC [US/US]; 1920 Fifth Street, Davis, CA 95616 (US).</b>		
(72) Inventors; and (75) Inventors/Applicants (for US only): <b>MCBRIDE, Kevin, E. [US/US]; 1309 Marina Circle, Davis, CA 95616 (US). NEHRA, Narender [AU/US]; 14971 Appalachina Trail, Chesterfield, MO 63017 (US). RUSSELL, Douglas, A. [US/US]; 1610 Frisch Road, Madison, WI 53711 (US). STALKER, David, M. [US/US]; 870 W. Southwood, Woodland, CA 945695 (US).</b>		
(74) Agent: <b>PATENT DEPARTMENT CENTRAL; Monsanto/G.D. Searle, P.O. Box 5110, Chicago, IL 60680-5110 (US).</b>		
<b>(54) Title: EXPRESSION OF EUKARYOTIC PEPTIDES IN PLANT PLASTIDS</b>		
<b>(57) Abstract</b>  Constructs and methods are provided for expressing peptides derived from eukaryotic organisms in plant plastids. Constructs have a promoter functional in a plant plastid, a DNA sequence encoding a peptide derived from an eukaryotic organism and a transcription termination region. Other elements include a selectable marker for selection of plant cells comprising a plastid expressing the marker and DNA regions of homology to the genome of the plastid and optionally a ribosome binding site joined to the promoter. By methods using such constructs high levels of eukaryotic peptides, such as mammalian proteins, are produced in a plant cell by growing plant cells under conditions whereby the DNA encoding sequences are expressed to produce eukaryotic peptide in said plastid.		

•(Referred to in PCT Gazette No. 29/2000, Section II)

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## EXPRESSION OF EUKARYOTIC PEPTIDES IN PLANT PLASTIDS

5

### INTRODUCTION

#### Technical Field

This invention relates to the application of genetic engineering techniques to  
10 plants. Specifically, the invention relates to compositions and methods for enhancing  
expression of proteins in plant plastids.

#### Background

The plastids of higher plants are an attractive target for genetic engineering. Plant  
15 plastids (chloroplasts, amyloplasts, elaioplasts, etioplasts, chromoplasts, etc.) are the major  
biosynthetic centers that, in addition to photosynthesis, are responsible for production of  
industrially important compounds such as amino acids, complex carbohydrates, fatty acids,  
and pigments. Plastids are derived from a common precursor known as a proplastid and  
thus the plastids present in a given plant species all have the same genetic content. Plant  
20 cells contain 500-10,000 copies of a small 120-160 kilobase circular genome, each  
molecule of which has a large (approximately 25kb) inverted repeat. Thus, it is possible to  
engineer plant cells to contain up to 20,000 copies of a particular gene of interest which  
potentially can result in very high levels of foreign gene expression. In addition, plastids  
of most plants are maternally inherited. Consequently, unlike heterologous genes  
25 expressed in the nucleus, heterologous genes expressed in plastids are not pollen  
disseminated, therefore, a trait introduced into a plant plastid will not be transmitted to  
wild-type relatives.

There remains a need for improved regulatory elements for expression of genes in a  
plant plastid. To date, the expression signals used routinely for plastid transgene  
30 expression derive from endogenous plastid genes. The plastid expression signals are  
typically derived from promoter regions of highly expressed plastid genes such as the  
promoter regions from the 16S ribosomal RNA operon (*Prm*), *psbA* gene (*PpsbA*) or the  
*rbcL* gene (*PrbcL*). The *psbA* and *rbcL* genes are highly transcribed, but their translation is

controlled by tissue-specific and light-regulated factors which limits their usefulness. In the case of *Prm*, a synthetic ribosome binding site (RBS) patterned after the plastid *rbcl* gene leader has been typically used to direct translation. However, this *Prm*/RBS is translated inefficiently due to poor ribosome binding.

Plastids of higher plants present an attractive target for genetic engineering. As mentioned above, plastids of higher plants are maternally inherited. This offers an advantage for genetic engineering of plants for tolerance or resistance to natural or chemical conditions, such as herbicide tolerance, as these traits will not be transmitted to wild-type relatives. In addition, the high level of foreign gene expression is attractive for engineered traits such as the production of pharmaceutically important proteins.

Expression of nucleic acid sequences encoding for enzymes providing for herbicide tolerance as well as pharmaceutical proteins from plant plastid genome offers an attractive alternative to expression from the plant nuclear genome.

## SUMMARY OF THE INVENTION

The present invention provides nucleic acid sequences useful in enhancing expression of a wide variety of genes, both eukaryotic and prokaryotic, in plant plastids. Furthermore, plastid expression constructs are provided which are useful for genetic engineering of plant cells and which provide for enhanced expression of the EPSP synthase proteins or the hGH protein in plant cell plastids. The transformed plastids should be metabolically active plastids, and are preferably maintained at a high copy number in the plant tissue of interest, most preferably the chloroplasts found in green plant tissues, such as leaves or cotyledons.

The plastid expression constructs for use in this invention generally include a plastid promoter region capable of providing for enhanced expression of a DNA sequence, a DNA sequence encoding an EPSPS protein or human growth hormone (hGH), and a transcription termination region capable of terminating transcription in a plant plastid.

The plastid promoter region of the present invention is preferably linked to a ribosome binding site which provides for enhanced translation of mRNA transcripts in a plant plastid.

The plastid expression construct of this invention is preferably linked to a construct having a DNA sequence encoding a selectable marker which can be expressed in a plant



plastid. Expression of the selectable marker allows the identification of plant cells comprising a plastid expressing the marker.

In a preferred embodiment, vectors for transfer of the construct into a plant cell include means for inserting the expression and selection constructs into the plastid  
5 genome. The vectors preferably comprise regions of homology to the target plastid genome which flank the constructs.

The constructs of the present invention preferably comprise a promoter sequence linked to a ribosome binding site capable of enhancing the translation of mRNA transcripts in the plant plastid. The ribosome binding site is preferably derived from the T7  
10 bacteriophage gene 10 leader sequence.

Of particular interest in the present invention is the high level of expression of nucleic acid sequences in plant plastids. Of particular interest is the high level expression of nucleic acid sequences encoding for enzymes involved in herbicide tolerance and encoding for pharmaceutical proteins.

The constructs of the present invention preferably comprise a DNA sequence encoding 5-Enolpyruvylshikimate-3-phosphate synthase (USPN 5,633,435, the entirety of which is incorporated herein by reference), nitrilase, phytoene desaturase, aprotinin or a  
15 DNA sequence encoding human growth hormone (USPN 5,424,199, the entirety of which is incorporated herein by reference).

Plant cell plastids containing the constructs are also contemplated in the invention, as are plants, plant seeds, plant cells or progeny thereof containing plastids comprising the construct.  
20

The present invention also includes methods for enhanced expression of DNA sequences in plant plastids.

The invention also includes a method for the enhanced expression of an enzyme encoding hGH in plastids of the plant cell.  
25

The present invention further includes methods for obtaining a protein expressed from a plant cell, including a plastid, having a non-methionine N-terminus. In addition, plant cells and plastids which include non-methionine N-terminus proteins are  
30 contemplated.

Thus, the present invention relates to a chimeric gene containing a coding sequence of a pharmaceutical protein, a plant plastid expression vector containing a promoter operably linked to a T7 Bacteriophage Polymerase gene 10 ribosome binding site capable

of enhanced expression in a plant plastid operably linked to a herbicide tolerance or pharmaceutical coding gene, a plant transformation vector having inserted therein a herbicide tolerance or pharmaceutical coding gene expressed from a plastid promoter linked to a T7 Bacteriophage Polymerase gene 10 ribosome binding site, plant cells  
5 transformed using such vectors and plants regenerated therefrom which exhibit a substantial degree of expression of nucleic acid sequences and proteins and methods for producing such plants and such plants.

10

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleotide sequence of the G10L ribosome binding site.

Figure 2 provides an amino acid sequence encoding for aprotinin.

Figure 3 provides the results of RP-HPLC analysis for characterization of hGH protein expressed in the plastid. Peak I (tallest peak) indicates the expected retention time  
15 for properly folded, native 22 kDa GP2000.

Figure 4 provides an electrospray ionization mass spectrometry (MS) analysis using a Micromass Q-ToF electrospray time-of-flight mass spectrometer. In particular, a series of ions corresponding to the specie(s) present in the sample with varying numbers of protons attached is provided. The axes of the spectrum are intensity versus mass-to-charge  
20 ratio of the specie(s) present.

Figure 5 provides a graphic representation of the bioactivity of hGH expressed from a plant plastid. The samples represented on the graph are bovine prolactin (bPL), hGH expressed from *E. coli* (Ala-hGH), and a null transgenic spiked with bovine prolactin (SPFF Null Spike) as positive controls, a null transgenic (SPFF Null) as a negative control,  
25 and transgenic samples from a sepharose column (SPFF Sample, SPFF Sample) and a transgenic sample eluted from the sepharose column at pH3.5 (SPFF pH3.5 Eln).

### DETAILED DESCRIPTION OF THE INVENTION

In accordance with the subject invention, plastid expression constructs are provided  
30 which generally comprise a promoter functional in a plant plastid, a ribosome binding site derived from the T7 Bacteriophage Polymerase gene 10 leader, a DNA sequence encoding for a gene of interest, and a transcription termination region capable of terminating

transcription in a plant plastid. These elements are provided as operably joined components in the 5' to 3' direction of transcription.

Furthermore, the constructs of the present invention may also include a nucleic acid sequence encoding a peptide capable of targeting said DNA sequence encoding a protein to the thylakoid lumen within the chloroplast.

Of particular interest in the present invention are methods for the production of proteins in a host plant cell plastid having a non-methionine N-terminus. Such methods generally involve the use of fusion proteins having an N-terminus sequence which is recognized by an endogenous protease. In particular, a DNA sequence encoding a cleavable ubiquitin peptide is fused to a DNA sequence encoding a protein of interest. After expression of the fusion protein in the plastid, an endogenous protease acts on the fusion to cleave off the ubiquitin portion of the protein.

Also of interest in the present invention is the use of the plastid expression constructs to direct the high level transcription and translation (expression) of nucleic acid sequences. Such plastid expression constructs find use in directing the high level expression of DNA sequences encoding for enzymes involved in herbicide tolerance or encoding for the production of pharmaceutical proteins.

Of more particular interest in the present invention is the use of the plastid expression constructs to direct the high level translation of transcribed messenger RNA.

DNA sequence and biochemical data reveal a similarity of the plastid organelle's transcriptional and translational machineries and initiation signals to those found in prokaryotic systems. In fact, plastid derived promoter sequences have been reported to direct expression of reporter genes in prokaryotic cells. In addition, plastid genes are often organized into polycistronic operons as they are in prokaryotes.

Despite the apparent similarities between plastids and prokaryotes, there exist fundamental differences in the methods used to control gene expression in plastids and prokaryotes. As opposed to the transcriptional control mechanisms typically observed in prokaryotes, plastid gene expression is controlled predominantly at the level of translation and mRNA stability by trans-acting nuclear encoded proteins.

Translation is a multi-stage process which first involves the binding of messenger RNA (mRNA) to ribosomes. Beginning at the translation start codon, the mRNA codons are read sequentially as the ribosomes move along the mRNA molecule. The specified

amino acids are then sequentially added to the growing polypeptide chain to yield the protein or polypeptide encoded in the mRNA.

As mentioned, the first step in the translation process is the binding of the mRNA molecule to the ribosome. The nature of this interaction (i.e. binding) has been only partially elucidated. Analysis of RNase-resistant oligonucleotides isolated from bacterial translation initiation complexes indicate that a RNA fragment approximately 30 to 40 nucleotides in length comprises the initial ribosome binding site (RBS). Thus, a RBS is hereinafter understood to comprise a sequence of mRNA surrounding the translation start codon which is responsible for the binding of the ribosome and for initiation of translation.

Recently, ribosome binding sites have been identified which are capable of directing translation in a prokaryotes. For example, a ribosome binding site derived from the T7 bacteriophage gene 10 leader, G10L (USPN 5,232,840, the entirety of which is incorporated herein by reference), has been identified which enhances expression of nucleic acid sequences in prokaryotes.

Herbicides such as N-phosphonomethylglycine, halogenated hydroxybenzonitriles, and norflurazon have been the subject of a large amount of investigation.

N-phosphonomethylglycine, commonly referred to as glyphosate, inhibits the shikimic acid pathway which leads to the biosynthesis of aromatic compounds including amino acids, plant hormones and vitamins. Specifically, glyphosate curbs the conversion of phosphoenolpyruvic acid (PEP) and 3-phosphoshikimic acid to 5-enolpyruvyl-3-phosphoshikimic acid by inhibiting the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (hereinafter referred to as EPSP synthase or EPSPS).

Glyphosate tolerant plants have been produced by transformation of various EPSP synthase genes into the nuclear genome of a plant. A gene for EPSP synthase has been cloned from *Agrobacterium tumefaciens* sp strain CP4 (USPN 5,633,435) and confers a high level of glyphosate tolerance in plants. Furthermore, high levels of glyphosate tolerance has been achieved in a number of crop plants by fusing EPSPS to a chloroplast transit peptide (CTP) for targeted expression in plastids. In addition, variants of the wild-type EPSPS enzyme have been isolated which are glyphosate tolerant as a result of alterations in the EPSPS amino acid coding sequence (Kishore and Shah, *Ann. Rev. Biochem.* (1988) 57:627-663; Shulze et al., *Arch. Microbiol.* (1984) 137:121-123; Kishore et al., *Fed. Proc.* (1986) 45:1506). These variants typically have a higher  $K_i$  for glyphosate than the wild-type EPSPS enzyme which confers the glyphosate tolerant phenotype, but

these variants are also characterized by a high  $K_m$  for PEP which makes the enzyme kinetically less efficient (Kishore and Shah, *Ann. Rev. Biochem.* (1988) 57:627-663; Sost et al., *FEBS Lett.* (1984) 173: 238-241; Shulze et al., *Arch. Microbiol.* (1984) 137:121-123; Kishore et al., *Fed. Proc.* (1986) 45:1506; Sost and Amrhein, *Arch. Biochem. Biophys.* (1990) 282: 433-436).

In addition to engineering plants for glyphosate tolerance, plants have also been engineered to tolerate other classes of herbicides such as halogenated hydroxybenzonitriles, and norflurazon using nucleic acid sequences expressed in the nucleus.

Halogenated hydroxybenzonitriles, such as Bromoxynil, are suggested to act herbicidally by inhibiting the quinone-binding protein complex of photosystem II, inhibiting electron transfer (Van Rensen (1982) *Physiol. Plant* 54:515-520, and Sanders and Pallett (1986) *Pestic. Biochem. Physiol.* 26:116-122). Herbicides such as norflurazon inhibit the production of carotenoids.

Plants which are resistant to Bromoxynil have been produced by expressing DNA sequences encoding for enzymes capable of detoxifying Bromoxynil (nitrilases) in the plant cell nucleus. DNA sequences encoding for such nitrilases have been cloned from bacteria such as *Klebsiella pneumoniae* and used to construct vectors to direct the expression of the DNA sequence in plant cell nucleus (USPN 4,810,648, the entirety of which is incorporated herein by reference).

Plants which are resistant to Norflurazon have been engineered by expressing nucleic acid sequences which encode for enzymes in the carotenoid biosynthetic pathway in plant cell nuclei. For example, expressing a phytoene desaturase from *Erwinia uredovora* provides tolerance to norflurazon.

While plants transformed to express nucleic acid sequences encoding for such enzymes from the nuclear genome have found utility in engineering herbicide tolerant plants, it would be increasingly beneficial to obtain herbicide tolerant plants via plastidial expression.

In the examples provided herein, DNA sequences encoding for enzymes involved in herbicide tolerance are used in constructs to direct the expression of the sequences from the plant plastid. DNA sequences encoding for 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS), bromoxynil nitrilase (Bxn), phytoene desaturase (crtI (Misawa et al, (1993) *Plant Journal* 4:833-840, and (1994) *Plant Jour* 6:481-489), and acetohydroxyacid

synthase (AHAS (Sathasiivan *et al.* (1990) *Nucl. Acids Res.* 18:2188-2193)) are used in the expression constructs of the present invention to direct the expression of said herbicide tolerance nucleotide sequences from the plant plastid.

Transplastomic tobacco plants are identified which are homoplasmic for the DNA sequences encoding the herbicide tolerance genes. Homoplasmic plants demonstrate a high level of protein expression from the plastid. Furthermore, homoplasmic plants demonstrate a high level of tolerance for the respective herbicide. For example, as described in more detail in the example below, plants transformed to express EPSPS from the plastid demonstrate a high level of tolerance for the herbicide glyphosate. In addition, homoplasmic tobacco lines expressing nitrilase or phytoene desaturase demonstrate high levels of tolerance for the herbicides bromoxynil and norflurazon, respectively.

An artisan skilled in the art to which the present invention pertains will recognize that additional sequences may be employed to in the plastid expression constructs of the instant invention to produce herbicide tolerant plants. Other nucleic acid sequence which may find use in the plastid expression constructs herbicide tolerant plants include the *bar* gene for tolerance to glufosinate (DeBlock, *et al.* (1987) *EMBO J.* 6:2513-2519).

Furthermore, additional glyphosate tolerance genes may be employed in the constructs of the present invention. Additional glyphosate tolerant EPSPS genes are described in U.S. Patent Number 5,627,061, Padgett *et al.* (1996) *Herbicide Resistant Crops*, Lewis Publishers, 53-85, and in Penaloza-Vazquez, *et al.* (1995) *Plant Cell Reports* 14:482-487, the entireties of which are incorporated herein by reference.

It should be noted that the herbicide tolerance constructs of the present invention may also include sequences encoding genes involved in other stress tolerance genes, for example insect or disease resistance/tolerance genes. As described in more detail in the examples that follow, plastid expression constructs are used to regenerate plants which are resistant to the herbicide Buctril, and which also express the *Bacillus thuringiensis cry1Ac* protein.

In addition, the plastid expression constructs also find use in directing the production of human biological proteins (pharmaceutical proteins) from the plant plastid. As set forth in detail in the examples, constructs are provided for expression of aprotinin and human growth hormone in the plant plastid. Other sequences which may find use in the expression constructs of the present invention for the production of human biologics include sequences encoding for insulin or insulin precursors. However, the skilled artisan

will recognize that many nucleotide sequences encoding for human biologics may be employed in the constructs of the present invention to direct their expression from a plant plastid such as those described in Goodman and Gelman (1990) *Pharmacological Basis of Therapeutics*, Pergaman Press, 8<sup>th</sup> Edition, Sections 14 and 15. As, it is contemplated that  
5 any protein for which the nucleotide sequence has been identified can be used in the constructs of the present invention.

The present invention also provides methods for producing a pharmaceutical protein with a non-methionine N-terminus in a plant plastid. In general, the methods comprise expressing a fusion protein including a ubiquitin gene fused to a protein of  
10 interest in a plastid. The ubiquitin gene is obtained from a natural source and cloned into an appropriate vector, as described in WO 88/02406, supra, the disclosure of which is incorporated herein by reference, or it is synthesized chemically, using, e.g., the method described by Ecker et al., J. Biol. Chem., 262:3524-3527 (1987) and Ecker et al., J. Biol. Chem., 262: 14213-14221 (1987), the disclosures of which are incorporated by reference.  
15 The ubiquitin fusion proteins are recognized by ubiquitin protease, contrary to previous reports (Vierstra (1996) *Plant Mol. Biol.* 32:275-302), which cleaves immediately downstream of the carboxy terminal glycine residue of ubiquitin. This property has allowed production of recombinant proteins containing N-terminal residues other than methionine (Baker (1996) *Current Opin. Biotech.* 7:541-546).

20 Additional methods for the production of pharmaceutical proteins with a non-methionine N-terminus in a plant plastid are also provided. As described more fully in the Examples below, constructs are prepared to direct the production of a methionine-hGH (M-hGH) in a plant cell plastid. The constructs generally comprise a transcriptional initiation region and a DNA sequence encoding hGH. Surprisingly, N-terminal amino  
25 acid sequencing of the extracted hGH produced in transplastomic plants reveals that the N-terminal methionine is cleaved from the mature hGH protein, producing hGH with an alanine N-terminus (A-hGH). This result indicates the interaction of the expressed hGH with a methionine amino peptidase (MAP) in the plant cell. While it is anticipated that any amino acid may follow in the N-terminal methionine, the second amino acid is  
30 preferably selected from the group consisting of alanine, cysteine, glycine, proline, serine, threonine, and valine.

As described in more detail below, nucleic acid sequences encoding for the human growth hormone (hGH) are employed in plastid expression constructs of the present

invention. Further, transplastomic tobacco plants containing such constructs demonstrate a high level of expression of hGH. In addition, the hGH protein expressed from the plant plastid exhibits characteristics of proper processing as well as proper protein folding.

Human growth hormone (hGH) participates in much of the regulation of normal human growth and development. This 22,000 dalton pituitary hormone exhibits a multitude of biological effects including linear growth (somatogenesis), lactation, activation of macrophages, insulin-like and diabetogenic effects among others (Chawla, *Ann. Rev. Med.*(1983) 34:519; Edwards, *et al.*, *Science* (1988) 239:769; Thorner *et al.*, *J. Clin. Invest.* (1988) 81:745). hGH is a member of a family of homologous hormones that include placental lactogens, prolactins, and other genetic and species variants or growth hormone (Nicoll, *et al.*, *Endocrine Reviews*(1986) 7:169). hGH is unusual among these in that it exhibits broad species specificity and binds to either the cloned somatogenic (Leung, *et al.*, *Nature* (1987) 33:537) or prolactin receptor (Boutin, *et al.*, *Cell* (1988) 53:69). The primary use of hGH is in the treatment of hypopituitary dwarfism in children. Additional indications are in treatment of Turner syndrome, chronic renal failure, HIV wasting syndrome and the treatment of the elderly and critically ill (Tritos, *et al.* (1998) *Am. J. Med.* 105:44-57).

As produced in the pituitary gland, hGH enters the secretory system, coincident with removal of its signal peptide and formation of two disulfide bonds (Chawla, *et al.* (1983) *supra*). In the pituitary gland, removal of the signal peptide from hGH (also referred to as human somatotropin or hST) during secretion leaves phenylalanine as the N-terminal amino acid (Chawla, *et al.* (1983) *Annu. Rev. Med.* 34:519-547). As normal translation in plastids initiates at methionine, a ubiquitin-hGH fusion was designed to yield a phenylalanine N-terminus (F-hGH) in the final hGH product.

Surprisingly, although ubiquitin protease was previously reported to not be present in chloroplasts (Vierstra (1996) *Plant Mol. Biol.* 32:275-302), the ubiquitin-hGH fusion was processed during synthesis, accumulation or purification from the plants to produce a phenylalanine N-terminus hGH product (F-hGH). The control construct carrying the full-length cDNA encoded methionine and alanine as the first amino acids of hGH.

As described in the Examples below, constructs comprising nucleic acid sequences encoding aprotinin (also known as bovine pancreatic trypsin inhibitor, BPTI) were employed in plastid expression constructs of the present invention. Aprotinin is a basic protein present in several bovine organs and tissues, such as the lymph nodes, pancreas,



lungs, parotid gland, spleen and liver. Aprotinin is known to inhibit various serine proteases, including trypsin, chymotrypsin, plasmin and kallikrein, and is used therapeutically in the treatment of acute pancreatitis, various stages of shock syndrome, hyperfibrinolytic hemorrhage and myocardial infarction. In addition, administration of aprotinin in high doses significantly reduces blood loss in connection with cardiac surgery, including cardiopulmonary bypass (Bidstrup, *et al.* (1989) *Cardiovasc Surg.* 44:640-645)

In developing the constructs, the various fragments comprising the regulatory regions and open reading frame may be subjected to different processing conditions, such as ligation, restriction enzyme digestion, PCR, *in vitro* mutagenesis, linkers and adapters addition, and the like. Thus, nucleotide transitions, transversions, insertions, deletions, or the like, may be performed on the DNA which is employed in the regulatory regions or the DNA sequences of interest for expression in the plastids. Methods for restriction digests, Klenow blunt end treatments, ligations, and the like are well known to those in the art and are described, for example, by Maniatis *et al.* (in *Molecular Cloning: A Laboratory Manual* (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

During the preparation of the constructs, the various fragments of DNA will often be cloned in an appropriate cloning vector, which allows for amplification of the DNA, modification of the DNA or manipulation of the DNA by joining or removing sequences, linkers, or the like. Preferably, the vectors will be capable of replication to at least a relatively high copy number in *E. coli*. A number of vectors are readily available for cloning, including such vectors as pBR322, vectors of the pUC series, the M13 series vectors, and pBluescript vectors (Stratagene; La Jolla, CA).

In order to provide a means of selecting the desired plant cells, vectors for plastid transformation typically contain a construct which provides for expression of a selectable marker gene. Marker genes are plant-expressible DNA sequences which express a polypeptide which resists a natural inhibition by, attenuates, or inactivates a selective substance, including, but not limited to, antibiotic, herbicide *etc.*

Alternatively, a marker gene may provide some other visibly reactive response, *i.e.*, may cause a distinctive appearance or growth pattern relative to plants or plant cells not expressing the selectable marker gene in the presence of some substance, either as applied directly to the plant or plant cells or as present in the plant or plant cell growth media.

In either case, the plants or plant cells containing such selectable marker genes will have a distinctive phenotype for purposes of identification, *i.e.*, they will be

distinguishable from non-transformed cells. The characteristic phenotype allows the identification of cells, cell groups, tissues, organs, plant parts or whole plants containing the construct.

Detection of the marker phenotype makes possible the selection of cells having a second gene to which the marker gene has been linked. This second gene typically comprises a desirable phenotype which is not readily identifiable in transformed cells, but which is present when the plant cell or derivative thereof is grown to maturity, even under conditions wherein the selectable marker phenotype itself is not apparent.

The use of such a marker for identification of plant cells containing a plastid construct has been described by Svab *et al.* (1993, *supra*). In the examples provided below, a bacterial *aadA* gene is expressed as the marker under the regulatory control of chloroplast 5' promoter and 3' transcription termination regions, specifically the regulatory regions of the *psbA* gene (described in Staub *et al.*, *EMBO J.*(1993) 12(2):601-606). Numerous additional promoter regions can also be used to drive expression of the selectable marker gene, including various plastid promoters and bacterial promoters which have been shown to function in plant plastids.

Expression of the *aadA* gene confers resistance to spectinomycin and streptomycin, and thus allows for the identification of plant cells expressing this marker. The *aadA* gene product allows for continued growth and greening of cells whose chloroplasts comprise the selectable marker gene product. Cells which do not contain the selectable marker gene product are bleached. Selection for the *aadA* gene marker is thus based on identification of plant cells which are not bleached by the presence of streptomycin, or more preferably spectinomycin, in the plant growth medium.

A number of markers have been developed for use with plant cells, such as resistance to chloramphenicol, the aminoglycoside G418, hygromycin, or the like. Other genes which encode a product involved in chloroplast metabolism may also be used as selectable markers. For example, genes which provide resistance to plant herbicides such as glyphosate, bromoxynil or imidazolinone may find particular use. Such genes have been reported (Stalker *et al.*, *J. Biol. Chem.* (1985) 260:4724-4728 (glyphosate resistant EPSP); Stalker *et al.*, *J. Biol. Chem.* (1985) 263:6310-6314 (bromoxynil resistant nitrilase gene); and Sathasivan *et al.*, *Nucl. Acids Res.* (1990) 18:2188 (AHAS imidazolinone resistance gene)).

Stable transformation of tobacco plastid genomes by particle bombardment is reported (Svab *et al.* (1990), *supra*) and Svab *et al.* (1993), *supra*). The methods described therein may be employed to obtain plants homoplasmic for plastid expression constructs.

5 Generally, bombarded tissue is cultured for approximately 2 days on a cell division-promoting media, after which the plant tissue is transferred to a selective media containing an inhibitory amount of the particular selective agent, as well as the particular hormones and other substances necessary to obtain regeneration for that particular plant species. Shoots are then subcultured on the same selective media to ensure production and  
10 selection of homoplasmic shoots.

Transplastomic tobacco plants are analyzed for a pure population of transformed plastid genomes (homoplasmic lines). Homoplasmy is verified using Southern analysis employing nucleic acid probes spanning a region of the transgene and chloroplast genome (i.e. the insertion region). Transplastomic plants which are heteroplasmic (i.e. contain a  
15 mixture of plastid genomes containing and lacking the transgene) are characterized by a hybridization pattern of wild type and transgenic bands. Homoplasmic plants show a hybridization pattern lacking the wild type band.

Alternatively, homoplasmy may be verified using the polymerase chain reaction (PCR). PCR primers are utilized which are targeted to amplify from sequences from the  
20 insertion region. For example, a pair of primers may be utilized in a PCR reaction. One primer amplifies from a region in the transgene, while the second primer amplifies from a region proximal to the insertion region towards the insertion region. A second PCR reaction is performed using primers designed to amplify the region of insertion. Transplastomic lines identified as homoplasmic produce the expected size fragment in the  
25 first reaction, while they do not produce the predicted size fragment in the second reaction.

Where transformation and regeneration methods have been adapted for a given plant species, either by *Agrobacterium*-mediated transformation, bombardment or some other method, the established techniques may be modified for use in selection and regeneration methods to produce plastid-transformed plants. For example, the methods  
30 described herein for tobacco are readily adaptable to other solanaceous species, such as tomato, petunia and potato.

For transformation of soybean, particle bombardment as well as *Agrobacterium*-mediated nuclear transformation and regeneration protocols have been described (Hinchee

*et al.* USPN 5,416,011, and Christou *et al.* USPN 5,015,580). The skilled artisan will recognize that protocols described for soybean transformation may be used

In *Brassica*, *Agrobacterium*-mediated transformation and regeneration protocols generally involve the use of hypocotyl tissue, a non-green tissue which might contain a low plastid content. Thus, for *Brassica*, preferred target tissues would include microspore-derived hypocotyl or cotyledonary tissues (which are green and thus contain numerous plastids) or leaf tissue explants. While the regeneration rates from such tissues may be low, positional effects, such as seen with *Agrobacterium*-mediated transformation, are not expected, thus it would not be necessary to screen numerous successfully transformed plants in order to obtain a desired phenotype.

For cotton, transformation of *Gossypium hirsutum* L. cotyledons by co-cultivation with *Agrobacterium tumefaciens* has been described by Firoozabady *et al.*, *Plant Mol. Bio.* (1987) 10:105-116 and Umbeck *et al.*, *Bio/Technology* (1987) 5:263-266. Again, as for *Brassica*, this tissue may contain insufficient plastid content for chloroplast transformation. Thus, as for *Brassica*, an alternative method for transformation and regeneration of alternative target tissue containing chloroplasts may be desirable, for instance targeting green embryogenic tissue.

Other plant species may be similarly transformed using related techniques. Alternatively, microprojectile bombardment methods, such as described by Klein *et al.* (*Bio/Technology* 10:286-291) may also be used to obtain nuclear transformed plants comprising the viral single subunit RNA polymerase expression constructs described herein. Cotton transformation by particle bombardment is reported in WO 92/15675, published September 17, 1992. Suitable plants for the practice of the present invention include, but are not limited to, soybean, cotton, alfalfa, oil seed rape, flax, tomato, sugar beet, sunflower, potato, tobacco, *maize*, wheat, rice and lettuce.

The vectors for use in plastid transformation preferably include means for providing a stable transfer of the plastid expression construct and selectable marker construct into the plastid genome. This is most conveniently provided by regions of homology to the target plastid genome. The regions of homology flank the construct to be transferred and provide for transfer to the plastid genome by homologous recombination, via a double crossover into the genome. The complete DNA sequence of the plastid genome of tobacco has been reported (Shinozaki *et al.*, *EMBO J.* (1986) 5:2043-2049). Complete DNA sequences of the plastid genomes from liverwort (Ohya *et al.*, *Nature*

(1986) 322:572-574) and rice (Hiratsuka *et al.*, *Mol. Gen. Genet.* (1989) 217:185-194), have also been reported.

Where the regions of homology are present in the inverted repeat regions of the plastid genome (known as IRA and IRB), two copies of the transgene are expected per transformed plastid. Where the regions of homology are present outside the inverted repeat regions of the plastid genome, one copy of the transgene is expected per transformed plastid. The regions of homology within the plastid genome are approximately 1kb in size. Smaller regions of homology may also be used, and as little as 100 bp can provide for homologous recombination into the plastid genome. However, the frequency of recombination and thus the frequency of obtaining plants having transformed plastids decreases with decreasing size of the homology regions.

Examples of constructs having regions of homology within the plastid genome are described in Svab *et al.* (1990 *supra*), Svab *et al.* (1993 *supra*) and Zoubenko *et al.* (*Nuc Acid Res* (1994) 22(19):3819-3824).

As described in more detail in the examples below, constructs are described which provide for enhanced expression of DNA sequences in plant plastids. Various promoter/ribosome binding site sequences are employed to direct expression in plant plastids. Promoter sequences of the 16S ribosomal RNA operon (*Prm*) are linked to a ribosome binding site (RBS) derived from the T7 bacteriophage gene 10 leader sequence (G10L). DNA sequences expressed under the regulatory control of the *Prm*/G10L sequence show a significantly higher level of protein expression than those levels obtained under the control of other promoter/RBS combinations, while expression of mRNA may or may not be higher in these plants.

In the examples below, nucleic acid sequences encoding CP4 EPSP synthase (USPN 5,633,435) are placed into expression constructs for expression of EPSP synthase enzyme from the plant plastid. Furthermore, a DNA sequence encoding for hGH (USPN 5,424,199) is also placed into expression construct for the expression of human growth hormone from the plant plastid. The constructs prepared utilize a ribosome binding site designed after the T7 bacteriophage gene 10 leader (G10L) to increase the expression of the nucleic acid sequences in the plant plastid.

Plastid expression constructs encoding for the expression of EPSPS and hGH are introduced via a chloroplast transformation vector.

Tobacco lines containing the native encoding sequence to the EPSPS enzyme expressed in plastids under the control of the *Prm*/G10L promoter/ribosome binding site sequence demonstrate a significantly higher level of protein expression than those levels obtained from EPSPS expressed under the control of the *Prm*/rbcL RBS sequence.

5 However, EPSPS mRNA is expressed at a higher level in plants expressing CP4 EPSPS from the plastid under the control of the *Prm*/rbcL(RBS). These results indicate that translation from transcripts containing the T7 bacteriophage gene 10 ribosome binding site is more efficient. In addition, protein expression levels of EPSPS obtained from transplastomic tobacco lines expressing EPSPS under the control of the *Prm*/G10L RBS  
10 provide for a high level of glyphosate tolerance.

Furthermore, transplastomic tobacco lines transformed to express hGH under the control of the *Prm*/G10L promoter/ribosome binding site sequence demonstrate a significantly higher level of protein expression than those levels obtained from hGH expressed under the control of the *PpsbA* promoter/RBS sequence.

15 Increases in protein expression levels of at least approximately 200 fold may be obtained from constructs utilizing *Prm*/G10L ribosome binding site for expression of EPSPS and hGH over the expression levels obtained from other promoter/RBS combinations for plastid expression. In addition, protein levels obtained from plastid expression constructs utilizing the *Prm*/G10L promoter/RBS sequence may accumulate 50  
20 to 3500 fold higher levels than from nuclear expression constructs. Thus, inclusion of the G10L ribosome binding site in plastid expression constructs may find use for increasing the levels of protein expression from plant plastids.

Furthermore, the constructs of the present invention may also include sequences to target the expressed protein to a particular suborganellar region, for example, the thylakoid  
25 lumen of the chloroplast. For example, as described in the examples below, a nucleotide sequence encoding a peptide from the plastid genome cytochrome *f* targets the expressed aprotinin protein to the thylakoid membrane. Such targeting of expressed proteins may provide for a compartmentalization of the protein allowing for increased oxidative stability and proper protein folding.

30

The invention now being generally described, it will be more readily understood by reference to the following examples which are included for purposes of illustration only and are not intended to limit the present invention.

## EXAMPLES

### Example 1 Expression Constructs

5           Constructs and methods for use in transforming the plastids of higher plants are described in Zoubenko *et al.* (*Nuc Acid Res* (1994) 22(19):3819-3824), Svab *et al.* (*Proc. Natl. Acad. Sci.*(1990) 87:8526-8530 and *Proc. Natl. Acad. Sci.*(1993) 90:913-917) and Staub *et al.* (*EMBO J.* (1993) 12:601-606). Constructs and methods for use in transforming plastids of higher plants to express DNA sequences under the control of a  
10           nuclearly encoded, plastid targeted T7 polymerase are described in U.S. Patent Number 5,576,198. The complete DNA sequences of the plastid genome of tobacco are reported by Shinozaki *et al.* (*EMBO J.* (1986) 5:2043-2049). All plastid DNA references in the following description are to the nucleotide number from tobacco.

          The complete nucleotide sequence encoding the tobacco cytochrome *f* (*petA*) is  
15           described in Bassham *et al.*, (1991) *J Biol Chem* 266:23606-23610 and Konishi *et al.* (1993) *Plant Cell Physiol* 34:1081-1087.

#### 1A. Promoter/Ribosome Binding Site Sequences

          The promoter region of the plastid 16S ribosomal RNA operon (*Prrn*) is linked to a  
20           synthetic ribosome binding site (RBS) patterned on the plastid *rbcL* gene leader to create the *Prrn/rbcLRBS* fragment. The *Prrn/rbcLRBS* sequence is as described in Svab *et al.* (1993, *supra*) for the *Prrn/rbcL(S)* fragment.

          The promoter region of the plastid *psbA* promoter (*PpsbA*) and terminator sequences (*TpsbA*) are described in Staub *et al.* (1993, *EMBO J.*, 12, 601-606).

25           The *Prrn/G10L* sequence was constructed by annealing two oligonucleotide sequences, T7lead1 and T7lead2 (Table 1), to create the G10L plastid ribosome binding site (Figure 1). The G10L sequence was ligated to the 3' terminus of the *Prrn* promoter sequence as an *EcoRI/NcoI* fragment to create the *Prrn/G10L* sequence.

Table 1

---

T7lead1	5'-AAT TGT AGA AAT AAT TTT GTT TAA CTT TAA GAA GGA GAT ATA CC-3'
---------	---

---

5	T7lead2	5'-CAT GGG TAT ATC TCC TTC TTA AAG TTA AAC AAA ATT ATT TCT AC-3'
---	---------	---

---

Chimeric genes are preferably inserted into the expression vector to direct their transcription from the *Prn* promoter. Thus, in the plastid genome, chimeric genes are transcribed from the *Prn*/RBS promoter, or the *Prn*/G10L promoter in the plant plastid.

10

#### 1B. CP4 EPSPS Plastid Expression Constructs

A plastid expression vector pMON30117 is constructed from a precursor vector pPRV111B (Zoubenko, *et al.* 1994, *supra*, GenBank accession U12813). The vector pMON30117 carries a multiple cloning site for insertion of a passenger gene in a *Prn*/rbcLRBS/*Trps16* expression cassette. The *Prn*/rbcLRBS sequence is cloned into pPRV111B vector as an *EcoRI*/*NcoI* fragment, and the terminator region from the plastid *rps16* gene (*Trps16*) is cloned 3' of the *Prn* promoter as a *HindIII*/*NcoI* fragment. The *Trps16* fragment comprises the *rps16* gene 3'-regulatory region from nucleotides 5,087 to 4,939 in the tobacco plasmid DNA.

The pPRV111B backbone of the vector pMON30117 contains a marker gene, *aadA*, for selection on spectinomycin and streptomycin, and *rps 7/12* for the integration, by homologous recombination, of the passenger DNA into *tmV-rps7/12* intergenic region.

The plastid expression construct pMON30118 was prepared by cloning the native CP4 EPSPS gene fused with the N-terminal five (5) amino acids from the plastid *rbcL* (described in Svab *et al.*, 1993 *supra*) gene as an *NcoI*/*SmaI* fragment into the multiple cloning site of the vector pMON30117.

The plastid expression construct pMON30123 is essentially the same as pMON30118 with the exception of the deletion of the N-terminal five (5) amino acids from the plastid *rbcL*.

The plastid expression construct pMON30130 was created by replacing the native CP4 EPSPS of pMON30123, with a synthetic CP4 gene. This construct also lacks the N-terminal 5 amino acid fusion from the plastid *rbcL* gene.



The plastid expression construct pMON38773 was constructed by replacing the *Prrn*/RBS sequence of pMON30123 with the *Prrn*/G10L promoter sequence described above. The EPSPS DNA sequence of pMON38773 also lacks the N-terminal 5 amino acid fusion from the plastid *rbcL* gene.

5        A plastid expression construct, pMON38766 was constructed using the promoter from T7 phage gene 10 (P-T7), including G10L, CP4 (native) gene coding region, and the terminator sequence from plastid *rps16* gene (*Trps16*).

      A plastid expression construct, pMON38797 was constructed using the promoter from T7 phage gene 10 (P-T7), including G10L, CP4 (synthetic) gene coding region,  
10       terminator from plastid *rps16* gene (*Trps16*).

      A plastid expression construct, pMON38798 was constructed using the promoter of the 16SrDNA operon (*Prrn*), G10L, CP4 (synthetic) gene coding region, terminator from plastid *rps16* gene (*Trps16*).

      A plastid expression construct, pMON38793 was constructed using the promoter  
15       of the 16SrDNA operon (*Prrn*), a synthetic ribosome binding site (RBS) patterned from the plastid *rbcL* gene, the glyphosate tolerant *Petunia* EPSP synthase gene (P-EPSPS, Padgett, *et al.* (1987) *Arch. Biochem. Biophys.* 258:564-573) carrying the mutation Glycine to Alanine at amino acid position 101, terminator from plastid *rps16* gene (*Trps16*).

20       A plastid expression construct, pMON38796 was constructed using the promoter of the 16SrDNA operon (*Prrn*), synthetic ribosome binding site (RBS) patterned from the plastid *rbcL* gene, the glyphosate tolerant *Achromobacter* (strain LBAA) EPSP synthase gene (U.S. Patent Number 5,627,061, the entirety of which is incorporated herein by reference) carrying the mutation Glycine to Alanine at amino acid position 100, terminator  
25       from plastid *rps16* gene (*Trps16*).

      A plastid expression construct, pMON45204, was constructed using the promoter of the 16SrDNA operon (*Prrn*) with the G10L, the glyphosate tolerant *Pseudomonas* (strain LBAA) EPSP synthase gene carrying the mutation Glycine to Alanine at amino acid position 100, terminator from plastid *rps16* gene (*Trps16*).

30       A plastid expression construct, pMON45201, was constructed using the promoter of the 16SrDNA operon (*Prrn*), synthetic ribosome binding site (RBS) patterned from the plastid *rbcL* gene, wild-type glyphosate tolerant *Bacillus subtilis* *aroE* (EPSPS) (U.S. Patent Number 5,627,061) gene, terminator from plastid *rps16* gene (*Trps16*).

### 1C. *Bucril (bxn) Plastid Expression Constructs*

The *bxn* herbicide resistance gene (U.S. Patent Number 4,810,648, the entirety of which is incorporated herein by reference) was removed from the plasmid pBrx47 as an  
5 *Nco* I to *Asp*718 restriction fragment and cloned into *Nco*/*Asp*718 cut pUC120 resulting in plasmid pBrx87. Plasmid pBrx87 was then digested with *Nco*/*Xba* and cloned into the *Nco*/*Xba* sites of the plasmid pLAA21 which contains the *Prrn* plastid promoter and the *rpsL* 3' region for plastid expression. The resulting plasmid was designated pBrx89. Plasmid pBrx89 was digested with *Sac* I and *Hind* III and the 1.5 kb chimeric *bxn* gene  
10 with plastid expression signals was inserted into the *Sac*/*Hind* III sites of the tobacco plastid homology vector pOVZ44B (Zoubenko et al, Nuc Acids Res 22: 3819-3824 (1994)) to create plasmid pCGN5175.

To construct plasmid pCGN6114, plasmid pBrx90 (a Bluescript plasmid containing the *bxn* gene encoding the bromoxynil specific nitrilase) was digested with *Nco*  
15 *I*/*Asc* I and the *bxn* structural gene was substituted for the GUS gene in the *Nco*/*Asc* digested plasmid pCGN5063 resulting in plasmid pCGN6107. This plasmid contains the *bxn* gene under the control of the T7 promoter/gene10 leader at the 5' end and the *psbA*/T7 hybrid transcriptional terminator at the 3' end of the chimeric gene. This T7 promoter/*bxn* chimeric gene was excised from pCGN6107 as a *Hind* III/*Not* I DNA  
20 segment and moved into the chloromphenical plasmid BCSK+ (Stratagene) at the *Hind* III/*Not* sites to create plasmid pCGN6109. The chimeric gene was then moved as a *Hind* III/*Not* fragment from pCGN6109 into the chloroplast homology vector pOVZ44B described above to create plasmid pCGN6114. Tobacco plants transformed with pCGN6114 require the T7 RNA polymerase be provided in the plant plastid background to  
25 activate transcription of the chimeric *bxn* gene via the T7 promoter. This system has previously been detailed in McBride *et al.*, PNAS, 91:7301-7305 (1994) and McBride *et al.*, US Patent Number 5,576,198.

### 1D. *BXN/AHAS Plastid Expression Constructs*

30 A plastid expression construct, pCGN5026, is prepared to direct the expression of BXN and AHAS from the plant plastid. The AHAS nucleotide sequence (described in EP Publication Number 0 525 384 A2, the entirety of which is incorporated herein by reference) is translationally linked to the BXN nucleotide sequence (U.S. Patent Number

4,810,648, the entirety of which is incorporated herein by reference). The AHAS structural gene encoding acetohydroxyacid synthase was cloned from the plasmid pCGN4277 as an *Nco* I to *Age* DNA fragment into the *Nco/Xma* sites of plasmid pUC120 to create plasmid pCGN5022. This plasmid was then digested with the enzymes *Bam*H I and *Pst* and a 1.3 kb *Bam/Pst* DNA segment containing the *bxn* gene encoding the bromoxynil-specific nitrilase was excised from the plasmid pBrx26 and cloned into the *Bam/Pst* sites of pCGN5022 to create plasmid pCGN5023. Plasmid pCGN5023 contained a 3.3 kb DNA segment containing the AHAS/*bxn* operon segment and this fragment. This plasmid was cut at the unique *Pst* site and this *Pst* site was removed and replaced with a synthetic linker containing a unique *Xba* I restriction site generating plasmid pCGN5024. Plasmid pCGN5024 was digested with *Nco/Xba* and the 3.3 kb *Nco/Xba* DNA fragment was cloned into the plasmid promoter cassette vector pLAA21(*Pst*) that had been digested with *Nco* and *Xba* to remove the GUS gene. The plasmid resulting from this cloning was designated plasmid pCGN5025 and contained the herbicide operon under the control of the plastid promoter *Prm* and the *rpsL* 3' DNA segment. The entire chimeric herbicide operon under the control of the plastid expression elements was excised from pCGN5025 as a *Sac* I/*Pst* DNA fragment and cloned into the *Sac/Pst* sites of the plastid homology cassette vector pOVZ44B (Zoubenko *et al*, *Nuc Acids Res* 22:3819-3824 (1994)) to facilitate transfer into the tobacco chloroplast genome.

#### 1E. *Bt cryIAc* and *bxn* Plastid Expression Construct

Plasmid pBrx9 (Stalker and McBride, (1987) *J Bacteriol* 169:955-960), an original clone from *Klebsiella* containing a *bxn* gene DNA segment, was used as a template to generate an ~450 bp *Bam*H I/*Cla* I PCR DNA fragment that encompasses the N-terminal end of the *bxn* gene and includes 44 bp of the 5' untranslated portion of the native gene. This fragment was exchanged with the ~400 bp *Bam/Cla* fragment in the plasmid pBrx90 resulting in plasmid pBrx90.1. This plasmid contains the entire *bxn* gene and the 44 bp untranslated 5' DNA segment. The *bxn* gene was excised from plasmid pBrx90.1 as a *Bam/Asc* I DNA segment and inserted into plasmid pCGN5146 at the *Bgl* II/*Asc* I sites to generate plasmid pCGN5191. Plasmid pCGN5146 is a pKK233-2 (Pharmacia) derivative containing the full-length *cryIAc* gene encoding the HD-73 Bt protoxin. Plasmid pCGN5191 then contains the *cryIAc* and *bxn* genes in an operon configuration with the *bxn* gene being the distal gene in the operon. Both genes are under the control of the *Ptac*

promoter for *E coli* expression in 5191. Plasmid pCGN5191 was digested with *Nco*/*Asc* and the *Nco*/*Asc* DNA fragment containing the *Bt/bxn* operon was cloned into the *Nco*/*Asc* sites of the chloroplast homology vector pCGN5155, a derivative of pOVZ44B. The resulting plasmid, pCGN5197 contains the *Bt/bxn* operon under the control of the *Prrn* plastid promoter and *rpsL* transcription terminator regions. This plasmid facilitated transfer of the *Bt/bxn* chimeric operon into the tobacco plastid genome.

#### 1F. Phytoene desaturase Plastid Expression Constructs

The *crtI* gene was obtained as a *Hind* III/*Sal* I PCR fragment from the original plasmid containing the *Erwinia carotova crt* operon (Misawa et al, (1994) *Plant Jour* 6:481-489)) and cloned as a *Hind* III/*Sal* I DNA segment into BCSK+ (Stratagene) at the *Hind* III/*Sal* sites to generate plasmid pCGN5172. The *crtI* fragment was cloned from pCGN5172 as an *Nco* I/*Sal* I fragment into pCGN5038 (a derivative of pOVZ44B) to create the plastid expression construct pCGN5177. This construct directs the expression of the *crtI* sequence from the *Prrn* promoter and the *rps16* terminator sequence. This plasmid facilitated the transfer of the chimeric *crtI* gene into the tobacco plastid genome.

#### 1G. hGH Expression Constructs for Plant Transformation

##### Nuclear Expression Constructs

The construct pWRG4747 was constructed to direct the expression of hGH in the plant nuclear genome. This vector contains the hGH operably linked to the Figwort Mosaic Virus promoter (USPN 5,378,619, the entirety is incorporated herein by reference) and the CTP2 leader for directing the hGH protein into the plastid. The FMV/CTP2L::hGH::NpA fragment is cloned along with the DNA sequence conferring resistance to Kanamycin between the right and left borders (RB and LB) of the transfer DNA (tDNA) of *Agrobacterium tumefaciens* to direct the integration into the nuclear genome.

The nuclear transformation vector pWRG4744 contains essentially the same elements as pWRG4747 except the construct lacks the CTP2 leader and the hGH protein is directed to the plant cell cytoplasm.

### Plastid Expression Constructs

The plastid expression vector pWRG4838 was constructed using the full length hGH gene expressed from the promoter and terminator region from the psbA gene, PpsbA and TpsbA, respectively (described in Staub *et al.* (1993), *supra*). This chimeric  
5 promoter-gene-terminator fusion (PpsbA::hGH: :TpsbA) is cloned adjacent to the selectable marker gene *aadA* also driven by the plastid expression elements of the psbA gene. The two chimeric gene sequences are cloned into a vector between two sequences which direct the integration of the chimeric gene sequences into the tobacco plastid  
10 genome upstream of the plastid 16SrDNA. This is joined to a 1 kb Ampicillin resistance gene which provides for selection of *E. coli* containing the construct and the pUC origin of replication for plasmid maintenance in *E. coli*.

The plastid expression construct pMON38755 was prepared using the hGH DNA sequence translationally fused at the N-terminus with the yeast ubiquitin gene (Ozkaynak, *et al.* (1984) *Nature* 312:663-666), creating the Ubi-hGH fusion gene. The Ubi-hGH  
15 fusion gene is cloned next to the *aadA* gene for selection of transplastomic tobacco on media containing spectinomycin or streptomycin (from pPRV112B described in Zoubenko *et al.* (1994) *supra*). Sequences are included for the homologous recombination of sequences encoding for hGH and *aadA* expression. These sequences are obtained from the vector pPRV112B described in Zoubenko *et al.* (1994, *supra*). These sequences are  
20 joined to a 1 kb ampicillin resistance gene which provides for selection of *E. coli* containing the construct and the pUC origin of replication for plasmid maintenance in *E. coli*.

The plastid expression construct pMON38794 contains essentially the same elements as pMON38755, with the exception that the 0.15 kb psbA promoter sequence is  
25 replaced with the *Prm/G10L* promoter sequence described above.

### *1H. Constructs for the Expression of Aprotinin in Plastids*

A series of constructs were prepared to direct the expression of the pharmaceutical protein aprotinin from the plastid. The nucleic acid sequence encoding for aprotinin  
30 (Figure 2) was cloned into a plastid expression construct to control the expression of aprotinin from the T7 gene 10 leader promoter which is induced from a nuclearly expressed, plastid targeted T7 Polymerase. The constructs used in which the aprotinin sequence was cloned are as described in U.S. Patent Number 5,576,198, the entirety of

which is incorporated herein by reference. The plastid transformation vector pCGN6146 is designed by replacing the DNA sequence encoding for GUS from pCGN4276 (described in USPN 5,576,198) with the coding sequence of aprotinin. The tobacco plastid transformation construct pCGN6147 contains the same elements as pCGN6146 except pCGN6147 contains the six 5' amino acids of the GUS encoding sequence ligated to the 5' terminus of the aprotinin encoding sequence. The six amino acids of the 5' terminus of the GUS nucleotide sequence are included to aid in the translation of the aprotinin protein. The tobacco plastid transformation vector pCGN6156 is essentially the same as pCGN4276 except the coding region of aprotinin is cloned to the 3' end of the GUS coding sequence. Thus, pCGN6156 contains as operably linked the T7 promoter, a DNA sequence encoding for GUS fused with the DNA sequence encoding for aprotinin and the psbA 3' transcription termination sequence.

A plastid expression construct, pCGN6154, was constructed from pCGN4276 by replacing the GUS coding sequence with the aprotinin protein operably linked to the 3' terminus of the coding sequence of cytochrome *f* (*petA*) of the tobacco chloroplast. Thus, pCGN6154 contains the T7 promoter sequence operably linked to the nucleotide sequence of *petA* and aprotinin. The *petA* sequence is included to direct the expressed aprotinin protein to the thylakoid.

## Example 2 Plant Transformation

### 2A. Nuclear Transformation

Tobacco plants transformed to express the constructs pWRG4744 and pWRG4747 in the nucleus of a plant cell may be obtained as described by Horsch *et al.* (*Science* (1985) 227:1229-1232).

### 2B. Plastid Transformation

Tobacco plastids are transformed by particle gun delivery of microprojectiles as described by Svab and Maliga (*Proc. Natl. Acad. Sci.* (1993) 90:913-917), and described herein.

Dark green, round leaves are cut, preferably from the middle of the shoots, from 3-6 week old *Nicotiana tabacum* cv. Havana which have been maintained *in vitro* on hormone free MS medium (Murashige and Skoog, (1962) *Physiol Plant.* 15, 473-497) supplemented with B5 vitamins in Phytatrays or sundae cups with a 16 hour photoperiod at

24°C. Each cut leaf is then placed adaxial side up on sterile filter paper over tobacco shoot regeneration medium (TSO medium: MS salts, 1mg/l *N*<sup>6</sup>-benzyladenine, 0.1mg/l 1-naphthaleneacetic acid, 1 mg/l thiamine, 100mg/l inositol, 7g/l agar pH 5.8 and 30g/l sucrose). Leaves are preferably placed in the center of the plate with as much contact with the medium as possible. The plates are preferably prepared immediately prior to use, but may be prepared up to a day before transformation by particle bombardment by wrapping in plastic bags and storing at 24°C overnight.

Tungsten or gold particles are sterilized for use as microcarriers in bombardment experiments. Particles (50mg) are sterilized with 1 ml of 100% ethanol, and stored at -20°C or -80°C. Immediately prior to use, particles are sedimented by centrifugation, washed with 2 to 3 washes of 1 ml sterile deionised distilled water, vortexed and centrifuged between each wash. Washed particles are resuspended in 500 µl 50% glycerol.

Sterilized particles are coated with DNA for transformation. Twenty-five microliter aliquots of sterilized particles are added to a 1.5 ml microfuge tube, and 5 µg of DNA of interest is added and mixed by tapping. Thirty-five microliters of a freshly prepared solution of 1.8M CaCl<sub>2</sub> and 30 mM spermidine is added to the particle/DNA mixture, mixed gently, and incubated at room temperature for 20 minutes. The coated particles are sedimented by centrifuging briefly. The particles are washed twice by adding 200µl 70% ethanol, mixing gently, and centrifuging briefly. The coated particles are resuspended in 50µl of 100% ethanol and mixed gently. Five to ten microliters of coated particles are used for each bombardment.

Transformation by particle bombardment is carried out using the PDS 1000 Helium gun (Bio Rad, Richmond, CA) using a modified protocol described by the manufacturer.

Plates containing the leaf samples are placed on the second shelf from the bottom of the vacuum chamber and bombarded using the 1100 p.s.i. rupture disk. After bombardment, petriplates containing the leaf samples are wrapped in plastic bags and incubated at 24°C for 48 hours.

After incubation, bombarded leaves are cut into approximately 0.5 cm<sup>2</sup> pieces and placed abaxial side up on TSO medium supplemented with 500 µg/ml spectinomycin. After 3 to 4 weeks on the selection medium, small, green spectinomycin resistant shoots will appear on the leaf tissue. These shoots will continue to grow on spectinomycin containing medium and are referred to as primary putative transformants.

When the primary putative transformants have developed 2 to 3 leaves, 2 small pieces (approximately 0.5 cm<sup>2</sup>) are cut from each leaf and used for either selection or for a second round of shoot regeneration. One piece is placed abaxial side up on plates containing TSO medium supplemented with 500 µg/ml spectinomycin, and the other piece is placed abaxial side up on TSO medium supplemented with 500 µg/ml each of spectinomycin and streptomycin. Positive transformants are identified as the shoots which form green callus on the TSO medium containing spectinomycin and streptomycin.

After 3 to 4 weeks, the tissue placed on TSO medium containing only spectinomycin, which has been identified as positive on the TSO medium with spectinomycin and streptomycin, will develop green shoots. Two to four shoots of each positive transformant are selected and transferred to TSO medium supplemented with 500 µg/ml spectinomycin for generation of roots. Southern analysis is performed on 2 shoots to confirm homoplasmy as described below. Shoots from homoplasmic events are transferred to the greenhouse for seed production, while transformants which are not homoplasmic are sent through a second round of regeneration on TSO medium with 500 µg/ml spectinomycin to attain homoplasmy.

### **Example 3 Analysis of Transplastomic Tobacco Plants Transformed with Herbicide Tolerance Constructs**

#### **3A. Southern Analysis**

Transformed plants selected for marker *aadA* marker gene expression are analyzed to determine whether the entire plastid content of the plant has been transformed (homoplasmic transformants). Typically, following two rounds of shoot formation and spectinomycin selection, approximately 50% of the transgenic plantlets which are analyzed are homoplasmic, as determined by Southern blot analysis of plastid DNA. Homoplasmic plantlets are selected for further cultivation.

Genomic DNA is isolated from transformed tobacco plants, electrophoresed, and transferred to filters as described in Svab *et al.* ((1993), *Proc Natl Acad Sci*, 90:913-917).

Homoplasmic tobacco plants transformed to express CP4 EPSPS in plastids were identified using a probe prepared from a 2.4 kb *EcoRI/EcoRV* fragment from the vector pOVZ2 (similar to pOVZ15 described in Zoubenko, *et al.* 1994, *supra*). The 2.4 kb probe fragment encompasses part of the targeting sequence.



Results of the Southern hybridizations identified 3 homoplasmic lines from tobacco transformed with the constructs pMON30123 and pMON30130 and 1 line from tobacco transformed with pMON38773 for further analysis.

The complete disappearance of the 3.27 Kb native tobacco *Bam*HI fragment in the lines 30123-19-1A, 30123-23-2A, 30123-18-1B, 30130-51-2A, 30130-51-2P, 30130-57-1P, and 38773-6 with a probe covering the region of integration, and the appearance of expected sized bands for the inserted DNA fragments in those transformants, 5.14 kb and 0.9 kb, establishes that the transformed plants are homoplasmic for the intended constructs.

Results of the Southern hybridizations identified 3 homoplasmic lines from tobacco transformed with pCGN5177, lines 74-1B-P, 74-2 and 74-7.

Transplastomic 5175 and 6114 tobacco lines were analyzed by Southern hybridization for homoplasmy as described above. Results of the Southern hybridizations identified 4 homoplasmic lines from tobacco transformed with pCGN6114.

Results from hybridizations of 5175 transplastomic tobacco lines identified one line, 76-4A-F, as homoplasmic, and a second line as 95% homoplasmic.

Homoplasmic tobacco plants transformed to express BXN/AHAS in plastids were identified using Southern hybridizations as described above.

Results of the Southern hybridizations identified 14 homoplasmic lines from tobacco transformed with pCGN5026. The filters were reprobed with a BXN gene fragment, and 21 lines were found to contain BXN, 14 lines of which were homoplasmic.

### 3B. Northern Analysis

In order to determine the level of transcription of the EPSPS, BXN or AHAS mRNA expressed in the transplastomic tobacco plants, Northern blot hybridizations were performed with total RNA isolated from each of the lines identified. Total RNA was isolated using TRIzol reagent (Gibco-BRL Life Technologies, Gaithersburg, MD) according to the manufacturers protocol. Total RNA, 2µg, was separated on a denaturing agarose gel and transferred to nylon membrane (Maniatis *et al.*, 1989, *supra*). Radioactive probes for hybridizations were prepared using random primer labeled (using Random Primer labeling kit from Boehringer Mannheim) CP4 EPSPS, phytoene desaturase, BXN, or AHAS fragments and hybridizations were carried out in 2x SSPE (Maniatis, *et al.*, 1989, *supra*), at 60°C. Filters were stripped and reprobed with a plastid 16S ribosomal

RNA gene probe (from pPRV112A, Zoubenko, *et al.*, 1994, *supra*) to confirm homogenous loading of RNA on the filter.

Results of the Northern hybridizations performed with EPSPS probes demonstrate that all seven (7) lines examined express CP4 EPSPS mRNA. Hybridizations performed with the 16S ribosome probe confirm that denaturing gels were loaded with similar amounts of total RNA for each sample. Furthermore, transplastomic tobacco lines expressing EPSPS from the *Prrm/rbcL*(RBS) (pMON30123) regulatory elements express EPSPS mRNA to higher levels than tobacco plants homoplasmic for EPSPS controlled by the *Prrm/G10L* (pMON38773) promoter/RBS sequences.

Results of Northern hybridizations performed with BXN, AHAS and *crtI* probes demonstrates that all homoplasmic 5026, 5175, and 5177 tobacco lines expressed *crtI*, BXN and/or AHAS mRNA.

### 3C. Western Blot Analysis of Tobacco CP4 EPSPS

To determine the expression of the EPSPS, Western blot analysis was performed on a single line from each construct, pMON30123, pMON30130, and pMON38773.

Total soluble protein was extracted from frozen leaf tissue by grinding 250 mg tissue in 250µl of PBS buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, Na<sub>2</sub>HPO<sub>4</sub>, 0.137M NaCl, 2.7 mM KCl pH 7.0) containing protease inhibitors. The homogenate is centrifuged for 5 minutes, and the supernatant is transferred to a fresh tube. The concentration of the protein in the supernatant is determined using a protein concentration assay (BioRad, Richmond, CA).

Extracted total protein is electrophoresed on a 4-20% SDS-PAGE gel (Sigma, St Louis, MO), and transferred to PVDF membrane in 1x SDS-PAGE buffer (Maniatis *et al.* 1989, Cold Spring Harbor Press). Standards of quantitated purified CP4 EPSPS protein were used to quantify the expression of the CP4 EPSPS as expressed in the plant plastid.

Western hybridizations are performed as described in Staub and Maliga (1993) *EMBO Journal*, 12(2) 601-606, except using antibodies raised to EPSPS. PVDF membranes containing the transferred electrophoresed protein were incubated in a blocking solution of PBS buffer containing 0.05% Tween-20 (PBS-T) and 5% milk overnight at 4°C. The membranes are then incubated in a solution of PBS-T containing 1% milk and a primary antibody raised in goats to the CP4 EPSPS for 2 hours at room temperature. The membranes are washed three times in a solution of PBS-T containing

0.1% milk, each wash for 5 minutes at room temperature. The membranes are then incubated in a solution of PBS-T containing 1% milk and sheep anti-goat antibody for 1 hour at room temperature, and washed again in PBS-T containing 0.1% milk, three times for 10 minutes at room temperature. A final wash using only PBS-T is performed before  
 5 developing the membranes using a nonradioactive detection kit (ECL, Amersham).

**Table 2**

Construct Number	Event Number	% Total Soluble Protein
pMON30123	T18-23-2A	0.001
pMON30130	T18-51-2P	0.002
pMON38773	9706-6-1	0.2

10

The results listed in Table 2 demonstrate that significant increases in the level of EPSPS protein may be obtained from plants transformed to express EPSPS from the *Prrm*/G10L promoter. These results demonstrate that EPSPS expression driven by the *Prrm*/rbcLRBS regulatory sequences may produce approximately 0.001% of the total  
 15 soluble protein as EPSPS, while in plants expressing EPSPS from the *Prrm*/G10L regulatory sequences express 0.2% of the total soluble protein as EPSPS. Subsequent lines have demonstrated total soluble protein of about 1% EPSPS when expressed from the *Prrm*/G10L regulatory sequences. These results, taken together with the results of the Northern hybridizations above, indicate that more efficient translation may be obtained  
 20 from the G10L ribosome binding site.

Western immunoblot hybridization were also performed on 2 homoplasmic 5026 tobacco lines as described above, using antibodies raised against bromoxynil. The results of Western immunoblot analysis of total soluble protein extracted from tobacco lines transformed with pCGN5026 demonstrated that both homoplasmic lines produced nitrilase  
 25 protein.

Western immunoblot analysis was performed as described above from total protein extracted from tobacco lines transformed with pCGN6114 and pCGN5197.

The results of the analysis demonstrated that bromoxynil was produced in 6114 tobacco lines ranging from 1% to 2% of the total soluble leaf protein.

- 5 The results of the Western analysis of the 20 5197 tobacco lines demonstrated that bromoxynil and Bt were both produced as 1% of the total soluble leaf protein.

### 3D. Analysis of EPSPS Enzyme Activity

- 10 The EPSPS enzyme activity in transplastomic tobacco plants containing the plastid expression vector pMON38773 was determined using a high pressure liquid chromatography (HPLC) assay.

Methods for the analysis of EPSPS enzyme activity are described in Padgett *et al.* (*J. Biol. Chem.* (1988)263:1798-1802 and *Arch. Biochem. Biophys.* (1987)258:564-573) and Wibbenmeyer *et al.* (*Biochem. Biophys. Res. Commun.* (1988)153:760-766).

- 15 The results are summarized in Table 3 below.

**Table 3**

<b><u>Nuclear</u></b> <b>Enzymatic Activity</b> <b>Range</b>	<b><u>Nuclear</u></b> <b>% Total Plants</b> <b>In Range</b>	<b><u>Chloroplast</u></b> <b>38773-6</b>
1-3.7 $\mu\text{mol/mg}$	1%	
>0.1 $\mu\text{mol/mg}$	16%	
>10 nmol/mg	55%	16.39 nmol/mg
>1 nmol/mg	32%	
0 nmol/mg	3%	

- 20 These results demonstrate that EPSPS expression in plastids produces active EPSPS enzyme.

### 3E. Analysis for Glyphosate Tolerance

A transplastomic tobacco line homoplasmic for the construct pMON38773 was tested *in vitro* to determine the highest level of glyphosate tolerance. Explant tissue was prepared from leaf pieces of nontransgenic wild type tobacco control, *Havanna*, plants and the homoplasmic tobacco line 38773-6 and cultured for regeneration of shoots on TSO medium (described above) supplemented with glyphosate levels of 50 $\mu$ M, 75 $\mu$ M, 100 $\mu$ M, 150 $\mu$ M and 200 $\mu$ M. The results are summarized in Table 4 below. The number of explants producing shoots was determined at 3 weeks and 6 weeks after explant preparation and culturing on glyphosate containing medium.

10

Table 4

Glyphosate Level ( $\mu$ M)	Total Number Explants	Number Regenerating 3 Weeks	Number Regenerating 6 Weeks	% Explant Regeneration
<b>Wild Type</b>				
50	10	0	0	0
75	10	0	0	0
100	10	0	0	0
150	10	0	0	0
200	10	0	0	0
<b>38773-6</b>				
50	8	5	8	100
75	18	14	18	100
100	17	12	15	88
150	18	10	16	89
200	16	8	15	86

The above results demonstrate that at all levels of glyphosate examined, shoots regenerated from explants prepared from a tobacco line homoplasmic for pMON38773,

15

while no shoots regenerated from explants prepared from nontransformed control plants. These results suggest that tobacco plants expressing EPSPS in plastids demonstrate tolerance to glyphosate levels of at least 200 $\mu$ M.

Additional transplastomic lines were tested *in vitro* for glyphosate tolerance as described above. The results are shown in Table 5.

TABLE 5

**Summary of tobacco plastid transformation experiments with various constructs containing EPSPS genes.**

Construct	Spec/strep (+)	No. of shoots
		Gly 50 $\mu$ M(+)
pMON38766 (Wild)	1	0
15 pMON38766 (T7)	6	0
pMON38773 (Wild)	9	5 (1)
pMON38797 (Wild)	2	0
pMON38798	6	6
pMON38793	8	0
20 pMON38796	4	0
pMON45201	9	3
pMON45204	12	*

(No. of shoots positive at 1 mM glyphosate)

These results demonstrate that these transplastomic lines show tolerance to glyphosate. The numbers in parentheses are the number of shoots resistant to selection at 1 mM glyphosate. Thus, as can be seen in table 5, tobacco lines are generated that are tolerant of selection at 1 mM glyphosate.

Homoplasmic tobacco plants of the line 38773-6 are sprayed with glyphosate using a track sprayer at concentrations corresponding to 0oz/acre, 16oz/acre, 32oz/acre and 64oz/acre to test for whole plant tolerance. Plant height was measured before and after

spraying with glyphosate. The vegetative injury data was collected two weeks after spraying, while the reproductive injury data was collected at plant maturity.

Initial results indicate that homoplasomic tobacco lines sprayed are tolerant of glyphosate at the concentration of 16oz/acre as demonstrated in the vegetative tissue injury (Table 6). As can be seen in Table 5 transplastomic lines were generated which demonstrated a good level of glyphosate tolerance at 32oz/Acre. In subsequent experiments with additional transformed lines, transplastomic lines have shown tolerance to glyphosate at a level of 64oz/Acre.

Tolerance is characterized by the continued growth and greening of tissues sprayed with glyphosate. However, as the concentration of glyphosate applied increased, there was a corresponding increase in the level of vegetative injury. In contrast, nontransformed control plants which were highly susceptible to glyphosate concentrations as low as 16 oz/Acre.

15

Table 6

Plant No.	Construct	Roundup rate (oz/A)	Plant height (cm) before spray	Plant height (cm) after spray	Vegetative injury	Fertility rating
1	38773	0	12.2	30.5	0	0
2	38773	0	13.6	34.0	0	0
3	38773	0	8.6	23.8	0	0
4	38773	0	8.6	26.2	0	0
5	38773	0	7.8	28.8	0	0
6	38773	0	12.8	31.5	0	0
7	38773	0	12.2	31.6	0	0
8	38773	0	11.6	35.5	0	0
9	38773	16	9.0	29.0	1	0
10	38773	16	14.4	31.0	0	0
11	38773	16	13.4	32.0	0	0
12	38773	16	13.2	30.0	0	0
13	38773	16	14.2	30.5	0	1
14	38773	16	14.0	33.0	0	0
15	38773	16	13.2	30.2	0	0
16	38773	16	14.9	30.4	0	0
17	38773	32	12.0	26.5	2	4
18	38773	32	11.6	25.4	1	1
19	38773	32	9.4	22.0	1	3
20	38773	32	11.2	23.0	2	4
21	38773	32	13.8	25.8	1	2
22	38773	32	12.4	23.0	1	4
23	38773	32	10.2	19.0	2	4
24	38773	32	13.8	23.2	2	3
26	38773	64	11.8	20.0	2	5
27	38773	64	13.0	22.0	2	5
28	38773	64	12.2	18.0	3	5



29	38773	64	15.8	23.0	2	5
30	38773	64	10.4	17.5	2	5
32	38773	64	15.0	18.5	2	5
33	38773	64	13.8	21.8	2	5
34	38773	64	13.6	19.0	3	5
35	38773	64	10.8	16.0	3	5
36	Wild type	0	21.0	40.6	0	0
37	Wild type	0	16.0	38.0	0	0
38	Wild type	0	15.0	34.6	0	0
39	Wild type	0	17.6	32.2	0	0
40	Wild type	0	15.0	31.6	0	0
41	Wild type	0	14.0	32.0	0	0
42	Wild type	16	10.0	11.8	3	5
43	Wild type	16	8.0	10.0	3	5
44	Wild type	16	8.6	11.0	3	5
45	Wild type	16	8.0	14.0	3	5
46	Wild type	16	9.8	11.0	3	5
47	Wild type	16	10.4	14.0	3	5
48	Wild type	32	10.8	13.2	3	5
49	Wild type	32	9.0	13.0	3	5
50	Wild type	32	8.0	10.2	3	5
51	Wild type	32	11.0	14.0	4	5
52	Wild type	32	9.8	13.0	3	5
53	Wild type	32	8.0	10.8	4	5
54	Wild type	64	7.5	8.6	4	5
55	Wild type	64	11.2	12.5	4	5
56	Wild type	64	10.2	12.8	4	5
57	Wild type	64	11.5	13.0	4	5
58	Wild type	64	13.0	15.0	4	5
59	Wild type	64	9.8	11.2	4	5

Vegetative injuries:

0=normal plant

1=slight chlorosis of new leaves and stunting

2=severe chlorosis of new leaves, malformation of new leaves, and severe stunting

3=dying plant

4=dead plant

Fertility ratings:

0 = Fertile, no delay in maturity, lots of seed

1 = Some abortion, slight delay in seed set, seed

2 = Significant abortion, significant delay in seed set, some seed

3 = Very severe abortion, immature seed pots, a few seed

4 = malformed flowers; if flowered, extreme delay in flowering and no seed produced

5=dead plant

### 3F. *BT/BXN Analysis*

Homoplasmic tobacco plants of the lines 5175 and 5197 are sprayed with Buctril herbicide at a concentration of 4% to test for whole plant tolerance.

Results of the spray test with Buctril demonstrated that all 5197 lines expressing *bxn* were completely resistant when sprayed with a solution containing 4% Buctril herbicide.

Two lines out of six 5175 lines tested were completely resistant to the herbicide when sprayed with a 4% solution containing Buctril.

### 10 3G. *Norflurazon Resistance Analysis*

An experiment was set up to determine the efficacy of the *Crt I* trait with respect to resistance to the herbicide Norflurazon. Three 5177 transformed lines, 74-1B-P, 74-2-A, and 74-7-C and three control lines were planted. Plants were grown for seven weeks and then watered with a 3 $\mu$ M Norflurazon solution. Plants negative for the presence of the *crtI* plastid-borne gene were bleached by Norflurazon treatment, positive plants stayed green and continued to grow.

The results show that the three homoplasmic 5177 tobacco lines were resistant to the 3 $\mu$ M Norflurazon solution, while the control plants were all susceptible to the solution (Table 7).

5

Table 7

Line	Control/Transgenic	Result
Xanthi	Control	Susceptible
2560A Xanthi	Control	Susceptible
75-5D-A	Control	Susceptible
74-1B-P	homoplasmic	Resistant
74-2-A	homoplasmic	Resistant
74-7-C	homoplasmic	Resistant

#### Example 4 Analysis of hGH Transgenic Tobacco Plants

##### 4A. Southern Analysis

10 Transformed plants selected for *aadA* marker gene expression are analyzed to determine whether the entire plastid content of the plant has been transformed (homoplasmic transformants). Homoplasmic plants are selected using Southern hybridization for further cultivation.

Genomic DNA is isolated from transformed tobacco plants, electrophoresed, and  
15 transferred to filters as described in Svab *et al.* ((1993), *Proc Natl Acad Sci*, 90:913-917).

Homoplasmic tobacco plants transformed to express hGH were identified using a probe prepared from a 2.4 kb *EcoRI/EcoRV* fragment from the vector pOVZ2 (similar to pOVZ15 described in Zoubenko, *et al.* 1994, *supra*). The 2.4 kb probe fragment encompasses part of the targeting sequence.

20 The complete disappearance of the 3.27 Kb native tobacco *BamHI* fragment in the lines with a probe covering the region of integration, and the appearance of the expected size band for the inserted DNA fragments in those transformants, 5.6 kb, establishes that the transformed plants are homoplasmic for the intended constructs.

#### 4B. Protein Expression Analysis

Homoplasmic tobacco lines expressing hGH and nuclear tobacco transformants are used to determine the expression of the hGH protein. Western blot analysis was performed on tobacco lines containing constructs pWRG4838, pMON38755 and pMON38794 for plastid expression and an ELISA assay was used for transgenic tobacco lines containing pWRG4744 and pWRG4747 for nuclear expression of hGH.

Total protein extractions and western blot procedures were performed as described above, with the exception of the primary antibody was raised against hGH.

**Table 8**

**Expression Levels of hGH in Tobacco Nuclear Genome and Plastid genome**

Construct	Expression	Expression Level % Total Soluble Protein
pWRG4744	nuclear	0.002-0.125%
pWRG4747	nuclear	0.002-0.025%
pWRG4838	plastid	0.2%
pMON38755	plastid	1.0%
pMON38794	plastid	7.0%

Results of the Western analysis (Table 8) demonstrates that hGH expressed in plastids of plant cells accumulates to significantly higher levels than hGH expressed in the nucleus and targeted to either the cytoplasm or plastid of plant cells. Tobacco plants transformed to express hGH in the nucleus accumulated hGH levels of 0.002% (cytoplasmic targeted) to 0.025% (plastid targeted) of total soluble leaf protein, while tobacco plants expressing hGH in the plastid accumulated hGH levels of 0.2% to 7.0% of the total soluble leaf protein as hGH. Furthermore, homoplasmic tobacco plants expressing hGH directed from the *Prm*/G10L regulatory sequences accumulate 35 fold higher levels of hGH than homoplasmic tobacco plants expressing hGH directed from the *PpsbA* promoter sequence. The higher level of expression may be due to the strong *Prm* promoter and/or to enhanced translation of the fusion gene mediated by the gene 10 leader rbs region. Leaves of different ages had varied hGH accumulation patterns, with mature

and old leaves having similar levels and younger leaves much less hGH. This is consistent with the lower chloroplast number in young leaves.

Interestingly, both ubiquitin-hGH and processed hGH accumulated in the post-harvest extracts of the Nt-38755 and Nt-38794 lines. Ubiquitin processing was often  
5 observed at >50% of total hST protein species, depending on extraction conditions. This result confirms the utility of the fusion protein approach in chloroplast-expressed proteins. The appearance of an extra band observed in the Nt-4838 sample is consistent with an hGH dimer.

For comparison of expression systems in plants, nuclear transgenic plants were  
10 generated that express hGH from two different sets of expression signals. The wrg4747 and wrg4776 constructs expresses hGH using the strong Figwort Mosaic Virus promoter or the Cauliflower Mosaic Virus 35S promoter, respectively. The wrg4747 construct employs a chloroplast transit peptide to post-translationally target hGH to chloroplasts (FMV::CTP-hGH), whereas the wrg4776 construct targets the hGH through the  
15 endoplasmic reticulum (ER) to the secretory pathway (35S::ER-hST). Transgenic lines for both constructs were obtained through particle bombardment. Expression of hST was quantitated by ELISA assay and shown to be less than 0.025% tsp. This level of expression is at least 300-fold lower than the pMON38794 lines, proving the feasibility of the chloroplast expression system for the potential production of hST.

20

#### *4C. Characterization of hGH Protein Expressed in the Plastid*

In order to determine whether the hGH expressed from plastids was properly processed, experiments were performed to determine correct folding and bioactivity.

Two bottom leaves of transplastomic tobacco lines containing pMON38794 were  
25 used to extract and purify hGH. Large veins were removed from the excised leaves, and the leaf tissue was cut into small sections (approximately 0.5 cm<sup>2</sup>). The leaf pieces were flash frozen in liquid nitrogen and ground to a fine powder in a chilled mortar and pestle. Ten grams of frozen, ground leaf tissue was added to ice cold 100 mM Tris base solution (30 ml) and mixed vigorously by vortexing for 5 minutes. The solution was filtered  
30 through a single layer of cheese cloth.

From the filtered solution, three separate samples were prepared. The first sample was prepared by centrifuging 4 ml of the filtrate for 1 minute at 16,000 rpm. The centrifugate was aliquoted into 1 ml vials and frozen in dry ice. The remaining filtrate was

centrifuged for 10 minutes at 4800 rpm, and several 0.5 ml aliquots were frozen as above for the second sample. To the remaining centrifuged filtrate (approximately 25 ml), 200 $\mu$ l of glacial acetic acid was added to lower the pH from 8.2 to 4.56. The solution was centrifuged at 4800 rpm for 30 minutes, and the supernatant was frozen over dry ice for the third sample.

Total soluble protein (TSP, Table 9) was calculated in these samples by standard protein assay procedures (Maniatis, ), and the percent purity of hGH was calculated based on results from Western blot analysis using known concentrations of starting material.

Table 9

Sample ID	TSP mg/mL	GP2000 mg/L	% Purity
Filtered Extract immediately centrifuged and frozen	6.3	28	0.45 %
Filtered extract centrifuged at 4800 rpm for 10 min and frozen	6.4	28	0.45
pH adjusted and centrifuged extract	0.75	21	2.8%

The pH adjusted and centrifuged extract was purified by Reverse Phase-HPLC (RP-HPLC) for electrospray mass spectrometry and amino-terminal amino acid sequencing. RP-HPLC was performed using a Perkin-Elmer series 200 pump and autosampler and a Vydac C8 (250 by 4.6 mm) RP-HPLC column. 750 microliters of sample was loaded onto the column equilibrated with 20 mM trifluoroacetic acid (TFA) and 50 % acetonitrile. After loading, the column was washed for 2 minutes with 50 % acetonitrile, 20 mM TFA followed by a 2% linear acetonitrile gradient over 10 minutes followed by a 10 % acetonitrile gradient over 1 minute. The flow rate was a constant 1.5 ml/minute with the column eluate monitored at 278 nm with a Perkin-Elmer 785 detector. Data was collected and analyzed with a PE-Nelson Turbochrom data system.

The results of the RP-HPLC analysis are shown in figure 3. Peak I (tallest peak) has the retention time expected for properly folded, native 22 kDa GP2000. This peak was

collected and dried down in a Savant Speed-Vac for amino terminal sequencing and electrospray mass spectrometry.

Electrospray ionization mass spectrometry (MS) analysis used a Micromass Q-ToF electrospray time-of-flight mass spectrometer. The samples were prepared by resuspending in 50% methanol + 2% acetic acid, and infused into the source of the mass spectrometer at a rate of 4mL/min. The raw data shown in Figure 4 shows a series of ions corresponding to the specie(s) present in the sample with varying numbers of protons attached. The axes of this spectrum are intensity versus mass-to-charge ratio of the specie(s) present. A deconvolution algorithm is used to convert this series of multiply charged ions into a molecular weight spectrum.

The results of the mass spectrometry of the RP-HPLC peak I shows 4 major protein species of different molecular mass. The 21,997 kDa species represents the predicted mass of hGH with the predicted N-terminal Phe removed by over-cleavage of the Ubiquitin protease with an N-terminal proline residue (P-hGH). The 22,124 kDa species represents the predicted mass of properly processed, correct amino acid sequence of hGH having the N-terminal phenylalanine (F-hGH). The 22,507 kDa and 22,664 kDa species are thought to represent an hGH with the N-terminal Phe and hGH which has been modified during plant extraction procedures, respectively. The calculated molecular mass of the proteins suggests that the hGH expressed from the plastid is properly folded (i.e. the correct disulfide bonds are created).

Equivalent mobility to refolded *E. coli* produced protein indicates formation of the two disulfide bonds and proper folding of the chloroplast derived hGH. This result was surprising because of the prokaryotic nature of chloroplasts. There are no known, plastid-expressed proteins that have disulfide bonds. However, nuclear-encoded, imported enzymes can be activated by disulfide bond oxidation/reduction cycles, presumably using the chloroplast thioredoxin system (Jacquot, *et al.* (1997) *New Phytol.* 136:543-570) or a recently discovered chloroplast protein disulfide isomerase (Kim and Mayfield (1997) *Science* 278:1954-1957). This result suggests that the prokaryotic organelle has the machinery needed to fold complex eukaryotic proteins in the soluble chloroplast stroma compartment. This is distinct from *E. coli*, where recombinant proteins tend to accumulate within inclusion bodies, and then require solubilization and refolding.

Amino terminal sequencing was done by standard Edman degradation, and confirmed the N-terminal sequences discussed above.

#### 4D. Bioactivity of hGH Expressed in Plant Plastids

Bioactivity of the pH adjusted and centrifuged extract was tested using cells from an Nb2 cell line. These cells proliferate in the presence of growth hormone and other estrogenic type compounds. The assay involves putting various concentrations of growth hormone-containing extract into a 96 well plate. Then a constant amount of cells are added to each well. The plate is incubated for 48hrs and then a reagent called MTS is added. Metabolizing cells take up the MTS and convert it to a blue colored substance. The more cells there are the more blue color in the well. The blue color is measured using a spectrophotometer. The number of cells should be proportional to the concentration of growth hormone in the media. At some high concentration one expects that the cells will become saturated with growth hormone and that the dose response will level off. At very low hGH concentrations essentially no enhanced growth is seen. A sigmoidal shape graph is expected to be produced graphing the cell number (or absorbance) versus hGH concentration graph.

Proper disulfide pairing in the chloroplast hGH implies that the protein should be biologically active. To test this hypothesis *in vitro*, a rat lymphoma cell line, Nb2, that proliferates in the presence of somatotropin (hGH) and other estrogenic type compounds was employed. Proliferation of this cell line is proportional to the amount of somatotropin in the culture medium, until saturation is reached. The ion exchange column eluate from transplastomic Nt-4838 and Nt-38794 plants or identically treated wild-type plants was added to the Nb2 cell culture medium. As control, *E. coli* produced, refolded hGH was used. The wild-type plant extract showed no activity in this assay, indicating that there is no endogenous plant compound capable of stimulating growth of the Nb2 cell line. In contrast, the Nt-4838 and Nt-38794 extracts both stimulated proliferation of the cell line to an equal extent as the positive controls: either wild-type plant extract that had been spiked with purified *E. coli* hGH or the pure hGH alone.

The Nb2 cell results show that the chloroplast derived hGH is biologically active. Previous studies of recombinant somatotropin produced in *E. coli* showed equivalent pharmacokinetics of the protein with either an N-terminal methionine or phenylalanine (Moore, *et al.* (1988) *Endocrinology* 122:2920-2926). In this study, ubiquitin cleavage of the fusion protein in Nt-38794 lines generated predominantly P-hST, suggesting that this species is also bioactive. The hST from Nt-4838 extracts was also characterized. Amino



acid analysis indicated >95% protein species with alanine at the N-terminus. This result suggests that a methionine aminopeptidase activity generated the alanine-hST, which is also bioactive. A similar aminopeptidase activity exists in *E. coli* (Meinzel, *et al.* (1993) *Biochimie* 75:1061-1075). This finding in plastids may be exploited in the future as an alternative means to generate a non-methionine N-terminus.

The results of the bioactivity assay (Figure 5) demonstrates that the hGH expressed from a plant plastid has a sigmoidal shape when graphed as absorbance versus hGH concentration.

## 10 **Example 5 Analysis of Aprotinin Transplastomic Tobacco Plants**

### 5A. *Western Analysis of Aprotinin Expression in Plastids*

Homoplasmic tobacco lines expressing are used to determine the expression of the aprotinin protein. Western blot analysis was performed on tobacco lines containing constructs pCGN6146, pCGN6147, pCGN6154 and pCGN6156 for plastid expression of aprotinin.

Total protein extractions and western blot procedures were performed as described above, with the exception of the primary antibody was raised against aprotinin.

The results of the Western analysis is shown in Figure 6. These results indicate that aprotinin is expressed from the T7 polymerase promoter when the aprotinin coding sequence is fused with either the PetA or full length GUS gene. Furthermore, these results indicate that the petA sequence efficiently targets the aprotinin protein to the plant cell thylakoid.

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claim.

## CLAIMS

What is claimed is:

5

1. A construct comprising the following components in the 5' to 3' direction of transcription:

- 10
- a) a promoter functional in a plant plastid;
  - b) a DNA sequence encoding a peptide derived from an eukaryotic organism; and
  - c) a transcription termination region;
- wherein said eukaryotic peptide is other than a peptide of a plant plastid.

15

2. The construct according to Claim 1, wherein said construct further comprises (d) a gene encoding a selectable marker for selection of plant cells comprising a plastid expressing said marker and (e) DNA regions of homology to the genome of said plastid, wherein said regions of homology in (e) flank components (a), (b), (c) and (d).

20

3. The construct according to Claim 1, wherein said construct further comprises (f) a ribosome binding site joined to said promoter component (a).

4. The construct according to Claim 3, wherein said ribosome binding site (f) is from a leader sequence selected from the group consisting of sites derived from plastid, bacterial or bacteriophage leader sequences.

25

5. The construct according to Claim 4, wherein said ribosome binding site is selected from the group consisting of the binding site of the gene 10 leader and the rbcLRBS site.

30

6. The construct according to Claim 1 wherein said DNA sequence encodes a plant nuclear peptide.

7. The construct according to Claim 6 wherein said plant nuclear peptide is a carbon cycle gene.

8. The construct according to Claim 7 wherein said a carbon cycle gene is selected from the group consisting of fructose 1,6 biphosphatase aldolase and seduheptulose biphosphatase,

5

9. The construct according to Claim 6 wherein said plant nuclear peptide is an antifungal peptide.

10. The construct according to Claim 1 wherein said DNA sequence encodes a mammalian peptide.

11. The construct according to Claim 10 wherein said mammalian peptide is a protein selected from the group consisting of interferons, monclonal antibodies, hematopoeitic agents, pituitary hormones, thyroid hormones, hypothalamic hormones, albumins and pancreatic hormones.

12. The construct according to Claim 11 wherein said mammalian peptide is the pancreatic hormone insulin.

13. The construct according to Claim 11 wherein said mammalian peptide is a pituitary hormone selected from the group consisting of somatomammotropic hormones, gonadotropic hormones, thyrotropic hormones and chorticotropic hormones.

14. The construct according to Claim 13 wherein said pituitary hormone is a gonadotropic hormone selected from the group consisting of chorionic gonadotropins, luteinizing hormones and follicle stimulating hormones.

15. The construct according to Claim 13 wherein said pituitary hormone is a somatomammotropic hormone selected from the group consisting of prolactin and growth hormones.

16. The construct according to Claim 15 wherein said somatomammotropic hormone is the growth hormone bGH.

17. The construct according to Claim 15 wherein said somatomammotropic hormone is the growth hormone hGH.

5           18. The construct according to Claim 15 wherein said somatomammotropic hormone is the prolactin hormone pBL.

19. The construct according to Claim 11 wherein said mammalian peptide is a hematopoietic agent selected from the group consisting of erythropoietins, interleukins,  
10           and colony stimulating factors.

20. The construct according to Claim 19 wherein said mammalian peptide is the colony stimulating factor G-CSF.

15           21. The construct according to Claim 11 wherein said monoclonal antibody is a single-chain F variable antibody.

22. The construct according to Claim 10 wherein said mammalian peptide is the non-enzymatic coagulation protein selected from the group consisting of factor V and  
20           factor VIII cofactor proteins.

23. The construct according to Claim 10 wherein said mammalian peptide is a proteinase inhibitor.

25           24. The construct according to Claim 10 wherein proteinase inhibitor is aprotinin.

25. The construct according to Claim 2 wherein said selectable marker is a selected from the group of aadA, spectinomycin resistance, streptomycin resistance kanamycin resistance and a glyphosate tolerance gene.

30

26. The construct according to Claim 1 wherein said DNA encoding sequence is the native encoding sequence to said gene.

27. The construct according to Claim 1 wherein said DNA encoding sequence is a synthetic encoding sequence to said gene.

5           28. A plant cell plastid containing the construct according to Claim 1.

29. A plant, plant seed, plant cell or progeny thereof containing a plant plastid according to Claim 29.

10           30. A method for producing a protein in a plant cell, wherein said method comprises transforming plastids of said plant cell with a construct comprising the following as operably joined components in the 5' to 3' direction of transcription:

(a) a promoter functional in a plant plastid;

15           (b) a DNA sequence encoding a peptide of an eukaryotic cell other than a peptide of a plant plastid; and

(c) a transcription termination region.,

and growing plant cells comprising said transformed plastids under conditions wherein said DNA encoding sequence is expressed to produce said eukaryotic peptide in said plastid.

20

31. The method according to Claim 30, wherein said construct further comprises (d) a gene encoding a selectable marker for selection of plant cells comprising a plastid expressing said marker and (e) DNA regions of homology to the genome of said plastid, wherein said regions of homology in (e) flank components (a), (b), (c) and (d).

25

32. The method according to Claim 30, wherein said construct further comprises (f) a ribosome binding site joined to said promoter component (a).

30           33. The method according to Claim 32, wherein said ribosome binding site (f) is from a leader sequence selected from the group consisting of sites derived from plastid, bacterial or bacteriophage leader sequences.

34. The method according to Claim 33, wherein said ribosome binding site is selected from the group consisting of the binding site of the gene 10 leader and the rbcLRBS site.

5           35. A plant cell produced according to the method of Claim 31 and comprising greater than about 0.01 % of total soluble protein as said eukaryotic peptide.

36. A plant cell according to Claim 31 and comprising greater than about 0.2 % of total soluble protein said eukaryotic peptide.

10

37. A plant cell according to Claim 31 and comprising greater than about 1 % of total soluble protein said eukaryotic peptide.

15           38. A plant cell according to Claim 31 and comprising 7 % or more of total soluble protein as said eukaryotic peptide.

39. A plant cell according to Claim 30 wherein said selectable marker comprises a glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthase.

20           40. A plant cell having a transformed plastid produced according to the method of Claim 30.

41. A plant, plant seed or plant part comprising a plant cell according to Claim 41.

25           42. The method according to Claim 30, wherein said construct further comprises (g) a coding sequence to a secondary protein fused to said DNA sequence encoding a peptide of an eukaryotic cell in (b).

30           43. The method according to Claim 42, wherein secondary protein is the thylakoid-targetting terminus of cytochrome f.

44. The method according to Claim 42, wherein secondary protein is the cleavable ubiquitin N-terminus.

45. The method according to Claim 44 whereby said cleavable ubiquitin N-terminus fusion is cleaved from said eukaryotic peptide by the step of harvesting said plant cells and exposing the contents of said transformed plastid to the cytosol of said plant cell.

5

46. The method according to Claim 45 whereby expression of said eukaryotic peptide is enhanced.

47. The method according to Claim 30 wherein said eukaryotic peptide other than a peptide of a plant plastid expressed in said plant plastid is folded with the correct number of disulfide bonds.

10

48. The method according to Claim 47 wherein said eukaryotic peptide is hGH

15

49. The method according to Claim 30 wherein said eukaryotic peptide other than a peptide of a plant plastid expressed in said transformed plant plastid is bioactive when isolated from said transformed plant plastid.

50. The method according to Claim 49 wherein said eukaryotic peptide is hGH.

20

51. A method for producing a non-methionine N-terminus protein in a plastid, wherein said method comprises:

transforming a plastid with a construct comprising, as operably joined components in the 5' to 3' direction of transcription

25

- (a) a promoter functional in a plastid,
- (b) a DNA sequence encoding a cleavable ubiquitin peptide,
- (c) a DNA sequence encoding a protein of interest, and
- (d) a transcription termination region; and

30

growing a plant cell comprising said transformed plastid under suitable conditions for expression of said protein of interest and said cleavable ubiquitin sequence in said plastid.

52. The method according to claim 51, wherein said construct further comprises (e) at least two DNA regions of homology to the genome of said plastid.

53. The method according to claim 51, wherein said construct further  
5 comprises (f) a gene encoding a selectable marker for selection of a plant cell comprising a plastid expressing said marker.

54. The method according to claim 51, wherein said construct further  
comprises (g) a ribosome binding site joined to said promoter (a).  
10

55. The method according to claim 54, wherein said ribosome binding site is derived from a leader sequence selected from the group consisting of a plastid leader sequence, a bacterial leader sequence and a bacteriophage leader sequence.

56. The method according to claim 54, wherein said ribosome binding site is  
15 selected from the group consisting of the binding site of the gene 10 leader and the rbcLRBS site.

57. A plastid having a protein of interest produced according to the method of  
20 claim 51.

58. The plastid according to claim 57 wherein said protein of interest comprises at least about 1.0 % of total soluble protein in said plastid.

59. The plastid according to claim 58 wherein said protein of interest comprises  
25 at least about 7.0% of total soluble protein in said plastid.

60. A plastid comprising a stably incorporated portion of the construct of claim  
51 within its genome.  
30

61. A plant cell comprising a plastid comprising a stably incorporated portion of the construct of claim 51 within its genome.



62. A plant cell comprising a transformed plastid produced according to the method of claim 51.

5 63. A plant, plant seed or plant part comprising a plastid according to claim 57.

64. A plant, plant seed or plant part comprising a plastid according to claim 60.

10 65. A plant, plant seed or plant part comprising a plant cell according to claim 61.

66. A plant, plant seed or plant part comprising a plant cell according to claim 62.

15 67. The method according to claim 51 wherein said protein of interest is folded with the correct number of disulfide bonds.

68. The method according to claim 51 wherein said protein of interest is hGH.

20 69. The method according to claim 51 wherein said protein of interest is bioactive when isolated from said plant cell.

70. The method according to claim 69 wherein said protein of interest is hGH.

25 71. A plastid comprising:  
a portion of a construct according to claim 51 stably integrated into its genome; and  
a non-methionine N-terminus protein.

30 72. A plant cell comprising a plastid having:  
a portion of a construct according to claim 51 stably integrated into its genome; and  
a non-methionine N-terminus protein.

73. A method for producing a non-methionine N-terminus protein in a plastid, wherein said method comprises:

transforming a plastid with a construct comprising, as operably joined components in the 5' to 3' direction of transcription

- 5 (a) a promoter functional in a plastid,  
(b) a DNA sequence encoding a protein of interest, wherein said protein of interest is capable of being recognized by a plant cell Methionine Amino Peptidase, and  
(c) a transcription termination region; and  
growing a plant cell comprising said transformed plastid under suitable conditions  
10 for expression of said protein of interest having a non-Methionine N-terminus.

74. The method according to Claim 73, further comprising the step of growing a plant having said plant cell.

- 15 75. The method according to Claim 74, further comprising the step of harvesting said plant and subjecting cells of said plant to means for substantially purifying said protein of interest.

76. The method according to Claim 73, wherein said plant cell Methionine Amino  
20 Peptidase cleaves the N-terminal methionine.

77. The method according to Claim 73, wherein the second amino acid of said protein is selected from the group consisting of alanine, cysteine, glycine, proline, serine, threonine and valine.

25

78. The method according to Claim 73, wherein the second amino acid of said protein is alanine.

5' - AAT TGT AGA AAT AAT TTT GTT TAA CTT TAA GAA GGA GAT ATA CC - 3'  
TTA ACA TCT TTA TTA AAA CAA ATT GAA ATT CTT CCT CTA TAT GG

**FIGURE 1****SUBSTITUTE SHEET (RULE 26)**

Arg-Pro-Asp-Phe-Cys-Leu-Glu-Pro-Pro-Tyr-Thr-Gly-Pro-Cys-  
Lys-Ala-Arg-Ile-Ile-Arg-Tyr-Phe-Tyr-Asn-Ala-Lys-Ala-Gly-  
Leu-Cys-Gln-Thr-Phe-Val-Tyr-Gly-Gly-Cys-Arg-Ala-Lys-Arg-  
Asn-Asn-Phe-Lys-Ser-Ala-Glu-Asp-Cys-Met-Arg-Thr-Cys-Gly-  
Gly-Ala

Figure 2




Figure 3




Figure 4

Summary Graph




Figure 5

SUBSTITUTE SHEET (RULE 26)

## SEQUENCE LISTING

&lt;110&gt; Calgene LLC

&lt;120&gt; Expression of Eukaryotic Peptides in Plant Plastids

&lt;130&gt; 15346WO

&lt;140&gt; new application

&lt;141&gt; 1999-07-07

&lt;150&gt; 09/316847

&lt;151&gt; 1999-05-21

&lt;150&gt; 09/113244

&lt;151&gt; 1998-07-10

&lt;160&gt; 2

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 88

&lt;212&gt; DNA

&lt;213&gt; from T7 bacteriophage from gene 10

&lt;400&gt; 1

```

aattgtagaa ataattttgt ttaacttttaa gaaggagata taccttaaca tctttattaa 60
aacaaattga aattcttcct ctatatgg                                     88

```

&lt;210&gt; 2

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Arg Pro Asp Phe Cys Leu Glu Pro Pro Tyr Thr Gly Pro Cys Lys Ala
 1              5              10              15

Arg Ile Ile Arg Tyr Phe Tyr Asn Ala Lys Ala Gly Leu Cys Gln Thr
          20              25              30

Phe Val Tyr Gly Gly Cys Arg Ala Lys Arg Asn Asn Phe Lys Ser Ala
          35              40              45

Glu Asp Cys Met Arg Thr Cys Gly Gly Ala
          50              55

```

SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/US 99/15473

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/15 C12N15/18 C12N15/62 C12N15/82 C12N5/10  
 A01H5/00 A01H5/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MAREK, LAURA FREDRICK ET AL: "Chlamydomonas chloroplast transformation using human carbonic anhydrase." PLANT PHYSIOLOGY (ROCKVILLE), (1994) VOL. 105, NO. 1 SUPPL., PP. 84. MEETING INFO.: ANNUAL MEETING OF THE AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS PORTLAND, OREGON, USA JULY 30-AUGUST 3, 1994, XP002118154 abstract ---	1-4,6, 9-16,18, 21,22, 25-33, 40,41,57
X	US 5 693 507 A (DANIELL HENRY ET AL) 2 December 1997 (1997-12-02)	57
A	see esp. example 4 ---	1-8, 25-47,49
A	WO 98 26083 A (MONSANTO CO) 18 June 1998 (1998-06-18) the whole document ---	6,9
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

8 March 2000

Date of mailing of the international search report

03. 04 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Kania, T

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/15473

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 437 320 A (KOREA INST SCIENCE TECHNOLOGY) 17 July 1991 (1991-07-17) the whole document ---	10-12
A	WO 91 13993 A (UPJOHN CO) 19 September 1991 (1991-09-19) the whole document ---	10,11, 13-16,18
A	WO 97 42313 A (SCRIPPS RESEARCH INST) 13 November 1997 (1997-11-13) the whole document ---	10,11,21
A	US 5 723 755 A (FORTIN MARC G) 3 March 1998 (1998-03-03) the whole document ---	10,22
A	MATSUMOTO S ET AL: "CHARACTERIZATION OF A HUMAN GLYCOPROTEIN ( ERYTHROPOIETIN ) PRODUCED IN CULTURED TOBACCO CELLS" PLANT MOLECULAR BIOLOGY, (MAR 1995) VOL. 27, NO. 6, PP. 1163-1172. ISSN: 0167-4412., XP002132161 the whole document ---	10,11,19
A	SAFFORD R. ET AL.: "Regulated expression of the rat medium chain hydrolase gene in transgenic rape seed" TRANSGENIC RESEARCH, vol. 2, 1993, pages 191-198, XP000884365 the whole document ---	10-29
A	KWON S Y ET AL: "EXPRESSION OF ACTIVE HUMAN INTERLEUKIN -6 IN TRANSGENIC TOBACCO" MOLECULES AND CELLS, (31 OCT 1995) VOL. 5, NO. 5, PP. 486-492. ISSN: 1016-8478., XP000884550 the whole document ---	10,11,19
A	LEE J S ET AL: "Establishment of a transgenic tobacco cell suspension culture system for producing murine granulocyte-macrophage colony stimulating factor." MOLECULES AND CELLS, (1997 DEC 31) 7 (6) 783-7. , XP000884527 the whole document ---	10,11, 19,20
A	CA 2 188 220 A (UNIV KINGSTON ;MINI OF AGRICULTURE AND AGRI F (CA)) 18 April 1998 (1998-04-18) see esp. ex. 4 ---	10,11,19
	--- -/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/15473

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DANIELL ET AL: "Containment of herbicide resistance through genetic engineering of the chloroplast genome" NATURE BIOTECHNOLOGY, vol. 16, 1 April 1998 (1998-04-01), pages 345-348, XP002090409 ISSN: 1087-0156 the whole document ---	1-8, 25-47,49
A	WO 95 16783 A (CALGENE INC ;MCBRIDE KEVIN E (US); STALKER DAVID M (US)) 22 June 1995 (1995-06-22) the whole document ---	1-8, 25-47,49
A	WO 98 11235 A (CIBA GEIGY AG ;HEIFETZ PETER (US); LEBEL EDOUARD (US); UKNES SCOTT) 19 March 1998 (1998-03-19) see esp. example C ---	1-8, 25-47,49
A	MCBRIDE ET AL: "Amplification of a chimeric Bacillus gene in chloroplasts leads to an extraordinary level of an insecticidal protein in tobacco" BIO/TECHNOLOGY, vol. 13, 13 April 1995 (1995-04-13), pages 362-365, XP002090404 ISSN: 0733-222X the whole document ---	1-8, 25-47,49
A	WO 95 24492 A (CALGENE INC ;STATE UNIVERSITY OF NEW JERSEY (US)) 14 September 1995 (1995-09-14) the whole document ---	1-8, 25-47,49
A	WO 97 17453 A (HOWARD JOHN A) 15 May 1997 (1997-05-15)  the whole document ---	1-5,10, 23-41, 47,49
A	WO 98 06860 A (CIBA GEIGY AG ;VERNOOIJ BARNARDUS THEODORUS M (NL); CHANDLER DANIE) 19 February 1998 (1998-02-19) see esp. ex. 6 ---	1-5,10, 25-41, 47,49
A	WO 91 02800 A (CAMBRIDGE ADVANCED TECH ;AGRICULTURAL GENETICS CO (GB); BIOTAL LTD) 7 March 1991 (1991-03-07) the whole document ---	43
A	WO 89 09829 A (MASSACHUSETTS INST TECHNOLOGY) 19 October 1989 (1989-10-19) the whole document ---	51-78
	---	
	-/--	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/15473

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BAKER R.: "Protein expression using ubiquitin fusion and cleavage" CURRENT OPINION IN BIOTECHNOLOGY, vol. 7, 1996, pages 541-546, XP002132162 cited in the application see esp. p.544 ---	51-78
A	US 5 773 705 A (CALLIS JUDY ET AL) 30 June 1998 (1998-06-30) see the whole document; esp. pp.4,5 ---	51-78
P,X	WO 98 31823 A (SCRIPPS RESEARCH INST ;MAYFIELD STEPHEN (US)) 23 July 1998 (1998-07-23)  see esp. examples ---	1-4,10, 11,21, 25-33, 40,47,49
P,X	WO 99 10513 A (DANIELL HENRY ;UNIV AUBURN (US)) 4 March 1999 (1999-03-04)  see the whole document; esp. pp.29-35; claims 100-121 ---	1-4, 10-12, 25-33, 40,41
T	WO 98 58069 A (MONSANTO CO) 23 December 1998 (1998-12-23) see examples -----	1-8, 25-47,49

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-8,25-47,49 all partially

Plant plastid expression constructs comprising: a promoter functional in a plant plastid, a DNA sequence, native or synthetic, encoding a eukaryotic peptide not being a peptide of a plant plastid, optionally being a fusion protein with cytochrome f thylakoid targetting terminus or cleavable ubiquitin N-terminus, a transcription termination region. Said constructs further comprising a selectable marker as specified, DNA regions of homology to the plastid genome flanking the other component, a ribosome binding site, preferably the binding site of the gene 10 leader or rbcLRBS.

Said DNA sequence encoding the plant nuclear peptide fructose 1,6 biphosphate aldolase. Plant cell plastids, plant cells, plants, and seeds comprising said constructs. Use of said constructs in a method for producing a protein in a plant cell. Said protein optionally having the correct number of disulfide bonds and being bioactive. Plant cells derived from said method comprising more than 0.01%-7% of said soluble protein. Plants and seeds derived from said method.

2. Claims: 1-8,25-47,49 all partially

idem, the peptide being seduheptulose biphosphatase

3. Claims: 1-7,25-47,49 all partially; 9 completely

idem, the peptide being a plant nuclear peptide, preferably a carbon cycle peptide, or an antifungal peptide not comprised in subjects 1 and 2

4. Claims: 1-5,10,11,25-47,49 all partially; 12 completely

idem, the peptide being insulin

5. Claims: 1-5,10,11,13-15,25-47,49 all partially; 16,17,48, 50 completely

idem, the peptide being a growth hormone

6. Claims: 1-5,10,11,13-15,25-47, 49 all partially; 18 completely

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/15473

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

idem, the peptide being prolactin

7. Claims: 1-5,10,11,13,14,25-47,49 all partially

idem, the peptide being a mammalian hormone not comprised in subjects 4-6

8. Claims: 1-5,10,11,19,25-47,49 all partially; 20 completely

idem, the peptide being G-CSF

9. Claims: 1-5,10,11,19,25-47,49 all partially

idem, the peptide being a hematopoietic agent not comprised in subject 8

10. Claims: 1-5,10,11,25-47,49 all partially; 21 completely

idem, the peptide being an antibody, preferably a single-chain F variable antibody

11. Claims: 1-5,10,11,25-47,49 all partially; 22 completely

idem, the peptide being a non-enzymatic coagulation protein, preferably selected from the group consisting of factor V and factor VIII cofactor proteins

12. Claims: 1-5,10,23,25-47,49 all partially; 24 completely

idem, the peptide being the proteinase inhibitor aprotinin

13. Claims: 1-5,10,23,35-47,49 all partially

idem, the peptide being a proteinase inhibitor not comprised in subject 12

14. Claims: 1-5,10,25-47,49 all partially

idem, the peptide being a mammalian peptide not comprised in subjects 4-13

15. Claims: 42,44-46 all partially; 51-78 completely

A method for producing a non-methionine N-terminus in a plastid comprising: transforming a plastid with a construct comprising a promoter functional in a plant plastid, DNA

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

sequences encoding a cleavable ubiquitin peptide and a protein of interest, a transcription termination region, and growing said plant cell in order to express said DNA sequences. Said construct further comprising DNA regions of homology to the plastid genome, a selectable marker, a ribosome binding site, preferably the gene 10 leader or rbcLRBS. Said protein being folded with the correct number of disulfide bonds and being bioactive, preferably being hGH. A plastid having a protein of interest produced according to said method, said protein comprising at least 1-7% of the soluble protein in said plastid. Plant cells, plants and seeds comprising said plastids.

A method for producing a non-methionine N-terminus in a plastid comprising: transforming a plastid with a construct comprising a promoter functional in plant plastid, a DNA sequence encoding a protein of interest capable of being recognized by a plant cell methionine amino peptidase, a transcription termination region, and growing said plant cell in order to express said DNA sequences.

Said method wherein said plant cell methionine amino peptidase cleaves the N-terminal methionine, the second amino acid of said protein being preferably alanine.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No  
PCT/US 99/15473

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5693507 A	02-12-1997	US 5932479 A	03-08-1999
WO 9826083 A	18-06-1998	AU 5794898 A	03-07-1998
		EP 0946739 A	06-10-1999
EP 0437320 A	17-07-1991	NONE	
WO 9113993 A	19-09-1991	AU 7583691 A	10-10-1991
		EP 0519011 A	23-12-1992
WO 9742313 A	13-11-1997	US 5959177 A	28-09-1999
		AU 2932397 A	26-11-1997
		EP 0946717 A	06-10-1999
US 5723755 A	03-03-1998	WO 9909187 A	25-02-1999
		AU 3936697 A	08-03-1999
CA 2188220 A	18-04-1998	NONE	
WO 9516783 A	22-06-1995	US 5576198 A	19-11-1996
		CA 2178645 A	22-06-1995
		EP 0734446 A	02-10-1996
		JP 9510342 T	21-10-1997
WO 9811235 A	19-03-1998	AU 4414697 A	02-04-1998
		CN 1230224 A	29-09-1999
		EP 0925362 A	30-06-1999
		PL 331767 A	02-08-1999
WO 9524492 A	14-09-1995	US 5545818 A	13-08-1996
		CA 2185340 A	14-09-1995
		EP 0749490 A	27-12-1996
		JP 10511261 T	04-11-1998
WO 9717453 A	15-05-1997	US 5824870 A	20-10-1998
		AU 1156797 A	29-05-1997
		CA 2233538 A	15-05-1997
		EP 0859852 A	26-08-1998
WO 9806860 A	19-02-1998	AU 4205297 A	06-03-1998
		CN 1228123 A	08-09-1999
		EP 0918873 A	02-06-1999
		PL 331563 A	19-07-1999
WO 9102800 A	07-03-1991	CA 2064903 A	15-02-1991
		EP 0487618 A	03-06-1992
		JP 7501681 T	23-02-1995
WO 8909829 A	19-10-1989	US 5132213 A	21-07-1992
		CA 1339842 A	28-04-1998
		EP 0408661 A	23-01-1991
		JP 2894357 B	24-05-1999
		JP 3503606 T	15-08-1991
		US 5496721 A	05-03-1996
		US 5093242 A	03-03-1992
		US 5646017 A	08-07-1997
		US 5847097 A	08-12-1998
		US 5196321 A	23-03-1993

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/US 99/15473

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5773705	A	30-06-1998	NONE		
WO 9831823	A	23-07-1998	AU 6027598 A		07-08-1998
WO 9910513	A	04-03-1999	AU 8457398 A		16-03-1999
WO 9858069	A	23-12-1998	AU 8144598 A		04-01-1999